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ABSTRACT 
 
New antibiotics are desperately needed to combat the disturbing rise of pathogenic 
microorganisms resistant to traditional treatments.  Throughout the history of modern medicine, 
natural products have played a leading role as a source and inspiration of new drugs, particularly 
antibacterial agents.  One emerging family of natural products, the lanthipeptides, is defined by 
the presence of the thioether-containing crosslinks lanthionine and methyllanthionine and 
includes many members with promising activities against clinically-relevant bacterial pathogens, 
including drug-resistant strains.  These peptides are biosynthesized by translation of a linear 
precursor peptide on the ribosome, followed by extensive post-translational modification that 
imparts substantial structural and functional diversity.  In order to improve the pharmacological 
properties of lanthipeptides and therefore foster their clinical application, a more detailed 
understanding of their biological activities is essential. 
In this thesis, complementary synthetic platforms have been developed to produce 
lanthipeptides and analogues, and subsequent biological evaluation has revealed important 
information about the underpinnings of antibacteria activity in several compounds.  In a 
chemoenzymatic approach described in Chapter II, the activity of an engineered biosynthetic 
enzyme involved in lacticin 481 maturation was reconstituted in vitro and used to produce a 
panel of lacticin 481 analogues from synthetic precursor peptides, several of which possessed 
improved antibacterial potency.  This enhanced potency was correlated with improved inhibition 
of transglycosylation during peptidoglycan biosynthesis.  Chapter III describes a chemical 
approach to lanthipeptide production; solid-phase peptide synthesis was utilized to generate the 
first reported analogues of the potent lanthipeptide epilancin 15X.  These efforts provided the 
first details into structure-activity relationship analysis of this compound and also established it 
as a pore-forming agent.  The total synthesis of lacticin 481 and analogues containing different 
crosslink stereochemical configurations was also accomplished, which revealed that the natural 
crosslink configurations are required for biological activity.  In Chapter IV, this solid-supported 
chemical approach was applied to the generation of potent analogues of the immunomodulatory 
peptide compstatin via substitution of the reduction-labile disulfide moiety for an isosteric 
thioether that is stable to reduction.  The generality of these synthetic platforms allows for 
similar engineering approaches in other lanthipeptides and other classes of bioactive cyclic 
peptides, in order to improve the therapeutic potential of these intriguing compounds. 
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CHAPTER 1: NATURAL PRODUCTS, PEPTIDES, AND DRUG DISCOVERY
*
 
 
1.1. ANTIBACTERIAL DRUGS AND NATURAL PRODUCTS 
 
 Throughout human history, natural products have played a leading role in drug discovery, 
as the inspiration for or even the direct source of many of the world’s medicines.1-3  Furthermore, 
such molecules have served as a major stimulus for the development of new synthetic strategies 
and methods, greatly expanding the frontiers of organic chemistry to generate increasingly 
complex structures.
4-7
  Despite this rich and storied history, recent decades have witnessed 
natural products making less impact in the pharmaceutical arena due to declining success rates in 
screening for novel compounds and difficulties in production, among other complications.
8-11
  
However, the growing availability of genomic and bioinformatic data has given new life to 
natural product research by accelerating the discovery of new compounds beyond traditional 
screening procedures.
11-14
  Indeed, more than one-third of all newly approved small molecule 
drugs in the United States from 1981-2010 were either natural products or semisynthetic 
derivatives (Fig. 1.1a), and this number has been trending higher over the past decade.
15
  Even 
within the subset of “synthetic” compounds, a substantial population contains a pharmacophore 
based on a bioactive natural product. 
   
Fig. 1.1.  Natural products as a source of new drugs in the United States from 1981-2010.  (a) Sources of newly 
approved small molecule drugs.  (b) Sources of newly approved antibacterial drugs, including non-small molecule 
vaccines.  Adapted from a survey by Newman and Cragg.
15 
 
1.1.1. Mechanisms of antibacterial activity and resistance 
 
Natural product-based drug discovery has been especially fruitful in the pursuit of clinical 
antibacterials;
15-18
 nearly two-thirds of all newly approved antibacterial drugs from 1981-2010 
                                                          
*
 Reproduced in part with permission from: Knerr, P. J.; van der Donk, W. A., “Discovery, biosynthesis, and 
engineering of lantipeptides.”  Annu. Rev. Biochem. 2012, 81, 479-505.  Copyright 2012 Annual Reviews. 
a b 
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were small molecule natural products or semisynthetic derivatives (Fig. 1.1b).
15
  Unlike drugs in 
other medicinal areas, such as oncology or metabolic disorders, antibacterial natural products 
have evolved specifically to achieve the intended outcome, killing bacteria, as desired for 
therapeutic application.  Harnessing these potent molecules, therefore, taps into nature’s own 
paradigm by which microorganisms compete against each other.  The discovery of new 
antibiotics is even more pertinent in the context of the development in pathogenic bacteria of 
resistance to many of the traditional classes of antibacterials, which has been widely recognized 
as a worldwide crisis for decades.
19-25
  Infections caused by methicillin-resistant Staphylococcus 
aureus (MRSA) have been increasing steadily for over a decade and kill more than 20,000 
people in the United States each year.
26, 27
  Other drug-resistant pathogens, such as vancomycin-
resistant Enterococcus (VRE) and multidrug-resistant Pseudomonas aeruginosa and 
Acinetobacter baumannii have also become epidemic in hospital settings.
19, 28
  Furthermore, the 
emergence of extensively drug-resistant tuberculosis, resistant to multiple first- and second-line 
treatments, threatens millions in the developing world.
29, 30
  As a striking example of the scarcity 
in the contemporary antibacterial pipeline, the approval of the diarylquinoline bedaquiline in 
2012 represented the first new treatment for tuberculosis in 40 years.
31
  Similarly to 
antibacterials, alarming rates of resistance development have been recognized in other 
antimicrobial drugs, including antivirals,
32
 antifungals,
33
 and antimalarials.
34
 
The vast majority of clinical antibacterials exert their biological activity through one of 
four mechanisms (Fig. 1.2): inhibition of ribosomal polypeptide synthesis (including the 
aminoglycoside, macrolide, and tetracycline classes), inhibition of nucleic acid synthesis 
(quinolones, rifamycins), inhibition of cell wall synthesis (β-lactams, glycopeptides), and 
inhibition of folate synthesis (2,4-diaminopyrimidines, sulfonamides).
35
  Somewhat ironically, 
the same evolutionary history exploited in the discovery of natural product antibacterials also 
operates in the other direction; organisms appear to have evolved mechanisms of resistance to 
such compounds long before their use in human medicine.
36-38
  While each drug or drug class 
possesses its own resistance profile, several general mechanisms are commonly operative across 
classes.
39, 40
  The biological target of the drug can be modified in several ways: through genetic 
mutation, as in the case of penicillin-binding proteins from MRSA; through enzyme-catalyzed 
alteration, such as ribosome methylation to block macrolide binding; or through molecular 
substitution, exemplified by alteration of the D-Ala-D-Ala motif of nascent peptidoglycan to D- 
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Fig. 1.2.  Representative structures of different classes of antibacterial drugs, listing the source of each drug (natural 
product, semisynthetic derivative of a natural product, synthetic).  General mode-of-action is color-coded: inhibition 
of polypeptide biosynthesis (red), inhibition of nucleic acid biosynthesis (blue), inhibition of cell wall biosynthesis 
(green), antifolates (purple), cell membrane disruption (gold). 
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Ala-D-Lac by VRE to evade vancomycin.  Drug or multidrug efflux pumps remove the drug from 
its site of activity inside the cell and have contributed to quinolone and tetracycline resistance in 
multiple species, including P. aeruginosa.  In addition, the evolution of enzymatic inactivation of 
antibacterials has spread across drug classes, including β-lactam hydrolysis, aminoglycoside 
acetylation or phosphorylation, and macrolide hydrolysis or phosphorylation. 
 
1.1.2. Recent developments in antibacterial natural products 
 
 The paucity of biological pathways targeted by clinical antibacterials is suspected to 
contribute to the rapid development of resistance,
35
 even to next-generation compounds and 
novel drug classes.  The observation of clinical resistance to linezolid, a fully synthetic ribosomal 
inhibitor that established the oxazolidinone class, followed within a year of its approval in 
2000,
41
 although subsequent global appraisals have documented that this resistance has remained 
very rare.
42
  The glycylcyclines, established by the approval of tigecycline in 2005, are 
semisynthetic tetracycline derivatives designed to evade common mechanisms of tetracycline 
resistance, but emerging resistance via efflux pumps was already observed during clinical 
trials.
43
  Therefore, new antibacterials with entirely novel biological targets and mechanisms-of-
action are sorely needed to combat rising rates and prevalence of resistance.  However, in the 
face of this great and growing need, a range of technical and financial aspects have contributed 
to a general withdrawal of the pharmaceutical industry from antibacterial discovery and 
development over the past several decades.
24, 44-46
 
In spite of these formidable obstacles, several new classes of natural product and natural 
product-derived antibacterials have reached the market in the past decade (see Fig. 1.2).  
Daptomycin, a macrocyclic lipopeptide isolated from the soil bacterium Streptomyces 
roseosporus, was approved in 2003 for the treatment of Gram-positive skin infections and is 
active against MRSA and VRE.
47
  This natural product is synthesized via non-ribosomal peptide 
synthesis (NRPS) machinery
48
 and employs a novel, yet poorly understood, mode of action: 
calcium-dependent depolarization of the cell membrane.
47, 49
  However, like other recently-
introduced antibacterial classes, strains of S. aureus utilizing diverse resistance mechanisms have 
been isolated in clinical settings.
50
  Retapamulin is a polycyclic, semisynthetic derivative of the 
fungal natural product pleuromutilin that was approved in 2007 to treat topical Gram-positive 
infections.
51
  Similar to many other antibacterials, it inhibits ribosomal peptide synthesis, but 
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through novel interactions with the 50S ribosomal subunit.
52
  Additionally, fidaxomicin 
established a new class of narrow-spectrum macrocyclic polyene antibacterials with its approval 
in 2011.  This fermentation product of the actinomycete Dactylosporangium aurantiacum 
inhibits RNA polymerase in Clostridium difficile while sparing many other species that comprise 
the intestinal flora, mitigating recurrent infections.
53, 54
  While these successes signify a starting 
point to address the problem of antibacterial resistance, the limited number of compounds 
currently in development, coupled with the observation of resistance to even newly introduced 
compounds, beckons for intensified efforts in this area.
55
 
 
1.2. THE IMPACT OF PEPTIDES IN DRUG DEVELOPMENT 
 
 Perhaps the converse to small molecule natural products, peptides have garnered greater 
attention as leads for drug discovery in recent decades after a long period of neglect.
56-58
  When 
compared to small molecules, peptides hold the potential to improve specificity, decrease off-
target effects, and inhibit large biomolecular interactions due to their large size and dense 
functionality, and screening technologies such as phage display have accelerated the discovery of 
bioactive peptides as new drug leads.
59-61
  However, limitations in stability and production have 
curbed enthusiasm for development of natural or synthetic peptides as drugs.  In 2012, five of the 
39 new drug approvals were peptides: the surfactant lucinactant for respiratory distress 
syndrome; erythropoietin analogue peginesatide for chronic kidney disease-related anemia; 
bacterial enterotoxin homologue linaclotide for irritable bowel syndrome; somatostatin analogue 
pasereotide for Cushing’s disease; and glucagon-like peptide-2 analogue teduglutide for short 
bowel syndrome.
62
  Peptide-based natural products have also been approved for therapeutic use 
in the past decade, including the cyclic antibacterial lipopeptide daptomycin (see Section 1.1.2) 
and the disulfide-rich ω-conotoxin ziconotide for the treatment of neuropathic pain.63  In light of 
this currently modest population of approved peptide drugs, recent advances in peptide 
stabilization and manufacturing have coalesced in a rich pipeline of bioactive peptides to treat a 
wide diversity of challenging disease states.
56, 64, 65
 
 
1.2.1. Improving peptides for in vivo applications 
 
In order to address the pharmacological limitations of peptides, the field of 
peptidomimetics has aimed to replicate the effects of biologically active peptides with more 
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stable scaffolds that preserve the spatial array of important functional groups.
66, 67
  In the context 
of peptides themselves, a variety of medicinal chemistry approaches have been used to stabilize 
lead compounds and reduce clearance rates.
68-70
  N- and C-terminal functionalization, backbone 
methylation, and introduction of D-amino acids and other non-proteinogenic residues have been 
widely demonstrated to improve stability to proteolysis.
71
  Conjugation with polyethylene glycol 
is known to decrease both the typically rapid in vivo clearance rate and potential immunogenicity 
of peptide drugs.
72
  Backbone or side-chain cyclization may have the doubly beneficial effect of 
improving proteolytic stability and constraining the peptide in a conformation conducive for 
binding its biological target.
73, 74
  In particular, the disulfide bond, commonly found among 
therapeutic peptides,
57
 has been the target of considerable engineering efforts to improve stability 
to cellular reducing agents while preserving the restricted conformation of the peptide.
66, 75
 
 
1.2.2. Recent developments in peptide synthesis and manufacturing 
 
 As interest grows in the potential therapeutic application of peptides, so also grows the 
need for efficient processes to synthesize longer and more structurally complex molecules.
76
  
Improved amino acid activating agents for use in solid-phase peptide synthesis (SPPS) have 
allowed for improved coupling yields with decreased side-reactions,
77
 but the need for 
stoichiometric, and often excess, reagents generates considerable waste.
78
  The large-scale 
production of the 36-residue antiretroviral peptide enfuvirtide via a combination of SPPS and 
fragment couplings over 106 chemical steps was a landmark achievement in the early 2000s for 
peptide process chemistry, but the synthesis of 1000 kg of final product necessitated over 45,000 
kg of raw materials.
79, 80
  Catalytic amidation reactions, while still in their infancy, have the 
potential to decrease greatly the waste generated during peptide synthesis.
81
  Novel chemistries 
for peptide cyclization have also been the subject of considerable scrutiny.
82
 
 Chemoselective ligation of unprotected peptide fragments holds promise to streamline the 
commercial synthesis of therapeutic peptides in a convergent manner and decrease difficulties in 
purification (Fig. 1.3).
81
  Native chemical ligation between an N-terminal cysteine and a C-
terminal thioester, the first such chemistry to be developed, generates a native amide bond under 
aqueous conditions in the presence of unprotected functionalities.
83
  Recent progress in the use of 
cysteine surrogates
84-86
 and the solid-phase synthesis of peptide thioesters
87-89
 has further 
expanded the impact of this powerful strategy, as highlighted by the recent syntheses of the 141 
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Fig. 1.3.  Schematic of three chemoselective approaches to peptide ligation: native chemical ligation (top), ketoacid-
hydroxylamine ligation (middle), and traceless Staudinger ligation (bottom). 
 
residue parathyroid hormone-related protein
90
 and the 166 residue, tetraglycosylated hormone 
erythropoietin.
91
  The ketoacid-hydroxylamine (KAHA) ligation first reported in 2006 presents 
an alternative approach to the amide-forming ligation of fully unprotected peptide fragments;
92
 
an N-terminal hydroxylamine and a C-terminal α-ketoacid react via a reagentless 
decarboxylative condensation.
93
  General SPPS-based approaches to the construction of peptides 
containing both reaction partners have been developed,
94, 95
 and the KAHA ligation has been 
applied to sequential reactions,
96
 peptide cyclization,
97
 and therapeutic peptide synthesis.
98
  A 
third approach, the traceless Staudinger ligation between an N-terminal azide and a C-terminal 
phosphinothioester, has been adapted for use in water,
99
 but lacks the broad functional group and 
substrate tolerance of native chemical and KAHA ligations.
100, 101
 
 
1.3. RIBOSOMALLY-SYNTHESIZED PEPTIDE NATURAL PRODUCTS 
 
Considering the difficulties encountered in antibacterial drug discovery as well as the 
growing potential of peptides as drugs, peptide-based natural products have been suggested as a 
viable source of new antibacterial drugs.
17, 18
  Peptides produced via NRPS biosynthesis, such as 
vancomycin and its variants, daptomycin, and bacitracin, have a rich history as clinical 
antibacterials.  However, a separate class of peptide natural products has emerged in the past 
decade: the ribosomally synthesized and post-translationally modified peptide natural products 
(RiPPs).
102
  Advances in genome sequencing and bioinformatic analysis have revealed that this 
class possesses much greater diversity with respect to structure and biological activity than 
previously anticipated.
103-106
  Over a dozen subfamilies of RiPPs are currently recognized, 
originating from all three domains of life.
102
  Initially limited to the 20 canonical amino acids 
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Fig. 1.4.  Representative members of different subfamilies of RiPPs, with post-translational modifications colored 
and labeled. 
 
during translation, the diversity of these compounds is greatly enhanced by extensive post-
translational modification (PTM), such as heterocyclization, macrocyclization, dehydration, 
acylation, glycosylation, halogenation, alkylation, and epimerization (Fig. 1.4).  Similarly 
diverse are the biological activities of these compounds, which include antibacterial, antiviral, 
antimalarial, cytotoxic, hemolytic, and analgesic activity.
102
  One RiPP has already reached the 
clinic, the ω-conotoxin ziconotide, which was approved for the treatment of intractable pain in 
2004.
63
 
Unlike NRPS systems,
107
 the biosynthesis of RiPPs directly connects the final product 
and the gene encoding its corresponding precursor peptide (Fig. 1.5).  This phenomenon renders 
RiPPs particularly suited for genome-mining strategies, which have demonstrated that these 
pathways are remarkably widespread throughout nature.
104
  The linear, ribosomally translated 
precursor peptide contains a core peptide, which is post-translationally modified to give the final 
product, and a leader peptide, which helps to direct the maturation process.  A variety of 
functions of the leader peptide in biosynthesis, export, and immunity have been proposed, which 
appear to vary from subfamily to subfamily.
108, 109
  The precursor peptide may also contain an N-
terminal signal peptide to guide subcellular localization in eukaryotic systems and/or a C- 
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Fig. 1.5.  General scheme of RiPP biosynthesis, showing the different portions of the precursor peptide.  Xn* 
indicates a post-translationally modified residue, which may include cyclization, glycosylation, epimerization, or 
other alterations.  An exception to this general scheme is bottromycin biosynthesis, in which the precursor peptide 
contains an N-terminal core peptide and a C-terminal follower peptide.
110, 111
 
 
terminal recognition sequence involved in excision and head-to-tail cyclization.  Interestingly, in 
bottromycin biosynthesis, the precursor peptide contains an N-terminal core peptide and a C-
terminal follower peptide, the latter of which is removed from the final product and is 
hypothesized to serve a similar role to the leader peptide of other RiPPs.
110, 111
  From a 
bioengineering standpoint, the relative brevity of RiPP biosynthetic pathways, as well as the 
substrate promiscuity of the leader-directed biosynthetic machinery, makes RiPPs particularly 
attractive.
102, 103
  Such engineering efforts are needed in order to develop a more full 
understanding of structure-activity relationships and modes-of-action.  This knowledge can then 
be utilized in the improvement of pharmacological properties, including potency, solubility, and 
in vivo stability, and thus the improvement of the therapeutic potential of these compounds. 
 
1.4. LANTHIPEPTIDES AND LANTIBIOTICS 
 
At present, the best-studied subfamily of RiPPs are the lanthipeptides: polycyclic 
peptides characterized by the presence of the thioether-crosslinked bis-amino acids meso-
lanthionine (Lan) and (2S,3S,6R)-3-methyllanthionine (MeLan) (Fig. 1.6).  Formerly known as 
lantibiotics for “lanthionine-containing antibiotics,” this family name has been broadened to 
lanthipeptides to encompass the discovery of compounds with nonantibiotic activities.
112
  Interest 
in these RiPPs as chemotherapeutics stems from the use of the prototypical lanthipeptide 
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Fig. 1.6.  Sequences, ring topologies, and post-translational modifications of representative lanthipeptides.  Modified 
residues are highlighted, and their chemical structures are shown.  The two known lanthipeptide-lipid II binding 
motifs are also indicated: the nisin motif (green dashed circle) and the mersacidin motif (red dashed circle).  Note 
that the A-ring of haloduracin β has been recently shown to contain (2R,3R,6R)-MeLan.113  (continued on next page) 
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Fig. 1.6.  (continued) 
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nisin as a food preservative for more than 50 years without substantial incidence of microbial 
resistance.
114
  Lantibiotics possess potent activity against many clinically relevant Gram-positive 
bacteria, including drug-resistant strains of Staphylococcus, Streptococcus, Enterococcus, and 
Clostridium, as well as against select Gram-negative pathogens, such as Neisseria and 
Helicobacter.
115, 116
  Highlighting the therapeutic potential of this family are several members 
currently in clinical development, including a natural cinnamycin analogue for the treatment of 
cystic fibrosis
117
 and a semisynthetic derivative of actagardine for the treatment of Clostridium 
difficile infections.
118, 119
  Additionally, mutacin 1140 is currently in preclinical development for 
the treatment of Gram-positive bacterial infections.
120
  Other applications, including in food 
preservation,
121, 122
 veterinary medicine,
122
 and molecular imaging,
123, 124
 are also emerging.   
With regard to the molecular topology of these compounds, the arrangement of the 
Lan/MeLan crosslinks varies widely within the family, from elongated molecules like nisin and 
lacticin 3147 A2 to more compact, globular structures as seen in cinnamycin (Fig. 1.6).  
Similarly diverse are the number of crosslinks, which currently ranges between two in lactocin 
S
125
 and seven in geobacillin I.
126
  These crosslinks are critical not only for the activity of the 
mature compounds
127-129
 but also for stability against proteolysis and heat denaturation.
130-133
  
Also commonly found are the α,β-unsaturated residues 2,3-didehydroalanine (Dha) and (Z)-2,3-
didehydrobutyrine (Dhb), the biosynthetic precursors to Lan and MeLan, respectively (see 
Section 1.4.1).  A wide variety of other tailoring PTMs are also suggested to play roles in 
stability
128, 134-136
 and/or activity
137, 138
 and include cyclic structures such as aminovinylcysteine 
and lysinoalanine, modified side-chains such as D-alanine, hydroxylated aspartate, and 
chlorinated tryptophan, and N-terminal acyl moieties (Fig. 1.6). 
It was long believed that lanthipeptides were produced only by a small group of Gram-
positive Firmicutes and select streptomycetes.
104, 139
  However, advances in both genome 
analysis and isolation studies have allowed for the identification of many new lanthipeptides, 
which now include approximately 100 isolated compounds, and thousands more have been 
predicted based on the identification of putative biosynthetic gene clusters.  Such genes are 
widely disseminated in actinomycetes, bacteroidetes, proteobacteria, and cyanobacteria,
112, 140-145
 
and have even been detected in mammals.
146, 147
  Homologues of lanthipeptide biosynthetic 
enzymes are also involved in the biosynthesis of other RiPPs, including lanthipeptide 
dehydratase-like enzymes that install Dha/Dhb in thiopeptides
148-151
 and goadsporin (Fig. 1.4).
152
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Given the rapid pace of genome sequencing and the implementation of freely available, 
automated in silico genome mining software,
153, 154
 the discovery of novel lanthipeptides is 
expected to continue its acceleration in coming years, potentially yielding further diversity in 
structure and function. 
 
1.4.1. Biosynthesis of lanthipeptides 
 
 Despite the structural diversity across the family, lanthipeptide biosynthesis is 
remarkably conserved.  In all known cases, lanthipeptides are biosynthesized on the ribosome as 
a linear precursor peptide, generically called a LanA.  Like most other RiPP systems, the LanA 
contains an N-terminal leader peptide and a C-terminal core peptide, the latter of which becomes 
the mature compound.  The distinguishing Lan/MeLan structures are installed post-
translationally into the core peptide via a two-reaction sequence: enzymatic dehydration of serine 
and threonine to the α,β-unsaturated residues Dha and Dhb, respectively, followed by enzymatic 
Michael-type addition of a cysteinyl thiol to yield the thioether crosslinks Lan and MeLan (Fig. 
1.7a).  In all cases investigated prior to this year, a D-configuration is installed at the newly 
formed Cα-stereocenter of the crosslink (as depicted in Fig. 1.6),
125-127, 155-157
 which promoted an 
assumption that the lanthipeptide biosynthetic machinery is only able to produce that particular 
configuration.  Very recently, however, the isomeric L-configuration was detected in three 
lanthipeptides, haloduracin β and both peptides of the enterococcal cytolysin, despite the fact that 
these compounds are biosynthesized by enzymes that have high sequence homology with other 
lanthipeptide synthetases.
113
  Adding further structural diversity to the lanthipeptides was the 
discovery of a third type of crosslink, labionin, which is formed by a second Michael addition 
between the enolate intermediate produced during Lan formation and another Dha to give a 
carbacycle (Fig. 1.7a).
158, 159
  Following crosslink installation, the maturation process is 
completed by removal of the leader peptide via proteolysis and export from the producing cell 
(Fig. 1.7b).  If the final product contains other tailoring PTMs, these moieties are installed by 
additional enzymes encoded in the biosynthetic gene cluster,
135-137, 160, 161
 but the order of these 
events with respect to other biosynthetic steps remains uncertain. 
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Fig. 1.7.  General scheme of lanthipeptide biosynthesis.  (a) Mechanism of the formation of the crosslinks Lan, 
MeLan, and labionin.  Xn indicates a generic sequence of amino acids.  (b) Reactions involved in the post-
translational maturation of nisin: dehydration by NisB, cyclization by NisC, and leader peptide removal by the 
serine protease NisP.  Although not explicitly shown, current data suggest that dehydration and cyclization are 
alternating processes.
162, 163
 
 
Biochemical and genetic analyses have revealed four distinct classes of lanthipeptides on 
the basis of their biosynthetic machinery (Fig. 1.8).
112, 164
  For class I lanthipeptides, such as 
nisin, microbisporicin, and Pep5, dehydration and cyclization are performed by two separate 
enzymes: the dehydratase LanB and the cyclase LanC, respectively.
162, 165, 166
  The very recent in 
vitro reconstitution of the nisin dehydratase NisB has finally provided insight into LanB 
catalysis, which involves glutamylation of substrate serine/threonine residues followed by 
elimination.
167
  LanC catalysis has been investigated through structural analysis of the nisin 
cyclase NisC, which revealed a critical active-site zinc ion bound by three conserved residues 
 
a 
b 
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Fig. 1.8.  Schematic representation of the four classes of lanthionine-generating biosynthetic machinery, 
highlighting domains and conserved motifs. 
 
that is believed to activate the cysteinyl thiol for nucleophilic attack.
168, 169
  For class II 
lanthipeptides, such as mersacidin, lacticin 3147, lacticin 481, and cinnamycin, the dehydration 
and cyclization reactions are catalyzed by a single bifunctional synthetase, LanM.
137, 170-172
  
Mechanistic insights have been provided by the in vitro reconstitution of the lacticin 481 
synthetase LctM, which uses an N-terminal dehydratase domain to catalyze dehydration via a 
phosphorylation/elimination sequence with adenosine 5’-triphosphate as cosubstrate173 and a C-
terminal cyclase domain homologous to LanC.
174
 
The remaining two classes of lanthipeptide biosynthetic machinery have been discovered 
more recently.  Class III lanthipeptides, such as SapB and the labyrinthopeptins, are modified by 
a trifunctional synthetase, called RamC or LanKC, which contains an N-terminal lyase domain, a 
central kinase domain, and a C-terminal cyclase domain that lacks many of the conserved active-
site residues found in LanC and LanM.
158, 175, 176
  Interestingly, the discovery of additional class 
III lanthipeptides in the past year has revealed that LanKC is able to catalyze the formation of 
both Lan and labionin,
176-178
 although the mechanism of cyclization remains unknown.  Finally, 
the class IV synthetase, LanL, has been described in the context of the novel lanthipeptide 
venezuelin and contains N-terminal lyase and kinase domains as in class III synthetases, but its 
C-terminal cyclase domain is homologous to LanC.
112, 179
  Taking these studies together, the 
multiplicity of distinct pathways to generate lanthipeptides demonstrates the convergent 
evolution of efficient, ribosome-based biosynthetic strategies and highlights the potential 
evolutionary advantage of accessing high chemical diversity at low genetic cost.
104, 164, 180
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1.4.2. Modes-of-action of lanthipeptides 
 
As the original class name “lantibiotic” suggests, many lanthipeptides are antibiotics, and 
more specifically antibacterials that target primarily Gram-positive organisms.  The mechanisms 
by which lantibiotics exert their antibacterial activity have been studied extensively in only a few 
instances,
139, 181, 182
 with nisin as the best understood case at present.
114
  Nisin has been 
demonstrated to employ two related mechanisms involving the essential peptidoglycan precursor 
lipid II (Fig. 1.9), a combination that results in very potent activity.
183
  Nisin binds to the 
pyrophosphate moiety of lipid II through a hydrogen bond network involving its A- and B-
rings;
184
 in doing so, it both inhibits the transglycosylation reaction necessary to synthesize 
peptidoglycan and also sequesters lipid II into nonfunctional locations.
185
  Interaction with lipid 
II is not a novel antibacterial mechanism, as glycopeptides and other antibacterial natural 
products are known to do the same, but nisin binds at a unique site in lipid II and shows no cross-
resistance with vancomycin (Fig. 1.9).
186, 187
  Furthermore, once bound to lipid II, nisin is able to 
 
 
Fig. 1.9.  Schematic of the two major lipid II-based reactions involved in the biosynthesis of peptidoglycan.  
Transglycosylation adds membrane-bound disaccharide units onto the growing polysaccharide chain, while 
transpeptidation crosslinks different chains through the lipid II pentapeptide segment.  The lipid II binding sites of 
nisin and vancomycin are indicated. 
17 
 
insert into the membrane and form pore complexes, leading to rapid membrane depolarization 
and termination of cellular processes.
188-190
  The nisin-lipid II binding motif is found in other 
class I lanthipeptides (Fig. 1.6), and while these compounds inhibit peptidoglycan biosynthesis, 
only some of them are able to form pores.
191-193
  Recently, nisin has been shown to bind to 
intermediates in the wall teichoic acid biosynthetic pathway, which may represent a further 
diversification of its antibacterial mechanisms.
194
  Intriguingly, the class I lanthipeptides Pep5, 
epilancin K7, and epilancin 15X, which do not possess the nisin-like binding motif, are able to 
form pores without interacting with lipid II,
195, 196
 suggesting that they may bind a different 
biological target.
197
 
A second lipid II binding motif has been described for the class II lanthipeptide 
mersacidin (Fig. 1.6), which interacts with lipid II though its C-ring
198
 and inhibits 
transglycosylation, but does not form pores.
199, 200
  This binding motif contains an essential 
acidic residue conserved in other class II lanthipeptides; mutation to a non-acidic residue has 
been shown to reduce severely or abolish activity in a variety of instances.
128, 201-203
  The 
importance of this conserved residue for interaction with lipid II was recently confirmed in the 
cases of nukacin ISK-1, a natural variant of lacticin 481,
204
 and the α-peptide of haloduracin.196  
For the two-component lanthipeptides lacticin 3147 and haloduracin, the α-peptide shares the 
mersacidin-like motif and binds lipid II, and this complex then recruits the β-peptide in order to 
form pores.
196, 205, 206
  This mode-of-action explains the observation that the individual peptides 
of two-component lanthipeptides display modest to negligible activity by themselves, but potent 
and synergistic activity in combination. 
Beyond antibacterial activity, lanthipeptides have demonstrated additional biological 
activities in recent years.  Cinnamycin and its natural variants, the duramycins, bind to the 
membrane phospholipid phosphatidylethanolamine; this interaction inhibits the release of 
arachadonic acid by phospholipase A2, which in turn inhibits the eicosanoid biosynthetic 
pathway.
123, 207, 208
  This mechanism has implications in the treatment of cystic fibrosis, and one 
duramycin is currently in clinical trials for this indication.
117
  The class III labyrinthopeptins 
have demonstrated antiviral and antiallodynic activities,
158
 both unique for lanthipeptides, 
although the underlying mechanisms are not yet known.  The class III lanthipeptides SapB and 
SapT trigger morphogenic changes in streptomycetes, possibly through a surfactant-like 
mechanism.
175
  Furthermore, nisin has recently demonstrated both immunomodulatory
209
 and 
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antitumor activities,
210
 which are very intriguing discoveries for a molecule that is already 
considered safe for human consumption. 
 
1.5. SUMMARY AND OUTLOOK 
 
In the search for new therapeutic drugs, natural products have been, and continue to be, 
of utmost importance both as direct medicinal sources and as guides in molecular design.  
Bioactive peptides, while lacking the storied history of natural products in drug development, 
have more recently become recognized as viable therapeutic systems, thanks in part to advances 
in their stabilization and production.  Therefore, it seems fitting that peptide-based natural 
products are emerging as a critical source of new drugs, particularly in the search for new 
antibacterial agents to combat the rapid rise of drug-resistant bacterial pathogens.  One subfamily 
of peptide natural products, the lanthipeptides, have been investigated for their potent biological 
activities and their fascinating modes-of-action.  However, as with many natural product- and 
peptide-based drug leads, the clinical application of lanthipeptides and lantibiotics requires 
general and versatile methods to analyze structure-activity relationships and biological 
mechanisms, and further to use this information in the design of next-generation compounds with 
enhanced pharmocological profiles. 
 This thesis presents the development of synthetic platforms to generate medicinally 
interesting analogues of lantibiotics and other bioactive cyclic peptides.  These approaches were 
anticipated to yield valuable information about the biological activities of these compounds that 
in turn would guide engineering efforts to improve therapeutic potential; in this light, several 
advances have already been made.  In Chapter 2 of this thesis, a chemoenzymatic approach to 
lanthipeptide synthesis is described, in which the biosynthetic machinery of the lantibiotic 
lacticin 481 was engineered and reconstituted in vitro to process synthetic linear substrates into 
the desired bioactive products in a single step.  In this way, a panel of lacticin 481 analogues 
were produced, and several of these compounds were found to possess improved potency to the 
natural product.  This panel of analogues was further used to establish the mode-of-action of 
lacticin 481: inhibition of peptidoglycan biosynthesis without pore formation.  In Chapter 3, an 
alternative approach for the generation of lantibiotic analogues via total chemical synthesis is 
described.  A collection of orthogonally-protected Lan/MeLan building blocks were synthesized 
and utilized to construct analogues of the lantibiotics epilancin 15X and lacticin 481 on the solid-
19 
 
phase.  Epilancin 15X analogues were used to investigate the importance of different PTMs for 
antibacterial activity and also to determine that epilancin 15X is a pore-forming agent.  Lacticin 
481 analogues containing stereoisomeric Lan/MeLan crosslinks demonstrated no biological 
activity, shedding light on the importance of stereochemistry during the evolution of these 
natural products.  Finally, Chapter 4 describes a synthetic approach for the in vivo stabilization of 
disulfide-containing bioactive peptides by substitution of the disulfide bond with cystathionine, 
an isosteric monosulfide crosslink.  Compstatin, a disulfide-containing immunomodulatory 
peptide, was used as a model system to demonstrate that this substitution improves the 
molecule’s reductive stability without sacrificing potency.  Taken together, these studies have 
established versatile synthetic approaches to construct bioactive cyclic peptides, and also have 
revealed details about the molecular underpinnings of biological activity in two lantibiotics.  It is 
hoped that these platforms will enable future efforts intended to better understand and engineer 
lantibiotics as potential drugs, as well as to stabilize disulfide-containing therapeutic peptides. 
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CHAPTER 2: BIOSYNTHETIC ENGINEERING AND MODE-OF-ACTION 
OF THE LANTIBIOTIC LACTICIN 481
*,†
 
 
2.1. INTRODUCTION 
 
 As introduced in Chapters 1.3 and 1.4, large-scale structure-activity relationship (SAR) 
analyses are necessary in order to develop ribosomally synthesized and post-translationally 
modified peptide natural products (RiPPs) as clinical drugs.  The use of biosynthetic engineering 
to generate panels of analogues has several key advantages for RiPPs compared to other families 
of natural products.
1, 2
  As the precursor peptide is genetically encoded, any mutation to its 
corresponding gene is directly conveyed to the final product, provided that the mutation is 
tolerated by the biosynthetic enzymes.  The biosynthetic pathways for RiPPs are well suited for 
bioengineering because they are considerably shorter than those for other natural products, and 
the enzymes involved in post-translational modification often exhibit substantial substrate 
promiscuity.  This latter observation is likely due to the leader-directed nature of the 
biosynthesis,
3-5
 which allows for variable core peptides to be recognized and modified by a 
single biosynthetic enzyme in several natural systems.
6-9
  Recent successes in the production of 
analogues of thiopeptides,
10, 11
 bottromycins,
12
 and cyanobactins
13
 have begun to bear out the 
potential of RiPP biosynthetic engineering. 
 Of the many subfamilies of RiPPs, the lanthipeptides (see Chapter 1.4 for an 
introduction) have been particularly fruitful for bioengineering, which has resulted in both an 
improved understanding of SAR and more potent analogues.
14-18
  In vivo bioengineering in 
producing strains and heterologous hosts has resulted in versatile biosynthetic systems for 
lanthipeptide engineering,
15, 19-24
 including the introduction of stabilizing lanthionine crosslinks 
into other therapeutically relevant peptides.
25-28
  Of particular interest is heterologous expression 
in Escherichia coli, which greatly expands the genetic toolbox accessible for lanthipeptide 
bioengineering and sometimes results in improved yields of the desired product compared to 
natural producing strains.
29-34
  Alternatively, the in vitro reconstitution of biosynthetic enzymes 
                                                          
Reproduced in part with permission from: 
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allows for a detailed examination of mechanism and substrate scope, and precludes 
complications inherent to in vivo bioengineering relating to expression, export, and toxicity.  The 
activity of one or more enzymes involved in the biosynthesis of several lanthipeptides, including 
epidermin,
35
 lacticin 481,
36, 37
 nisin,
38
 haloduracin,
39
 the prochlorosins,
6
 the labyrinthopeptins,
40
 
venezuelin,
41
 cinnamycin,
32
 bovicin HJ50,
33
 epilancin 15X,
42
 actagardine,
30
 and catenulipeptin
43
 
have been successfully reconstituted in vitro.  Of these, the lacticin 481 synthetase LctM has 
been the most rigorously investigated.  As a class II synthetase, LctM catalyzes both dehydration 
and cyclization of its substrate, the lacticin 481 precursor peptide LctA (Fig. 2.1).  The 
mechanism of dehydration involves phosphorylation of substrate serine and threonine residues 
using adenosine 5’-triphosphate (ATP) as cosubstrate, followed by elimination of phosphate to 
generate the α,β-unsaturated structures 2,3-didehydroalanine (Dha) and (Z)-2,3-
dedehydrobutyrine (Dhb).
44
  A separate domain in LctM is believed to catalyze cyclization using 
an active-site zinc ion,
45
 analogous to cyclization by the class I nisin cyclase NisC.
38, 46
 
 
 
Figure 2.1.  Biosynthesis of lacticin 481.  (a) LctM catalyzes both dehydration and cyclization of the linear 
precursor peptide LctA.  The leader peptide is then removed by the cysteine protease/transporter LctT, resulting in 
the mature lantibiotic.  For the chemical structures of modified residues, see Fig. 1.6.  (b) Catalytic mechanism of 
dehydration by LctM, using ATP as a cosubstrate. 
a 
b 
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 Lacticin 481 is a tricyclic class II lantibiotic from the dairy bacterium Lactococcus lactis 
subsp. lactis CNRZ 481, first reported in the early 1990s.
47
  A panel of natural analogues of 
lacticin 481 containing an identical ring topology, including nukacin ISK-1 and members of the 
salivaricins, have been isolated from other Gram-positive bacteria, although little was known 
about the mechanism(s) of antimicrobial activity of this subfamily at the outset at this work.
48
  
Lacticin 481 appears to contain a motif within its A-ring similar to the C-ring of mersacidin (Fig. 
1.6), which is known to be involved in binding the essential peptidoglycan precursor lipid II.
49
  
The in vitro reconstitution of LctM, and its substantial substrate promiscuity, has permitted the 
construction of lacticin 481 analogues and other lanthionine-containing peptides, including those 
bearing non-proteinogenic amino acids.
50-53
  In a synthetic scheme termed in vitro mutasynthesis 
(IVM), synthetic linear LctA analogues can be generated through chemical synthesis, then 
treated with LctM to install the desired modifications (Fig. 2.2); removal of the leader peptide 
with a commercial protease yielded a panel of lacticin 481 analogues containing non-
proteinogenic amino acids, several of which possessed antibacterial activity.
54
  However, the 
number of synthetic manipulations and purifications inherent in this IVM scheme severely 
restricted its throughput and yield, preventing quantitative analysis of SAR, exploration of mode-
of-action, and application to the construction of combinatorial peptide libraries.  Additionally, 
the use of LysC for leader proteolysis resulted in lacticin 481 analogues lacking the N-terminal 
lysine residue, which reduces potency compared to the full-length natural product.
54
 
 
Figure 2.2.  In vitro mutasynthesis of truncated lacticin 481 mutants.  Individually mutated residues are shown in 
the bottom structure.  TBTA, tris-(benzyltriazolylmethyl)amine. 
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In this chapter, an engineered in vitro biosynthetic system is described that overcomes the 
limitations of the IVM approach shown in Fig. 2.2.  This system has both streamlined the 
production of lacticin 481 analogues and also challenged previous beliefs about the role of the 
leader peptide in biosynthesis.  In addition, analogues produced using this system were used to 
determine that, like mersacidin, lacticin 481 inhibits transglycosylation involved in cell wall 
biosynthesis and contains a conserved glutamic acid residue essential for activity.  This work 
was the result of an extensive collaboration with Dr. Trent Oman, a 2011 doctoral graduate of the 
University of Illinois at Urbana-Champaign (UIUC), and experimental support from a number of 
other researchers at UIUC and Harvard University.  The individual contributions of each 
coworker are mentioned throughout the chapter and are listed in detail in the Experimental 
(Section 2.4). 
 
2.2. RESULTS AND DISCUSSION 
 
2.2.1. In trans activity of LctM 
 
 The primary source of inefficiency in the IVM approach described above is the need to 
attach and subsequently remove the leader peptide, which is not incorporated in any fashion into 
the final product.  In the development of LctM-catalyzed IVM, LctM was found to be able to 
process LctA core peptides, although incompletely, when the LctA leader peptide was provided 
in trans, or even in the complete absence of the leader peptide.
55
  To the best of our knowledge, 
the only other reported examples of leader-directed post-translational modification showing in 
trans activity are the vitamin K-dependent γ-carboxylation of glutamate during the maturation of 
the conopeptide conantokin-G,
56
 in vitro dehydration of the labionin-containing lanthipeptide 
catenulipeptin by the class III synthetase AciKC,
43
 in vitro lasso peptide formation in microcin 
J25 by McjB/McjC,
57
 and partial in vivo processing of nisin by NisB/NisC.
58
  These interesting 
observations contest an existing model in leader-directed biosynthesis, that the leader peptide is 
absolutely required for substrate recognition by the biosynthetic machinery.
3-5
  Therefore, 
optimization of the in trans activity of LctM to produce fully-modified lacticin 481 and 
analogues may represent a more efficient and scalable IVM approach. 
 In order to investigate further the in trans activity of LctM, standard solid-phase peptide 
synthesis (SPPS) was used to construct a panel of LctA core peptides (residues 1-27, Fig. 2.3): 
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Figure 2.3.  LctA core peptide sequences synthesized and studied in this chapter.  Modified Ser and Thr residues are 
highlighted in green and purple, respectively, and residues mutated from wild-type are shown in orange.  Nal, 3-(2-
naphthyl)alanine; Pal, 3-(4’-pyridyl)alanine. 
 
the wild-type sequence, a mutant replacing the conserved Glu13 residue (see Section 2.2.6), a 
double mutant N15R/F21H, and three mutants containing non-proteinogenic amino acids (see 
Section 2.2.4).  For initial studies, the N15R/F21H mutant was used due to its improved 
solubility to the wild-type sequence; importantly, the final product obtained after processing of 
this mutant is known to possess comparable antibacterial activity to authentic lacticin 481.
44
  The 
LctA leader peptide (residues -24 to -1, Fig. 2.1), synthesized by SPPS, was provided by Dr. 
Matthew Levengood (UIUC), and LctM was overexpressed in E. coli and purified by Dr. Oman. 
In vitro enzymatic assays were conducted similarly to previous reports:
36, 55, 59
 LctM (2 
μM) and the LctA core peptide substrate (20 μM) were incubated at room temperature in the 
presence of ATP, MgCl2 and pH 7.5 buffer, and substrate dehydration was monitored by matrix-
assisted laser desorption ionization/time-of-flight mass spectrometry (MALDI-TOF MS).  By 
increasing the concentration of the LctA leader peptide from 2 to 20 μM, the in trans activity of 
LctM could be improved to the point where the desired four-fold dehydrated substrate was 
present in substantial amounts, although varying amounts of incompletely processed substrates 
were also present (Fig. 2.4a).  As cyclization cannot be directly monitored by MS, analytical 
high-performance liquid chromatography (HPLC) and antibacterial assays against the indicator 
strain Lactococcus lactis subsp. cremoris HP were used to determine if the desired crosslinks 
were also installed, as all three crosslinks of lacticin 481 are essential for biological activity.
50
  
Indeed, the similar HPLC elution times and antibacterial activities of the purified in trans assay 
product to those of authentic lacticin 481 confirmed complete cyclization (Fig. 2.4b).  This 
represented the first demonstration that a fully processed, biologically active lacticin 481 
analogue could be produced via an in trans enzymatic reaction, as previous in trans reactions 
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Figure 2.4.  In trans activity of LctM to process LctA core peptide N15R/F21H.  (a) MALDI-TOF mass spectra of 
N15R/F21H modified by LctM at varying concentrations of LctA leader peptide.  Final assay concentrations were 
20 μM substrate and 2 μM enzyme, and reactions were run for 3 h.  The number above each peak indicates the 
number of dehydrations; an asterisk indicates a phosphorylated product; SM indicates starting material.  (b) 
Analytical HPLC comparison of purified, four-fold dehydrated product of the in trans LctM reaction (blue) with 
authentic lacticin 481 (red), showing very similar retention times.  Insert: antibacterial activity of the purified 
product (top, 50 μM, 20 μL) and authentic lacticin 481 (bottom, 50 μM, 20 μL) against L. lactis HP. 
 
only produced incompletely processed intermediates.
55
  When compared to the IVM approach in 
Fig. 2.2, this process reduces the number of chemical transformations needed to convert the 
synthetic core peptide substrate to the final product from four to one and also preserves the N-
terminal lysine of lacticin 481 in the final product.  
 
2.2.2. Development of LctCE-(GS)15, a constitutively active leader-LctM fusion enzyme 
 
 The surprising in trans activity of LctM challenges the notion that the leader peptide is 
absolutely required for post-translational modification of LctA.  As the leader and core peptides 
were not covalently linked, a direct role of the leader peptide in substrate recognition is unlikely.  
Instead, binding of the leader peptide to LctM may serve to stabilize or “trap” an active 
conformation of the enzyme, shifting an equilibrium population of conformations from 
predominantly inactive for catalysis to predominantly active, and thus permitting the processing 
of the LctA core peptide with greater efficiency (Fig. 2.5a).
59
  If this model is accurate, then 
covalent attachment of the leader peptide to LctM itself may increase the effective molarity 
 
a b 
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Figure 2.5.  Proposed model of LctM activation by the LctA leader peptide.  (a) LctM is thought to exist as an 
equilibrium population of inactive and active conformations, which is shifted upon binding of the LctA leader 
peptide (red) toward the more active conformation for catalysis.  (b) Tethering the leader peptide to LctM via a 
flexible linker (purple) may result in an enzyme trapped in the active conformation, permitting modification of the 
leaderless LctA core peptide (green).  Figure courtesy of Dr. Trent Oman (UIUC). 
 
between the species and further improve the catalytic activity of the enzyme (Fig. 2.5b).  The 
resulting fusion enzyme would thus possess constitutive activity to modify leaderless core 
peptide substrates.  This design is reminiscent of an approach used successfully to generate a 
constitutively active protease by fusing the NS3 protease/helicase from hepatitis C virus to its 
activator protein.
60
  Additionally, if the linker region between the leader peptide and LctM could 
be made of proteinogenic amino acids, the fusion enzyme could be recombinantly expressed.  
Thus, the overall efficiency of the IVM process could be further improved, as the leader peptide 
would no longer need to be synthesized separately. 
 In order to test this hypothesis of a constitutively active fusion LctM, a series of 
expression constructs were prepared by Dr. Oman, which encoded a hexa-histidine-tagged LctA 
leader peptide sequence fused to the N-terminus of LctM via a flexible linker composed of 
varying numbers of repeating glycine and serine residues.
61
  These fusion enzymes, termed 
LctCE-(GS)n (where n is the number of GlySer repeats), were heterologously expressed in E. coli 
and purified by immobilized metal affinity chromatography.  In vitro reconstitution of enzymatic 
activity, as for the in trans reactions in Section 2.2.1 except omitting the separate leader peptide, 
revealed that these fusion enzymes were able to process the leaderless LctA core peptide, and 
that catalytic efficiency correlated positively with linker length up to (GS)15, the longest linker 
investigated (Fig. 2.6).  In the absence of structural information, the exact influence of linker 
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Figure 2.6.  MALDI-TOF MS analysis of LctA core peptide N15R/F21H processing by LctCE enzymes.  Increasing 
linker length results in progressively improved enzyme efficiency.  Final assay concentrations were 20 μM substrate 
and 2 μM enzyme, and reactions were run for 1 h.  The number above each peak indicates the number of 
dehydrations; as asterisk indicates a phosphorylated product; SM indicates starting material.  Figure courtesy of Dr. 
Trent Oman (UIUC). 
 
length on LctCE efficiency is difficult to ascertain, but it can be speculated that the longer linker 
may allow sufficient conformational freedom for the leader peptide to reach its putative binding 
site in the synthetase. 
 
2.2.3. Comparison of LctCE-(GS)15 and LctM in trans 
 
 In order to provide definitive evidence of the importance of tethering the leader peptide to 
the synthetase, several comparisons between LctCE-(GS)15 and LctM with the leader peptide 
provided in trans were made.  To probe ring formation, aliquots of enzymatic assays were 
treated with 1-cyano-4-dimethylaminopyridinium tetrafluoroborate (CDAP), a thiol-selective 
cyanylating agent;
62, 63
 incomplete ring formation is detected by the presence of cyano adducts of 
the peptide (Fig. 2.7).  At early timepoints in both reaction systems, the dominant species is a 
three-fold dehydrated intermediate, which possesses between one and three crosslinks.  After 60 
min incubation, the four-fold dehydrated species in both systems appears and does not react with 
CDAP.  This indicates that all three cysteines in the fully dehydrated assay product were 
properly cyclized by both LctCE-(GS)15 and LctM in trans.  The four-fold dehydrated assay 
products of both reaction systems could be purified by RP-HPLC and demonstrated nearly 
43 
 
identical mass spectra (Fig. 2.8) and antibacterial activity (Fig. 2.9), final indications that the 
desired lacticin 481 analogues were indeed generated in both cases. 
 
   
   
 
Figure 2.7.  Analysis of ring formation by LctCE-(GS)15 and LctM using CDAP.  MALDI-TOF mass spectra are 
shown for assays of LctA core peptide N15R/F21H modified by LctCE-(GS)15 after (a) 5 min and (b) 60 min, and 
modified by LctM with the leader provided in trans after (c) 5 min and (d) 60 min.  “+xCN” designates x number of 
cyano adducts indicative of incomplete cyclization.  Final assay concentrations were 20 μM substrate and 2 μM 
enzyme, and 20 μM of LctA leader peptide for in trans assays. 
  
a b 
c d 
44 
 
    
Figure 2.8.  MALDI-TOF mass spectra of purified, four-fold dehydrated assay products of LctA core peptide 
N15R/F21H and (a) LctCE-(GS)15 or (b) LctM in trans with 20 μM LctA leader peptide.  Calc. [M+H]
+
 2932.3.  
Sodium adducts are indicated with an asterisk. 
 
              
 
Figure 2.9.  Antimicrobial agar diffusion assay against L. lactis HP for the purified assay product of LctA core 
peptide N15R/F21H incubated with LctCE-(GS)15 or LctM with the leader provided in trans (20 μL aliquots). 
 
 A comparison of processing activity at different time points revealed the superiority of 
LctCE-(GS)15 to LctM in trans for producing fully-modified lacticin 481 analogues (Fig. 2.10).  
While both systems generated the partially-processed, three-fold dehydrated intermediate within 
5 min, conversion to the four-fold dehydrated product proceeded more quickly with LctCE-
(GS)15 (Fig. 2.10a) than with LctM in the presence of a 10-fold excess of LctA leader peptide 
over enzyme (Fig. 2.10b).  Considering that the leader peptide is present in an effective 
stoichiometry of 1:1 with enzyme in the fusion construct, comparison to an in trans system with 
equimolar leader peptide and LctM was appropriate (Fig. 2.10c).  These conditions produced 
only trace amounts of the four-fold dehydrated product after 3 h, highlighting the importance of 
covalently fusing the leader and enzyme in LctCE-(GS)15 for improved catalytic efficiency. 
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Figure 2.10.  Comparison of the relative processing activity of LctA core peptide N15R/F21H by (a) LctCE-(GS)15; 
(b) LctM in trans with excess LctA leader peptide (20 μM); and (c) LctM in trans with equimolar LctA leader 
peptide (2 μM).  Reactions were quenched as the indicated times and analyzed by MALDI-TOF MS.  The number 
above each peak indicates the number of dehydrations; SM indicates starting material.  Final assay concentrations 
were 20 μM substrate and 2 μM enzyme. 
 
2.2.4. Generation of lacticin 481 analogues 
 
 The enzymatic activity of LctCE-(GS)15 to produce a bioactive lacticin 481 analogue 
prompted investigation of its ability to process other LctA core peptide analogues containing 
non-proteinogenic amino acids, as demonstrated for LctM with leader-containing substrates.
51-54
   
Lacticin 481 analogues containing 3-(4’-pyridyl)alanine (Pal) or 3-(2-naphthyl)alanine (Nal) 
were identified previously to possess near wild-type activity (when normalizing for the 
truncation of Lys1 in the IVM approach used).
54
  To examine if LctCE-(GS)15 preserved the 
substrate promiscuity of LctM, several double and triple mutants of the LctA core peptide were 
synthesized containing combinations of the following mutations (Fig. 2.3): Asn15Arg, 
Phe21His, Phe21Pal, and Trp23Nal.  As demonstrated in Fig. 2.11, all four substrates were 
accepted by LctCE-(GS)15, with substantial amounts of the four-fold dehydrated species 
produced.  In most instances, considerable amounts of a three-fold dehydrated intermediate and a 
three-fold dehydrated, singly phosphorylated intermediate were also present.  The incompletely 
processed residue was identified as Thr24,
61
 which is not involved in ring formation but lies 
adjacent to two cysteines that are cyclized.  The high degree of structural complexity in this 
region of lacticin 481, coupled with the lack of a leader peptide attached to the substrate, may 
hinder the enzyme from accessing this residue for phosphorylation or subsequent elimination, 
resulting in these incompletely-processed species.  This observation also agrees with the N-to- 
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Figure 2.11.  MALDI-TOF MS analysis of processing of LctA core peptide mutants by LctCE-(GS)15.  Starting 
material (blue) and crude assay products (red) after 3 h incubation are shown, with major products labeled, for (a) 
N15R/F21H, (b) N15R/F21Pal, (c) N15R/W19Nal/F21H, and (d) N15R/W19Nal/F21Pal.  Figure adapted from the 
doctoral thesis of Dr. Trent Oman (UIUC).
61
 
 
C directionality of processing by LctM proposed in previous work, although those studies were 
performed with full-length LctA substrate.
64
  The four-fold dehydrated assay products could be 
separated from the other reaction products by RP-HPLC, giving pure lacticin 481 analogues on 
half-milligram scales for biological evaluation (Fig. 2.12). 
 Nukacin ISK-1 is a lantibiotic that possesses an identical set of post-translational 
modifications as lacticin 481, but contains a total of seven mutated residues.  To probe further 
the substrate promiscuity of LctCE-(GS)15, the nukacin ISK-1 core peptide NukA(1-27) was 
synthesized and incubated with the fusion enzyme.  While not the dominant species, a substantial 
amount of the fully-processed, four-fold dehydrated species was obtained (Fig. 2.13).  This 
observation fits well with previous experiments that demonstrated LctM could process a 
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Figure 2.12.  MALDI-TOF mass spectra of LctCE-modified, purified lacticin 481 mutants (a) N15R/F21H, (b) 
N15R/F21Pal, (c) N15R/W19Nal/F21H, and (d) N15R/W19Nal/F21Pal.  Figure adapted from the doctoral thesis of 
Dr. Trent Oman (UIUC).
61
 
 
 
Figure 2.13.  MALDI-TOF MS analysis of processing of the NukA core peptide by LctCE-(GS)15.  In the peptide 
sequence, residues mutated from LctA are highlighted in orange. 
a b 
c d 
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chimeric substrate consisting of the LctA leader peptide and NukA core peptide as well as the 
full-length NukA precursor peptide, despite the divergence between their sequences.
59
 
 
2.2.5. Biological activities of lacticin 481 analogues 
 
 With these purified lacticin 481 analogues in hand, an analysis of biological activity was 
performed by Dr. Trent Oman (UIUC).  Whole-cell growth inhibition assays against the sensitive 
strain L. lactis HP (Fig. 2.14) demonstrated that the lacticin 481 double mutants N15R/F21H 
(IC50 = 428 ± 21 nM) and N15R/F21Pal (213 ± 9 nM) possessed improved antibacterial potency 
compared to the authentic compound (785 ± 19 nM).  In addition, the triple mutants 
N15R/W19Nal/F21H (1370 ± 48 nM) and N15R/W19Nal/F21Pal (2420 ± 60 nM) were found to 
be weaker growth inhibitors, giving a range of potencies over an order of magnitude with 
authentic lacticin 481 as the median. 
As mentioned in Section 2.1, lacticin 481 appears to contain within its A-ring the 
mersacidin-like lipid II binding motif (TXS/TXD/EC, where X is any residue), which is also 
present in several other class II lantibiotics known to interact with lipid II and disrupt 
 
 
Figure 2.14.  Quantitative growth inhibition analysis for authentic lacticin 481 and analogues against L. lactis HP in 
liquid culture.  Calculated IC50 values are shown in the legend.  Error bars represent the standard deviation from 
triplicate experiments.  Figure courtesy of Dr. Trent Oman (UIUC). 
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peptidoglycan biosynthesis (Fig. 1.6).
65-68
  Evidence that lacticin 481 forms complexes with lipid 
II was first provided in 2009 using thin-layer chromatography (TLC);
69
 more recently, a binding 
interaction between lipid II and nukacin ISK-1, which has an identical ring topology to lacticin 
481, was quantitatively determined using isothermal titration calorimetry.
70
  These observations 
suggested that lacticin 481 likely exerts its antibacterial activity, at least in part, via binding lipid 
II and inhibiting peptidoglycan formation.  Therefore, Dr. Oman, in collaboration with Dr. Tania 
Lupoli and Prof. Suzanne Walker (Harvard Medical School), investigated whether the changes in 
antibacterial potency seen in the panel of lacticin 481 analogues could be correlated with 
inhibition of transglycosylation using an established TLC-based assay.
71
  The transglycosylase 
PBP1b from Escherichia coli and a radiolabeled analogue of lipid II were incubated with lacticin 
481 and analogues, and the inhibition of transglycosylation was quantitated (Fig. 2.15).  The 
double mutants N15R/F21H (IC50 = 7.0 ± 2.9 μM) and N15R/F21Pal (5.4 ± 1.2 μM) exhibited 
stronger inhibition than lacticin 481 (12 ± 2.3 μM), while the triple mutants 
N15R/W19Nal/F21H (27 ± 5.6 μM) and N15R/W19Nal/F21Pal (105 ± 34 μM) were weaker 
inhibitors.  These results correlate strongly with the whole-cell antibacterial potencies measured 
in Fig. 2.14 and are similar to the IC50 values determined for known lipid II binders haloduracin 
 
 
Figure 2.15.  Inhibition of PBP1b-catalyzed peptidoglycan (PG) formation by authentic lacticin 481 and analogues, 
at 4 μM lipid II and 100 nM PBP1b.  Calculated IC50 values are shown in the legend.  Error bars represent the 
standard deviation from triplicate experiments.  Figure courtesy of Dr. Trent Oman (UIUC). 
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and ramoplanin using the same assay.
68, 72
  Furthermore, a whole-cell microscopy study has 
recently demonstrated that fluorescently-labeled lipid II localizes to the membrane in the same 
manner as known lipid II binders.
73
  Taken together, these results strongly suggest that lacticin 
481 exerts its biological activity via binding lipid II and inhibiting peptidoglycan biosynthesis. 
 
2.2.6. Determination of the importance of Glu13 for antibacterial activity 
 
 The mersacidin-like lipid II binding motif (see Section 2.2.5) contains a conserved 
aspartate/glutamate residue that has been established in multiple instances as critical for 
antibacterial activity; mutation to a non-acidic residue abolishes or severely attenuates the 
activity of a variety of class II lantibiotics.
23, 68, 74, 75
  A previous report stating that the same 
conserved residue in lacticin 481, Glu13, could be mutated without substantial loss in activity
59
 
was therefore surprising and merited additional investigation.  LctA core peptides representing 
the wild-type sequence and an E13A mutant (Fig. 2.3) were synthesized by SPPS, and 
incubation with LctCE-(GS)15 resulted in production of the four-fold dehydrated product as well 
as several incompletely processed intermediates (Fig. 2.16).  It should be noted that these assays 
proceeded substantially less to completion than assays with the double/triple mutants (Fig. 2.11).  
This reduced efficiency is likely due to the decreased solubility of the substrate under these assay 
conditions, as has been discussed previously.
44
  The crude enzymatic assays for these substrates, 
as well as the more soluble N15R/F21H mutant, were applied to a lawn of L. lactis to test for  
  
    
Figure 2.16.  MALDI-TOF MS analysis of LctA core peptide processing by LctCE-(GS)15.  Crude assay products 
are shown after 8 h incubation, with major products labeled for (a) wild-type and (b) E13A LctA core peptides. 
a b 
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antibacterial activity; unlike the modified wild-type and N15R/F21H peptides, the modified 
E13A mutant possessed no discernible activity (Fig. 2.17).  With regard to the previous study 
demonstrating activity for lacticin 481 E13A,
59
 the amount of peptide used in the bioassay was 
not quantified, and a relatively high concentration may have inadvertently been applied that gave 
the impression of preserved activity.  In the case of haloduracin α, the corresponding E22Q 
mutant was 40-fold less potent than the wild-type, but nonetheless did possess observable 
activity.
68
  In all, these experiments provided further evidence that lacticin 481 behaves similarly 
to other class II lantibiotics containing the mersacidin-like lipid II binding motif. 
 
Figure 2.17.  Antimicrobial agar diffusion assay against L. lactis HP for crude LctCE-(GS)15 assay products (100 
μM total peptide concentration, 20 μL) and authentic lacticin 481 (50 μM, 20 μL). 
 
2.2.7. Lacticin 481 analogue activity against L. lactis CNRZ 481 
 
 One of the inherent complications of in vivo mutagenesis of lantibiotics is the potential 
for exceptionally potent or highly mutated variants to circumvent the producing cell’s immunity 
mechanisms, killing the cell and preventing discovery in activity screens.
76, 77
  However, in the 
context of developing better clinical antibiotics, such lantibiotics would be of great interest, as 
they are already capable of overcoming a natural resistance mechanism.  In this light, the two 
lacticin 481 analogues with improved potency (N15R/F21H and N15R/F21Pal, Fig. 2.14) were 
tested for their ability to kill the natural lacticin 481 producing strain, L. lactis subsp. lactis 
CNRZ 481.  This strain expresses an ABC transporter complex LctFEG critical for immunity to 
lacticin 481, likely through expulsion of the compound from the membrane.
78
  Crude LctCE-
(GS)15 assay products were applied to lawns of L. lactis 481, and despite their potent activity 
against the sensitive non-producer L. lactis HP, neither of the double mutants showed 
substantially improved activity compared to wild-type against the producing strain (Fig. 2.18).  
While the rather modest alterations in the double mutants were not enough to evade the natural 
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Figure 2.18.  Antimicrobial agar diffusion assays against (a) L. lactis HP and (b) lacticin 481 producer L. lactis 481 
for crude LctCE-(GS)15 assay products (100 μM total peptide concentration, 20 μL), authentic lacticin 481 (50 μM, 
20 μL), and nisin (10 μM, 20 μL). 
 
immunity mechanisms, it is feasible that continued diversification of lacticin 481 analogues 
using this chemoenzymatic platform may produce variants able to kill the producing organism. 
 
2.2.8. Flow cytometry analysis of lacticin 481 membrane disruption 
 
 In addition to disrupting cell wall biosynthesis, several lantibiotics have been 
demonstrated to form pores in the membranes of susceptible bacterial strains, using lipid II as a 
docking molecule.  This phenomenon has been best characterized in the class I lantibiotic nisin
79-
81
 and the two-component class II systems lacticin 3147
66
 and haloduracin.
67, 68
  The combination 
of pore formation and inhibition of cell wall biosynthesis, mediated by lipid II binding, is critical 
for the full potency of these molecules.  Indeed, several nisin variants unable to form pores still 
possess antimicrobial activity, although up to 100-fold less potent than the parent molecule.
82
  
However, shorter lantibiotics such as mersacidin and mutacin 1140 are able to exert potent 
biological activity without forming pores, perhaps dictated by stronger affinity for lipid II.
81, 83, 84
 
To determine if lacticin 481 forms membrane-disrupting pores, two complementary flow 
cytometry assays were performed (Fig. 2.19).  In the first, the membrane potential-sensitive 
fluorescent dye 3,3’-diethyloxacarbocyanine iodide (DiOC2(3)) was used to monitor changes in 
membrane polarization in the presence of lacticin 481 or nisin.
85
  Bacillus subtilis ATCC 6633 
was used in these experiments due to the relatively similar potencies of lacticin 481 (IC50 = 980 
± 110 nM, determined by Ms. Chantal Garcia de Gonzalo, UIUC) and nisin (410 ± 170 nM)
67
 
against this organism, allowing for a direct comparison.  Over a concentration range of 0.2 to 20 
μM, nisin showed the expected concentration-dependent decrease in cell-associated mean 
fluorescence intensity (MFI) indicative of membrane depolarization and pore formation, while 
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Figure 2.19.  Flow cytometry analysis of membrane disruption by lacticin 481 and nisin.  (a) Membrane 
depolarization of Bacillus subtilis 6633 as measured by DiOC2(3) mean fluorescence intensity (MFI).  At each 
lantibiotic concentration, the difference in average MFI of triplicate measurements between lacticin 481 and nisin 
was statistically significant (P < 0.05).  (b) Representative histogram of cell count versus DiOC2(3) fluorescence 
intensity.  (c) Membrane permeability of L. lactis HP as measured by propidium iodide (PI) uptake, demonstrating 
pore formation for nisin at a concentration 15-fold above its IC50 value, but no such response for lacticin 481 at 
concentrations up to 25-fold above its IC50 value.  (d) Representative histogram of cell count versus PI fluorescence 
intensity. 
 
lacticin 481 gave no decrease in MFI (Fig. 2.19a-b).  Interestingly, at the highest lacticin 481 
concentration tested, cells exhibited a membrane hyperpolarization; this may represent a cell 
stress response, as has been reported for rifampicin-resistant Mycobacterium.
86
  A membrane 
integrity assay was also performed using L. lactis HP and the fluorescent dye propidium iodide, 
which can only accumulate in cells in the presence of a pore-forming agent.
87
  While nisin gave a 
large increase in MFI at a concentration 15-fold above its IC50 value indicative of pore 
formation, lacticin 481 did not induce increases in MFI above control levels at concentrations up 
to 20 μM, or 25-fold above its IC50 value (Fig. 2.19c-d).  Taken together, these data suggest that 
a c 
b d 
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lacticin 481 does not form membrane-associated pores, and that inhibition of peptidoglycan 
formation is the most likely mechanism of its antibacterial activity. 
 
2.2.9. Development of a constitutively-active serine/threonine kinase 
 
 The production of peptides and proteins with specific sites of phosphorylation has been 
widely explored in order to investigate the role of phosphorylation in a myriad of signal 
transduction pathways.
88-90
  The observation that LctM first phosphorylates its substrate, then 
eliminates the resulting phosphoester to generate α,β-unsaturated residues, was exploited in 
previous work to develop a leader peptide-dependent serine/threonine kinase; two elimination-
deficient mutants of LctM, R399M and T405A, were able to phosphorylate a wide variety of 
peptides attached to the LctA leader peptide.
91
  To determine if the corresponding mutations in 
LctCE-(GS)15 were able to phosphorylate leaderless substrates, ten diverse serine- or threonine-
containing peptides, including known substrates of endogenous kinases,
92-97
 were generated by 
SPPS (see Section 2.4.8).  Incubation of these potential substrates with LctCE-(GS)15 T405A by 
Dr. Oman resulted in phosphorylation in three of the ten peptides: the AKT/PKB substrate, the 
PKCμ substrate, and synthetic peptide RWVRSALLI.61  While it was encouraging that this 
enzyme was able to accept several leaderless peptides with no relation to its natural substrate, the 
system lacked the broad promiscuity necessary for development as a general serine/threonine 
kinase. 
 
2.3. CONCLUSIONS AND OUTLOOK 
 
 This chapter has described a unique approach to biosynthetic engineering of RiPPs: 
construction of a fusion leader-synthetase enzyme, LctCE-(GS)15, which is able to process 
synthetic substrates lacking a leader peptide to produce analogues of the lantibiotic lacticin 481 
in a single step.  This in vitro chemoenzymatic platform possesses dramatically improved 
efficiency and scale compared to previous in vitro systems (as in Fig. 2.2), as the leader peptide 
no longer needs to be attached to, and subsequently removed from, the core peptide substrate.  
Importantly, these substrates were amenable to standard SPPS, allowing the freedom to include a 
variety of non-proteinogenic amino acids in order to explore a wide chemical space.  Of the 
small panel of lacticin 481 analogues produced so far, two have already demonstrated improved 
antibacterial potency compared to the authentic natural product.  Additionally, analogues 
55 
 
produced using this biosynthetic platform have been used to investigate the mode-of-action of 
lacticin 481, which was found to inhibit transglycosylation involved in cell wall biosynthesis 
without forming membrane-associated pores. 
Larger-scale SAR analysis of lacticin 481, made possible by this technology, may permit 
the discovery of additional analogues with further improved pharmacological properties.  In 
order to produce interesting analogues in larger quantities for more detailed investigation, in vivo 
expression in E. coli can be used, incorporating non-proteinogenic amino acids via stop-codon 
suppression.
29, 31, 98
  In the case of lacticin 481, in vivo coexpression of LctA and LctM, followed 
by ex vivo leader peptide proteolysis to produce lacticin 481 ΔLys1 and mutants, has been 
carried out successfully by Mr. Noah Bindman (UIUC),
73, 99
 demonstrating the validity of this 
combined process to discover and scale-up improved lacticin 481 analogues. 
 Many questions remain answered surrounding the enzymatic activity of the fusion LctCE 
enzyme.  Does LctCE preserve the N-to-C directionality of LctM when processing natural, full-
length LctA?
64
  Can the leader-linker region be further optimized, including attachment to the 
enzyme elsewhere besides the N-terminus, to produce an even more active synthetase or 
serine/threonine kinase?  Biophysical and structural data detailing the leader-LctM interaction, 
which to date have not been successfully obtained, would greatly facilitate further optimization.  
Finally, can this fusion approach be applied to other lanthipeptides, or to unrelated leader-
directed biosynthetic systems?  Efforts to construct a constitutively-active haloduracin synthetase 
by Drs. Trent Oman and Rebecca Splain (UIUC, unpublished results) have not yet been 
successful in producing fully-modified haloduracin β, though this compound contains 
considerably more modifications (seven dehydrations and four cyclizations) than lacticin 481.
39
  
Preliminary results suggest that in trans activity of the parent synthetase may be able to predict 
an active fusion enzyme, although this hypothesis requires further investigation. 
 
2.4. EXPERIMENTAL 
 
2.4.1. Materials and general methods 
 
 Construction of expression plasmids, expression, and purification of LctCE enzymes 
were performed by Dr. Trent Oman (UIUC).
61, 99
  His6-LctM was expressed and purified by Dr. 
Oman using the known expression plasmid pET28b LctM.
36
  Authentic lacticin 481 was 
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provided by Dr. Juan Velásquez (UIUC) after isolation from Lactococcus lactis subsp. lactis 
CNRZ 481.
99, 100
  Lacticin 481 leader peptide (LctA -24–-1) was provided by Dr. Matthew 
Levengood (UIUC).
55
  Nisin was purified from Nisaplin, purchased from Danisco A/S, by Ms. 
Chantal Garcia de Gonzalo (UIUC) using a known procedure.
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Standard Fmoc-amino acids and resins for solid-phase peptide synthesis (SPPS), peptide 
coupling reagents N,N’-diisopropylcarbodiimide (DIC), O-(6-chlorobenzotriazol-1-yl)-
N,N,N’,N’-tetramethyluronium hexafluorophosphate (HCTU), and 1-hydroxybenzotriazole 
monohydrate (HOBt), and non-proteinogenic amino acids Fmoc-3-(4’-pyridyl)-L-alanine (Fmoc-
Pal-OH) and Fmoc-3-(2-naphthyl)-L-alanine (Fmoc-Nal-OH) were purchased from ChemImpex 
International.  Other chemicals and solvents for peptide synthesis, enzymatic reactions, and 
chromatography were purchased from Sigma Aldrich, ChemImpex International, or Fisher 
Scientific, and used without further purification.  Flow cytometry dyes 3,3'-
diethyloxacarbocyanine iodide (DiOC2(3)) and propidium iodide (PI) were purchased from 
Invitrogen/Life Technologies.  Cell culture media were purchased from BD Biosciences.   
Analytical reversed-phase high-performance liquid chromatography (RP-HPLC) was 
performed on a Beckman System Gold analytical HPLC system equipped with a Phenomenex 
Jupiter Proteo C12 (90 Å pore size, 250 mm × 4.6 mm × 10 μm) analytical column at a flow rate 
of 1 mL/min and a solvent gradient of 2-100% solvent B over 45 min, observing at an 
absorbance of 220 nm.  Preparatory RP-HPLC was performed using a Waters Delta 600 system 
equipped with a Vydac Delta-Pak C18 (100 Å pore size, 100 mm × 25 mm) column and a flow 
rate of 8 mL/min or a Phenomenex Jupiter Proteo C12 (90 Å pore size, 250 mm × 15 mm × 10 
μm) column and a flow rate of 10 mL/min.  Solvent gradients are described for each peptide.  All 
HPLC solvents were filtered with a Millipore filtration system equipped with a 0.22 μm nylon 
membrane filter prior to use.  HPLC solvent compositions: solvent A is 0.1% trifluoroacetic acid 
(TFA) in H2O; solvent B is 80:20 MeCN/H2O with 0.087% TFA. 
Peptides were analyzed by matrix-assisted laser desorption ionization/time-of-flight 
(MALDI-TOF) mass spectrometry using an Applied Biosystems Voyager DE-STR spectrometer 
or a Bruker Daltonics UltrafleXtreme TOF/TOF spectrometer at the Mass Spectrometry Facility 
(UIUC) in a matrix solution consisting of saturated α-cyano-4-hydroxycinnamic acid in 1:1:0.1 
H2O/MeCN/TFA.  If desalting was required prior to MS analysis, samples were desalted using 
Millipore ZipTipC18 pipette tips and eluted with matrix solution. 
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2.4.2. Synthesis of LctA core peptide and analogues 
 
Automated Fmoc-based SPPS was performed using either a CEM Liberty microwave 
peptide synthesizer or an Advanced ChemTech Apex 396 peptide synthesizer at scales of 0.05-
0.15 mmol on Fmoc-Ser(
t
Bu)-Wang polystyrene resin.  For the Liberty, Fmoc deprotection was 
performed using 20% piperidine in dimethylformamide (DMF; 7 mL) for two treatments of 1.5 
min each, and couplings were performed using 0.2 M Fmoc-amino acid in DMF (2.5 mL), 0.5 M 
HCTU in DMF (1 mL), and 2 M diisopropylethylamine in N-methylpyrrolidinone (0.5 mL) for 5 
min.  For the Apex, Fmoc deprotection was performed using 20% piperidine in DMF (4 mL) for 
two treatments of 6 min each, and couplings were performed using 0.35 M Fmoc-amino 
acid/0.38 M HOBt in DMF (2 mL), 0.38 M DIC in DMF (2 mL), and DMF (0.5 mL) for one 
treatment of 1.5 h with an additional treatment if necessary.  Solutions containing Fmoc-Pal-OH 
required at least 15% dimethylsulfoxide in DMF to achieve full solubility.  After the synthesis 
was completed, the resin-bound peptide was washed with CH2Cl2 and dried.  Concurrent side-
chain deprotection and cleavage from resin was performed by stirring the resin-bound peptide in 
91.5:5:2.5:1 TFA/water/triisopropylsilane/ethanedithiol for 2 h under N2.  After removing the 
cleaved resin by filtration, the filtrate was concentrated under a stream of N2.  The peptide was 
precipitated with cold Et2O, isolated by centrifugation at 12,000 ×g, dissolved in 1:1 
H2O/MeCN, and lyophilized to dryness.  The crude peptides were purified by RP-HPLC, 
employing the solvent gradients listed below, and fractions containing purified material were 
lyophilized to dryness.  See also Notebook I, pages 68, 73-75, 84, 86; Notebook II, pages 96-97; 
Notebook III, page 7; Notebook IX, pages 29, 31, 43-44. 
LctA core wild type.  Sequence: H-KGGSGVIHTISHECNMNSWQFVFTCCS-OH.  RP-
HPLC: Phenomenex Jupiter Proteo C12 column and a solvent gradient of 10% solvent B for 1 
min, 10-20% over 3 min, 20-48% over 28 min, 48-100% over 1 min.  Rt = 28.3-29.1 min.  
HRMS (MALDI-TOF) calc. [M+H]
+
 for C127H191N36O39S4 2972.295, found 2972.444. 
LctA core E13A.  RP-HPLC: same conditions as LctA core wild type.  Rt = 28.9-29.6 
min.  HRMS (MALDI-TOF) calc. [M+H]
+
 for C125H189N36O37S4 2914.289, found 2914.246.   
LctA core N15R/F21H.  RP-HPLC: Vydac Delta-Pak C18 column and a solvent gradient 
of 2% solvent B for 2 min, 2-20% over 2 min, 20-27% over 3 min, 27-42% over 30 min, 42-
100% over 1 min.  Rt = 29.8-31.0 min.  LRMS (MALDI-TOF) calc. [M+H]
+
 3004.3, found 
3004.4. 
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LctA core N15R/F21Pal.  RP-HPLC: Vydac Delta-Pak C18 column and a solvent 
gradient of 2% solvent B for 2 min, 2-18% over 3 min, 18-25% over 3 min, 25-40% over 30 min, 
40-100% over 1 min.  Rt = 34.0-35.6 min.  LRMS (MALDI-TOF) calc. [M+H]
+
 3015.3, found 
3015.4. 
LctA core N15R/W19Nal/F21H.  RP-HPLC: same conditions as LctA core N15R/F21H.  
Rt = 33.5-36.2 min.  LRMS (MALDI-TOF) calc. [M+H]
+
 3015.3, found 3016.3. 
LctA core N15R/W19Nal/F21Pal.  RP-HPLC: same conditions as LctA core N15R/F21H.  
Rt = 35.1-36.5 min.  LRMS (MALDI-TOF): calc. [M+H]
+
 3026.3, found 3027.1. 
NukA core.  Sequence: H-KKKSGVIPTVSHDCHMNSFQFVFTCCS-OH.  RP-HPLC: 
Vydac Delta-Pak C18 column and a solvent gradient of 2% solvent B for 1 min, 2-20% over 2 
min, 20-27% over 3 min, 27-43% over 34 min, 43-100% over 1 min.  Rt = 37.2-38.6 min.  
LRMS (MALDI-TOF): calc. [M+H]
+
 3031.6, found 3031.4. 
 
2.4.3. In vitro reconstitution of LctM and LctCE enzymatic activity 
 
Assays were performed in collaboration with Dr. Oman.
61
  For in trans LctM assays, 
LctA core peptide (final concentration 20 µM) and LctA leader peptide (2 or 20 μM) were 
incubated with purified His6-LctM (2 μM) at 25 
o
C for 3-24 h in a buffer (pH 7.5) consisting of 
50 mM Tris, 10 mM MgCl2, 2 mM ATP, and 25 µg/mL bovine serum albumin.  The extent of 
reaction was monitored by periodically removing aliquots (9 μL) of the reaction, which were 
quenched by the addition of 5% aqueous TFA (1 μL; final pH 1-2), desalted by ZipTipC18, and 
analyzed by MALDI-TOF MS.  For LctCE assays, the above components and concentrations 
were used except the leader peptide was omitted and purified LctCE enzyme was used in place 
of His6-LctM.  See also Notebook I, page 98; Notebook VIII, page 37-41; Notebook IX, pages 
47-48, 61-62. 
For examination of ring formation with 1-cyano-4-dimethylaminopyridinium 
tetrafluoroborate (CDAP), aliquots (9 μL) of the above reactions were removed after 5 min or 60 
min incubation and quenched by the addition of 1% aqueous TFA (0.5 μL).  A solution of 1 mM 
tris(2-carboxyethyl)phosphine/100 mM citrate/pH 3 (10 μL) was added and incubated for 5 min.  
A solution of 200 mM CDAP/100 mM citrate/pH 3 (10 μL) was then added and incubated for 15 
min.  The assays were desalted and analyzed as above.  See also Notebook VIII, page 45. 
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For preparative reactions, the total reaction volume was scaled to 5-20 mL and allotted 
into a series of 1-1.5 mL aliquots due to issues of substrate aggregation at large volumes.  The 
extent of reaction was monitored by MS as above.  After 12 h, starting material was generally 
consumed, at which time the aliquots were pooled, quenched by the addition of TFA (0.5% final 
concentration), and concentrated to ~1/4 volume by lyophilization.  The concentrated reaction 
mixture was centrifuged at 12,000 ×g to remove any insoluble material, and the resulting 
supernatant was purified by RP-HPLC using a Phenomenex Jupiter Proteo C12 column and a 
solvent gradient of 10% solvent B for 5 min, then 10-100% over 45 min.  Lacticin 481 analogues 
and partially processed intermediates eluted at 20.8-22.5 min.  All fractions were analyzed by 
MALDI-TOF MS as described above, and purified material was lyophilized to dryness.  See also 
Notebook II, pages 36-37; Notebook VIII, pages 42-44, 48-49. 
 
2.4.4. Solid culture growth inhibition assays 
 
Enzymatic assays (100 μL total volume) were lyophilized to dryness and taken up in 
sterile deionized water (SDW, 20 μL).  Cultures of Lactococcus lactis subsp. cermoris HP 
(ATCC 11602) or Lactococcus lactis subsp. lactis CNRZ 481 were grown at 30 
o
C in GM17 
medium (40 g/L M17, 0.5% glucose) for 12-18 h, then diluted with fresh GM17 to an optical 
density at 600 nm (OD600) of 1.0.  An aliquot of this culture (200 μL) and 20% aqueous glucose 
(500 μL) were added to melted and cooled GM17 containing 1.5% agar (20 mL), poured into a 
sterile Nunc dish and allowed to solidify over 20 min.  Another aliquot of culture (300 μL) and 
20% glucose (750 μL) were added to melted and cooled GM17 agar (30 mL) and poured over the 
first agar layer.  A sterile 96-well PCR tube rack was placed in this second layer, which was 
allowed to solidify over 30 min.  The rack was removed, and the agar was allowed to solidify 
over an additional 1 h.  Redissolved assays were spotted into individual wells, and the plate was 
incubated at room temperature for 12-24 h, then analyzed.  See also Notebook II, pages 5-6; 
Notebook VIII, pages 35, 51; Notebook IX, pages 33-34, 47-48, 61-62. 
 
2.4.5. Liquid culture growth inhibition assays 
 
Stock concentrations of lacticin 481 and analogues were generated by weighing 
lyophilized peptide using a Mettler-Toledo MT5 microbalance and dissolving in SDW to give 
200 μM stock solutions.  Serial two-fold dilutions of peptide stock solutions were prepared in 
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SDW to give 4x working concentrations.  Cultures of Lactococcus lactis subsp. cremoris HP 
were grown at 30 
o
C in GM17 medium for 12-18 h, then diluted with fresh GM17 to an OD600 of 
0.1.  Experiments were performed in triplicate in Corning-Costar 96-well flat-bottom assay 
plates.  Experimental wells contained diluted culture (150 μL) and 4x peptide solution (50 μL).  
Control wells contained either fresh GM17 (150 μL) and SDW (50 μL, negative control) or 
diluted culture (150 μL) and SDW (50 μL, positive control).  OD600 was recorded at hourly 
intervals using a BioTek Synergy H4 plate reader, and plates were incubated at 30 
o
C between 
readings.  Plots of blank-corrected OD600 vs. peptide concentration were fitted to a dose-response 
function with the equation: y = A1 + (A2-A1) / (1 + 10
(logx0 – x)p
), where p = variable Hill slope.  
Half maximal inhibitory concentration (IC50) values were calculated from this fit for each 
peptide after 5 h incubation, and triplicate calculations were averaged.  Assays were performed 
in collaboration with Dr. Oman.
61
  See also Notebook II, pages 43-45. 
 
2.4.6. Inhibition of transglycosylation by lacticin 481 analogues 
 
Thin-layer chromatography-based transglycosylation assays using the transglycosylation 
enzyme PBP1b from Escherichia coli and a [
14
C]GlcNAc-labeled heptaprenyl lipid II analogue 
were performed by Dr. Oman in collaboration with Dr. Tania Lupoli and Prof. Suzanne Walker 
(Harvard Medical School) as previously described.
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2.4.7. Flow cytometry analysis of membrane disruption 
 
For membrane potential assays using 3,3'-diethyloxacarbocyanine iodide (DiOC2(3)), 
cultures of Bacillis subtilis ATCC 6633 were grown at 37 
o
C in LB medium for 12-18 h, then 
diluted with fresh LB to an OD600 of 0.1.  Cells were combined with DiOC2(3) (final 
concentration 2 μM), HEPES (1 mM), and glucose (1 mM) and incubated for 20 min at room 
temperature.  Stock solutions of nisin or lacticin 481 were added to final concentrations of 0.2, 
2.0, or 20 μM and incubated for an additional 15 min prior to analysis; in the negative control, 
SDW was added instead of antibiotic.  Changes in cell-associated DiOC2(3) fluorescence were 
measured with a BD Biosciences LSR II flow cytometer at the Roy J. Carver Biotechnology 
Center (UIUC), using excitation at 488 nm with an argon laser and measurement of emission 
through a band-pass filter at 530/30 nm.  A minimum of 50,000 events were detected for each 
sample, and experiments were performed in triplicate.  Data analysis to calculate the geometric 
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mean fluorescence intensity (MFI) of gated cell populations was performed using FCS Express 
3.00.0311 V Lite Stand-alone software.  Assays involving B. subtilis were performed in 
collaboration with Ms. Garcia de Gonzalo. 
For membrane permeability assays using propidium iodide (PI), cultures of Lactococcus 
lactis subsp. cremoris HP were grown at 30 
o
C in GM17 medium for 12-18 h, then diluted with 
fresh GM17 to an OD600 of 0.1.  Cells were combined with PI (final concentration 25 μM), 
HEPES (1 mM), glucose (1 mM), and lacticin 481 (0, 0.2, 2.0, 20 μM) or nisin (0.2 μM), 
incubated for 15 min at room temperature, and analyzed.  Data acquisition and analysis were 
performed as for membrane potential assays, except emission was measured through a band-pass 
filter at 695/40 nm.  See also Notebook IX, pages 90-91, 97-98. 
 
2.4.8. Synthesis of phosphopeptide precursors 
 
 Serine/threonine-containing peptides for phosphorylation studies were synthesized via 
automated Fmoc-SPPS using an Advanced ChemTech Apex 396 synthesizer as described for 
LctA core peptide analogues (Section 2.4.2) and purified by RP-HPLC using a Vydac Delta-Pak 
C18 column and solvent gradients as described for each peptide.  Phosphorylation assays with 
LctCE-(GS)15 T405A  were performed by Dr. Oman.
61
  See also Notebook III, 42-43, 47-49, 79, 
82-91. 
AKT/PKB substrate.
92
  Sequence: H-ARKRERTYSFGHHA-OH.  RP-HPLC gradient: 
2% solvent B for 1 min, 2-10% over 2 min, 10-14% over 2 min, 14-26% over 24 min, 26-100% 
over 1 min.  Rt = 21.2-22.3 min.  LRMS (MALDI-TOF): calc. [M+H]
+
 1715.9, found 1716.3. 
Calcineurin/PP2B substrate.
93
  Sequence: H-DLDVPIPGRFDRVSVAAE-OH.  RP-
HPLC gradient: 2% solvent B for 1 min, 2-16% over 2 min, 16-20% over 2 min, 20-35% over 30 
min, 35-100% over 1 min.  Rt = 31.4-32.5 min.  LRMS (MALDI-TOF): calc. [M+H]
+
 2112.1, 
found 2113.0. 
PKCδ substrate.94  Sequence: H-RDMRQTVAVGVIKA-OH.  RP-HPLC gradient: 2% 
solvent B for 1 min, 2-14% over 2 min, 14-18% over 2 min, 18-33% over 30 min, 33-100% over 
1 min.  Rt = 26.2-26.9 min.  LRMS (MALDI-TOF): calculated [M+H]
+
 1543.9, found 1544.6. 
PKG substrate.
95
  Sequence: H-RKRSRAE-OH.  RP-HPLC gradient: 2% solvent B for 1 
min, 2-8% over 2 min, 8-18% over 20 min, 18-100% over 1 min.  Rt = 11.0-12.4 min.  LRMS 
(MALDI-TOF): calculated [M+H]
+
 902.5, found 902.7. 
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PKC substrate.
96
  Sequence: H-RRGRTGRGRRGIFR-OH.  RP-HPLC gradient: same as 
for AKT/PKB substrate.  Rt = 21.8-23.6 min.  LRMS (MALDI-TOF): calculated [M+H]
+
 1701.0, 
found 1701.3. 
PKCµ substrate.
97
  Sequence: H-AALVRQMSVAFFFK-OH.  RP-HPLC gradient: 2% 
solvent B for 1 min, 2-24% over 2 min, 24-28% over 2 min, 28-43% over 32 min, 43-100% over 
1 min.  Rt = 34.3-35.1 min.  LRMS (MALDI-TOF): calculated [M+H]
+
 1614.9, found 1615.2. 
Synthetic peptide 1.
91
  Sequence: H-RWVRSALLI-OH.  RP-HPLC gradient: 2% solvent 
B for 1 min, 2-20% over 2 min, 20-24% over 2 min, 24-39% over 30 min, 39-100% over 1 min.  
Rt = 32.4-33.5 min.  LRMS (MALDI-TOF): calculated [M+H]
+
 1113.7, found 1114.1. 
Synthetic peptide 2.
91
  Sequence: H-RLIKSFAYV-OH.  RP-HPLC gradient: 2% solvent 
B for 1 min, 2-18% over 2 min, 18-22% over 2 min, 22-37% over 30 min, 37-100% over 1 min.  
Rt = 25.9-27.3 min.  LRMS (MALDI-TOF): calculated [M+H]
+
 1096.6, found 1096.9. 
Synthetic peptide 3.
91
  Sequence: H-RLIKTFAYV-OH.  RP-HPLC gradient: same as for 
synthetic peptide 2.  Rt = 26.4-28.0 min.  LRMS (MALDI-TOF): calculated [M+H]
+
 1110.7, 
found 1110.9. 
Synthetic peptide 4.
91
  Sequence: H-LRRASVA-OH.  RP-HPLC gradient: same as for 
PKG substrate.  Rt = 20.3-21.7 min.  LRMS (MALDI-TOF): calculated [M+H]
+
 772.5, found 
773.7. 
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CHAPTER 3: CHEMICAL SYNTHESIS OF LANTIBIOTICS AND ANALOGUES
*,†
 
 
3.1. INTRODUCTION 
 
 As presented in Chapters 1 and 2, the engineering of lanthipeptides and lantibiotics has 
advanced greatly in recent years due largely to efforts in understanding and manipulating their 
biosynthetic machinery with powerful in vivo and in vitro platforms.
1-5
  As many of the enzymes 
involved in lanthipeptide maturation have demonstrated substantial substrate promiscuity, panels 
of mutants and analogues have been produced in these ways, including those containing non-
proteinogenic amino acids
6-10
 and additional or alternative crosslinks.
11-13
  These libraries have 
been vital to systematic studies of structure-activity relationships, mechanisms-of-action, and 
stability.  However, to date many lantibiotics remain unexplored in this regard as a result of a 
lack of genetic tools to alter the natural producing organism or an inability to reconstitute the 
biosynthetic pathway in vitro or in heterologous hosts.  Additionally, the generation of mutants 
using in vivo expression systems can be complicated at multiple stages, including post-
translational modification of the precursor peptide, export from the cell, and host immunity,
14, 15
 
which may preclude the discovery of interesting analogues. 
As an alternative to in vivo and in vitro biosynthetic platforms, chemical synthesis of 
lantibiotics presents the ability to remove all dependence on the biosynthetic machinery.
16, 17
  In 
this way, complications involving in vivo expression and in vitro reconstitution of enzymatic 
activity, as well as the necessity of the leader peptide, are eliminated.  Furthermore, the chemical 
space accessible in the generation of analogues is widened greatly.  For example, the chemical 
composition of the crosslinks can be modified beyond lanthionine (Lan) and methyllanthionine 
(MeLan), fragments of lantibiotics can be generated straightforwardly, and fluorophores and 
chemical handles can be freely incorporated.  Despite the promise of lantibiotic chemical 
synthesis, the precise control of stereochemistry and regiochemistry involved in crosslink 
formation is a formidable challenge.  Indeed, previous efforts involving the biomimetic syntheses 
of Lan/MeLan rings in short peptides containing cysteine and α,β-unsaturated residues have 
                                                          
Reproduced in part with permission from: 
*
 Knerr, P. J.; van der Donk, W. A., “Chemical synthesis and biological activity of analogues of the lantibiotic 
epilancin 15X.”  J. Am. Chem. Soc. 2012, 134, 7648-7651.  Copyright 2012 American Chemical Society. 
†
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confirmed these difficulties.
18-20
  Nevertheless, the first total chemical synthesis of a bioactive 
lantibiotic, nisin, was accomplished by Shiba and coworkers in the 1980s via the coupling of five 
protected segments synthesized in solution (Fig. 3.1).
21-25
  Lan/MeLan crosslinks were generated 
via a phosphine-promoted desulfurization reaction from the corresponding disulfides.  However, 
the synthesis was reported over a ten-year span and involved more than a dozen coworkers, 
certainly far from the ideal timeframe and scope for the generation of panels of analogues. 
 
Figure 3.1.  Solution-phase total synthesis of nisin by Shiba and coworkers.
25
  (a) Construction of Lan/MeLan rings, 
exemplified by ring A.  Desulfurization of cyclic disulfides generated Lan/MeLan, and a Hofmann elimination was 
used to install Dha/Dhb residues.  (b) Iterative coupling and deprotection of the five segments to generate nisin.  
Prior to treatment with HF, side-chains were protected as follows: Mbh for Asn, Cbz for Lys, and Bn for Ser.  
Abbreviations: Acm, acetamidomethyl; Bn, benzyl; Boc, tert-butoxycarbonyl; Cbz, benzyloxycarbonyl; Mbh, 4,4-
dimethoxybenzhydryl; Trt, trityl 
 
In the 2000s, an alternative “building block” approach for lanthipeptide synthesis 
emerged, which has greatly accelerated the development of chemical synthesis as a tool in 
lantibiotic engineering.
16, 26
  In this approach, orthogonally-protected Lan/MeLan bis-amino 
acids are used to construct cyclic peptides on the solid-phase (Fig. 3.2).  While the solution-
phase synthesis of lanthipeptides is still being explored in particular situations, as exemplified by 
a 
b 
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Figure 3.2.  SPPS-based approach to synthesize overlapping Lan/MeLan rings in peptides.  Lan/MeLan building 
blocks (boxed) containing orthogonal sets of protecting groups (red and green) can be used to construct complex 
lanthipeptide topologies with full stereochemical and regiochemical control.  Standard coupling conditions allow for 
cyclization on the solid-phase via amide-bond formation (purple). 
 
the construction of an aminovinylcysteine-containing fragment of mersacidin,
27, 28
 the 
applicability of 9-fluorenylmethoxycarbonyl-based solid-phase peptide synthesis (Fmoc-SPPS) 
is particularly noteworthy; reaction times and the number of purification steps can be 
dramatically reduced, and yields dramatically increased, compared to a solution-phase synthesis.  
Using this SPPS-based approach, Vederas and coworkers have recently completed the total 
syntheses of lactocin S
29
 and both peptides of lacticin 3147.
30
  Furthermore, this team also 
produced analogues containing ether,
31
 olefin,
32
 and methylene/methine crosslinks
33, 34
 in place 
of the natural thioether.  The methylene analogue of lactocin S is particularly interesting from an 
engineering standpoint, as it maintains the antibacterial activity of the parent compound while 
improving oxidative stability.
33
 
In this chapter, the application of the synthetic approach shown in Fig. 3.2 to the 
construction of two different lantibiotics, epilancin 15X and lacticin 481, and analogues is 
described.  Epilancin 15X (3.1, Fig. 3.3a), a lantibiotic first isolated in 2005 from the clinical 
strain Staphylococcus epidermidis 15X154,
35
 ranks among the most potent lantibiotics against 
drug-resistant pathogens, including methicillin-resistant S. aureus and vancomycin-resistant 
Enterococcus.
36
  This peptide contains a Lan ring and a set of overlapping MeLan rings toward 
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Figure 3.3.  (a) Sequence and ring topology of epilancin 15X (3.1) and lacticin 481 (3.2).  For the chemical 
structures of modified residues, see Fig. 1.6.  (b) Biosynthesis of the N-terminal D-lactyl cap of epilancin 15X.  
Following modification by ElxB/ElxC and leader proteolysis by ElxP, the N-terminal Dha residue spontaneously 
hydrolyzes to a pyruvyl group (Pyr), which is reduced to the D-lactyl (DLac) group by ElxO.
37 
 
its C-terminus, which resemble the C-terminal portion of nisin (Fig. 3.1) responsible for pore 
formation.
14, 38-40
  Toward its N-terminus, epilancin 15X contains an unusual cluster of α,β-
unsaturated residues as well as a D-lactyl (DLac) cap, which is installed biosynthetically by the 
oxidoreductase ElxO following proteolytic cleavage of the leader peptide by serine protease ElxP 
(Fig. 3.3b).
37
  No report has yet described biosynthetic manipulation of epilancin 15X in the 
producing organism, and previous efforts to reconstitute its biosynthesis in heterologous hosts or 
in vitro have not been successful to date.
37
  Consequently, no analogues of this natural product 
have been reported thus far, leaving many questions about its mechanism-of-action unanswered.  
Intriguingly, neither epilancin 15X
41
 nor the structurally-similar epilancin K7
42
 bind to lipid II, 
the most common biological target of lantibiotics; this suggests that these compounds may 
exhibit their antibacterial activity through binding of a different target.
43
  The work herein 
describes the first reported analogues of epilancin 15X, produced through total chemical 
synthesis, and the first details of its mode-of-action. 
As introduced in Chapter 1.4.1, the recent discovery of lantibiotics containing 
enzymatically-installed crosslinks bearing an LL-configuration,
44
 instead of the conventional DL-
configuration, has prompted questions about the role of Lan/MeLan stereochemistry on 
biological activity.  In order to address this issue systematically, chemical synthesis was again 
b 
a 
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utilized with lacticin 481 (3.2, Fig. 3.3a, see Chapter 2.1) as a model system.  Three analogues of 
lacticin 481 were generated, in which each of the three DL-crosslinks was replaced by its LL-
stereoisomer, and assayed for antibacterial activity.  These efforts not only demonstrated the 
importance of the natural stereoconfiguration of each crosslink for activity, but also represented 
only the fifth completed total synthesis of a lanthipeptide. 
 
3.2. RESULTS AND DISCUSSION 
 
3.2.1. Synthesis of Lan and MeLan building blocks 
 
 In order to achieve the solid-supported chemical synthesis of lanthipeptides, including 
those with overlapping ring topologies as outlined in Fig. 3.2, Lan/MeLan building blocks 
containing orthogonal sets of protecting groups were necessary.  These protecting groups would 
need to fulfill multiple criteria: 1) stability to the basic conditions employed during standard 
Fmoc-SPPS; 2) mild, solid-phase-amenable, and quantitative deprotection; 3) full orthogonality 
to other protecting groups used in the synthesis; and ideally 4) straightforward incorporation into 
building blocks.  A review of known protecting groups for amines and carboxylic acids 
uncovered multiple candidate protecting group strategies: allyl, 4,4-dimethyl-2,6-dioxocyclo-
hexylidene (also called dimedonyl), 4-nitrobenzyl, 2-trimethylsilylethyl, 2,2,2-trichloroethyl, and 
others.
45
  The peptide synthesis literature offered a variety of examples of the orthogonality 
among different combinations of these groups as well as conditions to permit mild and 
quantitative deprotection.
45-52
  Allyl and 4-nitrobenzyl were chosen for initial study, due to their 
successful incorporation into Lan and Lan-mimicking building blocks in previous reports.
26, 31, 53
  
Considering the rings topologies present in epilancin 15X and lacticin 481 (Fig. 3.3a), a total of 
four building blocks would be necessary for their syntheses (Fig. 3.4): a pair of orthogonal Lan 
building blocks (DL-3.3, DL-3.4) and a pair of orthogonal MeLan building (DL-3.5, DL-3.6). 
 
 
Figure 3.4.  Orthogonal Lan/MeLan building blocks for the chemical synthesis of lanthipeptides.  All, allyl; Aloc, 
allyloxycarbonyl; pNb, para-nitrobenzyl; pNz, para-nitrobenzyloxycarbonyl. 
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 The allyl-protected Lan DL-3.3 was synthesized with modifications from a previous report 
(Scheme 3.1).
53
  Commercially-available, inexpensive, and enantiomerically-pure amino acid 
starting materials were straightforwardly elaborated to bromoalanine D-3.8 and cystine 3.9.  The 
key transformation involved a one-pot, two-reaction sequence of reduction of 3.9 and subsequent 
base-promoted, phase-transfer condensation with D-3.8 to produce the thioether framework of DL-
3.10 in high yields without epimerization at the potentially labile α-positions.  Acid-promoted 
removal of the tert-butyl ester yielded DL-3.3, which was used directly for SPPS.  Unfortunately, 
the direct application of this convergent reaction scheme to nitrobenzyl-protected Lan 3.13 or 
allyl-protected MeLan 3.16 resulted in epimerization and/or severely reduced yields (Scheme 
3.2).  In the case of 3.13, the strongly electron-withdrawing nature of the nitrobenzyl ester likely 
lowered the pKa of the α-proton of 3.12 sufficiently for abstraction in the basic conditions used 
for condensation.  In the case of 3.16, a significant amount of allyl-protected dehydrobutyrine, 
the elimination product of 3.15, was observed during condensation; Michael addition of the 
liberated cysteine nucleophile into this dehydrobutyrine would be expected to result in a mixture 
of diastereomers, i.e. 3.16.  Elimination has been suggested previously as a competing reaction 
during condensations of haloalanines and thiol nucleophiles,
26, 54
 and the increased steric bulk of 
the secondary bromide in 3.15 likely permits this elimination to outcompete the desired 
displacement reaction. 
Given these disappointing results, alternative schemes to the nitrobenzyl-protected and 
MeLan building blocks were necessary to prevent loss of the stereochemical integrity of the 
 
Scheme 3.1.  Synthesis of Lan building block DL-3.3.
a 
 
a
 Reagents and conditions: a) AlocCl, Na2CO3, H2O, CH3CN; b) allyl bromide, NaHCO3, DMF, 59% (two steps); c) 
PPh3, CBr4, CH2Cl2, 78%; d) HClO4, 
t
BuOAc; e) FmocOSu, N-methylmorpholine, THF, 79% (two steps); f) PBu3, 
H2O, THF, then D-3.8, Bu4NBr, NaHCO3, H2O, EtOAc, 89%; g) CF3CO2H, PhSiH3, CH2Cl2, quant. 
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Scheme 3.2.  Unsuccessful syntheses of stereodefined Lan and MeLan building blocks.
a
 
 
a
 Reagents and conditions: a) 4-nitrobenzyl chloroformate, Na2CO3, H2O, 1,4-dioxane; b) 4-nitrobenzyl bromide, 
NaHCO3, DMF, 83% (two steps); c) PPh3, CBr4, THF, 76%; d) Fmoc-Cys-O
t
Bu, Bu4NBr, NaHCO3, H2O, EtOAc, 
87% (diastereomers); e) AlocCl, Na2CO3, H2O, CH3CN; f) allyl bromide, NaHCO3, DMF, 80% (two steps); g) PPh3, 
CBr4, CH2Cl2, 80%; h) Fmoc-Cys-O
t
Bu, Bu4NBr, NaHCO3, H2O, EtOAc, 26% (diastereomers). 
 
starting materials during synthesis.  If the electron-withdrawing nitrobenzyl groups were to 
blame for the epimerization seen in 3.13, it was hypothesized that switching the protecting 
groups of the bromoalanine and cysteine might result in more stable intermediates.  Gratifyingly, 
the success of such a strategy was indeed demonstrated for Lan DL-3.4 (Scheme 3.3).  Fmoc- and 
tert-butyl ester-protected bromoalanine 3.18 condensed cleanly with nitrobenzyl-protected 
cysteine D-3.20 under the basic phase-transfer conditions described in Scheme 3.1, resulting in 
the desired thioether DL-3.21 in high yield with full preservation of stereochemistry.  The 
diastereomeric purity of DL-3.21 was assessed through 
13
C NMR spectroscopy in comparison to 
the epimerized MeLan 3.13, which exhibited extra “sister signals” indicative of a mixture of 
diastereomers for both α- and β-carbons of the molecule (Fig. 3.5).53 
 
Scheme 3.3.  Synthesis of Lan building block DL-3.4.
a
 
 
a
 Reagents and conditions: a) tert-butyl 2,2,2-trichloroacetimidate, EtOAc, cyclohexane, 93%; b) PPh3, CBr4, 
CH2Cl2, 79%; c) pNzCl, Na2CO3, H2O, 1,4-dixoane; d) pNbBr, NaHCO3, DMF, 94% (two steps); e) CF3CO2H, 
i
Pr3SiH, CH2Cl2, 88%; f) 3.18, NaHCO3, Bu4NBr, EtOAc, H2O, Bu3P, 78%; g) CF3CO2H, PhSiH3, CH2Cl2, 95%. 
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Figure 3.5.  Comparison of the α- and β-carbon 13C NMR signals of (a) DL-3.21 and (b) 3.13.  The extra signals for 
3.13 are indicative of the presence of a mixture of diastereomers. 
 
This alternative scheme using bromoalanine 3.18 additionally allowed the 
stereocontrolled synthesis of MeLan DL-3.5 and DL-3.6 (Scheme 3.4).  Protected β-methylcysteine 
D-3.25 was synthesized in five steps from D-threonine using a published procedure.
54
  This 
compound proved to be a useful intermediate for both building blocks; protecting group 
manipulation, removal of the 4-methoxybenzyl (Mob) group protecting the thiol, condensation 
with 3.18, and tert-butyl ester removal resulted in DL-3.5 and DL-3.6 as single diastereomers.  
Despite the use of hindered secondary thiols, the condensation reactions leading to DL-3.27 and 
DL-3.29 proceeded in acceptable to high yields. 
For the synthesis of lanthipeptides with very complex ring topologies, such as 
cinnamycin, a third orthogonal set of protecting groups would be necessary.  The 
isovaleryldimedonyl (Ddiv) and 4-[(isovaleryldimedonyl)amino]benzyl ester (ODmab) groups 
have demonstrated utility in the Fmoc-SPPS of complex peptides,
51, 52, 55
 and their deprotection 
with dilute hydrazine is orthogonal to both allyl and nitrobenzyl protection.
49
  A dimedonyl-
protected Lan building block was synthesized, but attempted SPPS of peptides containing this 
residue led invariably to peptides containing cysteine in place of the desired Lan residue (Fig. 
 
α-carbons 
(single 
diastereomer) 
β-carbons 
(mixture of 
diastereomers) 
β-carbons 
(single 
diastereomer) 
α-carbons 
(mixture of 
diastereomers) 
Fmoc 
methine 
Fmoc 
methine 
a 
b 
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Scheme 3.4.  Synthesis of MeLan building blocks DL-3.5 and DL-3.6.
a
 
 
a
 Reagents and conditions: a) allyl alcohol, TsOH, PhMe, reflux; b) NsCl, Et3N, CH2Cl2, 79% (two steps); c) PPh3, 
diisopropylazodicarboxylate, THF, 83%; d) 4-methoxybenzyl mercaptan, BF3OEt2, CH2Cl2, 86%; e) 4-
methoxybenzenethiol, K2CO3, MeCN, DMSO, 91%; f) AlocOSu, 
i
Pr2NEt, CH2Cl2, 97%; g) Hg(OAc)2, PhOMe, 
CF3CO2H, then dithiothreitol; h) 3.18, NaHCO3, Bu4NBr, Bu3P, EtOAc, H2O, 64% (two steps); i) CF3CO2H, 
PhSiH3, CH2Cl2, 96%; j) 4-nitrobenzyl chloroformate, 
i
Pr2NEt, CH2Cl2, 96%; k) Pd(PPh3)4, PhNMe, THF; l) 4-
nitrobenzyl bromide, NaHCO3, DMF, 93% (two steps); m) 3.18, NaHCO3, Bu4NBr, Bu3P, EtOAc, H2O, 85% (two 
steps); n) CF3CO2H, PhSiH3, CH2Cl2, 95%. 
  
3.6).  The instability of this building block likely stems from the use of the Ddiv group; unlike 
carbamate-based protecting groups, Ddiv may promote a β-elimination reaction, potentially 
through a oxazolone-like intermediate,
56, 57
 resulting in the observed side-product.  This 
complication forced the abandonment of the dimedonyl protecting strategy for Lan/MeLan 
building blocks.  For the synthetic targets described here, only two sets of protecting group (i.e. 
allyl and nitrobenzyl) were necessary; should a third set be necessary in future studies, the 
trimethylsilylethyl strategy as reported previously may serve as a viable addition.
50
 
 
 
Figure 3.6.  Structure of Fmoc-DL-Lan(Ddiv/ODmab)-OH, and observed decomposition during SPPS. 
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3.2.2. Synthesis of Dha/Dhb-containing peptide fragments 
 
 In addition to regio- and stereocontrolled construction of Lan/MeLan rings, another 
challenge in the synthesis of lanthipeptides is the incorporation of the α,β-unsaturated residues 
Dha and Dhb, which are not amenable to standard iterative SPPS.
58
  Following coupling of an N-
protected Dha/Dhb residue, deprotection would result in an enamine, which would be present in 
equilibrium with its corresponding imine.  The imine is a weak nucleophile for peptide synthesis 
and is also prone to hydrolysis in the presence of water to give the corresponding ketone (as in 
Fig. 3.3b), impeding subsequent couplings.  Two alternatives were considered in order to install 
Dha/Dhb into peptides on the solid phase: use of a “masked” building block that could be 
straightforwardly coupled, deprotected, and later unmasked to reveal the α,β-unsaturated residue; 
and coupling of peptide fragments containing Dha/Dhb.  In the former approach, 
alkylcysteines
18, 19
 and alkyl- or arylselenocysteines
59-61
 have been described that undergo 
elimination within a peptide to give the desired α,β-unsaturated residue when treated with an 
oxidizing agent.  Unfortunately, these oxidative conditions are not compatible with thioether 
crosslinks present in lanthipeptides.  Alternatively, a fragment coupling strategy, in which a short 
peptide containing Dha/Dhb is synthesized separately and coupled as a single unit to the growing 
peptide, has been used successfully in the synthesis of Dha/Dhb-containing depsipeptides
62, 63
 
and lantibiotics.
29, 30
  Furthermore, epimerization of the C-terminal residue, a common 
complication of fragment-based couplings, can be avoided by placing the α,β-unsaturated residue 
at the C-terminus of the fragment. 
 For the synthesis of epilancin 15X (3.1, Fig. 3.3a), three such Dha/Dhb-containing 
fragments would be necessary: Phe27-Dhb28, Ala2-Dha3, and Lys6-Dhb7-Dhb8.  Lacticin 481 
(3.2) also contains a Phe-Dhb sequence (residues 23-24), so the same dipeptide fragment used 
for the synthesis of 3.1 would also be applied to 3.2.  The solution-phase synthesis of the three 
corresponding Fmoc-protected fragments 3.32, 3.35, and 3.39 are shown in Scheme 3.5.  Use of 
the water-soluble activator 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride 
(EDC) for amino acid couplings permitted reaction purification without the use of 
chromatography.  The α.β-unsaturated residue in dipeptide fragments 3.32 and 3.35 were 
constructed via a mesylation-elimination sequence of side chain-unprotected serine or threonine, 
which in the case of Dhb has been shown previously to be selective for the desired (Z)-olefin.
32
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Scheme 3.5.  Synthesis of Dha/Dhb-containing fragments for epilancin 15X total synthesis.
a
 
 
a
 Reagents and conditions: a) EDC, HOBt, 
i
Pr2NEt, CH2Cl2, 98%; b) MsCl, Et3N, CH2Cl2; c) DBU, Cl(CH2)2Cl, 
reflux, 90% (two steps); d) CF3CO2H, CH2Cl2; e) FmocOSu, Na2CO3, H2O, dioxane, 95% (two steps); f) EDC, 
HOBt, 
i
Pr2NEt, CH2Cl2, 96%; g) DBU, CH2Cl2, 97% (two steps); h) FmocOSu, Na2CO3, H2O, dioxane, 43% (two 
steps); i) allyl alcohol, TsOH, PhMe, reflux; j) Boc-Thr-OH, EDC, HOBt, 
i
Pr2NEt, CH2Cl2, 92% (two steps); k) 
Aloc-Lys(Boc)-OH, EDC, HOBt, 
i
Pr2NEt, CH2Cl2, 90% (two steps); l) EDC, CuCl, CH2Cl2, 64%; m) Pd(PPh3)4, 
PhNHMe, THF; n) FmocOSu, Na2CO3, H2O, dioxane, 89% (two steps). 
 
For the tripeptide fragment 3.39, an attempted double mesylation-elimination of 3.37 resulted in 
an inseparable mixture of compounds.  Instead, an EDC/CuCl dehydration reaction, also 
selective for the (Z)-olefin,
64
 was used to give the desired fragment 3.38, which was elaborated in 
two steps to 3.39. 
 A prominent question relating to SAR analysis of epilancin 15X is the importance of the 
N-terminal DLac cap (Fig. 3.3b), compared to its biosynthetic precursor, a pyruvyl (Pyr) cap.
65
  
Therefore, epilancin 15X analogues containing Pyr instead of DLac were desired.  However, 
while D-lactic acid can be directly coupled to peptides by SPPS, the coupling of pyruvic acid 
would be expected to be more challenging, considering the presence of two potential 
electrophilic sites.  Although the direct coupling of pyruvic acid has been reported,
66
 several 
attempts with test peptides in relation to this work failed to give the desired Pyr-capped 
sequences in acceptable yields.  Instead, an additional fragment 3.42 was synthesized, bearing N-
82 
 
terminal Boc protection of a Dha-Ala dipeptide (Scheme 3.6).  This fragment could be directly 
coupled, and upon acidic cleavage/global deprotection, a biomimetic enamine/imine hydrolysis 
would result in the desired Pyr-capped peptide.
37
 
 
Scheme 3.6.  Synthesis of Dha-containing dipeptide fragment for inclusion of N-terminal Pyr.
a 
 
a
 Reagents and conditions: a) EDC, HOBt, 
i
Pr2NEt, CH2Cl2, 85%; b) MsCl, Et3N, CH2Cl2; c) DBU, CH2Cl2, 80% 
(two steps); d) LiOH, H2O, dioxane, 66%. 
 
3.2.3. Total synthesis of epilancin 15X analogues 
 
 With these Lan/MeLan and Dha/Dhb-containing building blocks in hand, the solid-
supported total chemical synthesis of epilancin 15X (3.1) was explored (Scheme 3.7).  Fmoc-
SPPS was commenced using preloaded Wang resin, the substitution of which was manually 
lowered to 0.1-0.15 mmol/g to prevent intermolecular side reactions during cyclization observed 
at higher resin substitution densities.  The use of N,N’-diisopropylcarbodiimide (DIC) and 1-
hydroxybenzotriazole (HOBt) or 1-hydroxy-7-azabenzotriaole (HOAt) for amino acid couplings 
effectively minimized side reactions involving the Lan/MeLan building blocks, which were 
encountered when using conditions that necessitated the addition of base.  Dipeptide fragment 
3.32 and MeLan building blocks DL-3.5 and DL-3.6 were successfully coupled to the growing 
solid-supported peptide backbone using this chemistry, giving linear intermediate 3.43 (Scheme 
3.7). 
To construct the C-ring, the nitrobenzyl protecting groups of 3.43 were removed via 
reduction with stannous chloride and catalytic HCl, which left the allyl groups unaltered.  Fmoc 
removal with piperidine revealed the N-terminal amine, which was reacted with the carboxylate 
of the deprotected MeLan residue using (7-azabenzotriazol-1-yloxy)tripyrrolidinophosphonium 
hexafluorophosphate (PyAOP),
67
 HOAt, and 2,4,6-collidine to give the monocyclic intermediate 
3.44.  These optimized cyclization conditions promoted complete conversion in a reasonable 
reaction time (4 h per cyclization) without epimerization of one or both MeLan residues present 
in the peptide, as analyzed by reversed-phase high-performance liquid chromatography (RP-
HPLC).  Uronium-based coupling agents such as HBTU are known to give side reactions during  
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Scheme 3.7.  Solid-supported synthesis of analogues of epilancin 15X.
a,b
 
 
a 
Reagents and conditions: a) SPPS; b) SnCl2, HCl, DMF; c) piperidine, DMF; d) PyAOP, HOAt, 2,4,6-collidine, 
DMF; e) Pd(PPh3)4, PhSiH3, DMF, CH2Cl2; f) CF3CO2H, H2O, PhSiH3 (or PhOMe). 
b
 Prior to cleavage from resin 
(step f), all residues contained appropriate side-chain protecting groups for Fmoc-SPPS: Boc for Lys, Pbf for Arg, 
and Trt for His.  Green residues are those modified from the natural product. 
 
peptide cyclizations,
68
 and PyAOP was found empirically to outperform DIC as well as the next-
generation coupling agent O-[(cyano-(ethoxycarbonyl)methyliden)-amino]-yloxytripyrrolidino-
phosphonium hexafluorophosphate (PyOxim)
69
 in conversion and reaction time.  In addition, 
2,4,6-collidine was used for its known suppression of epimerization in sensitive peptide moieties 
compared to more common amine bases, such as diisopropylethylamine (
i
Pr2NEt).
70
 
 Following formation of 3.44, leucine was coupled, setting the stage for a second 
cyclization to yield the B-ring.  The allyl protecting groups were removed using 
tetrakis(triphenylphosphine)palladium(0) and phenylsilane as a scavenger.  Fmoc deprotection 
and cyclization as detailed above yielded the bicyclic intermediate 3.45.  Continued SPPS, 
including coupling of the allyl-protected Lan DL-3.3, gave 3.46, which was deprotected and 
cyclized as for the B-ring to give intermediate 3.47, containing all three rings of epilancin 15X.  
To complete the total synthesis, fragments 3.35 and 3.39 were needed to install the remaining 
Dha and Dhb residues in the peptide.  Unfortunately, substantial difficulties were encountered 
84 
 
with tripeptide fragment 3.39.  Very poor conversion was observed when coupling 3.39 
regardless of activator (DIC, PyAOP, O-(6-chlorobenzotriazol-1-yl)-N,N,N’,N’-tetramethyl-
uronium hexafluorophosphate (HCTU), and fluoro-N,N,N’,N’-bis(tetramethylene)form-
amidinium hexafluorophosphate (TFFH)) and reaction time (up to 48 h), with as much as 95% of 
peptide remaining uncoupled by RP-HPLC analysis.  Furthermore, the product of 3.39 coupling 
was found to degrade during subsequent treatment with piperidine; mass spectrometric analysis 
suggested that the amide bond between Dhb residues was hydrolyzed.  These difficulties 
thwarted the original goal of a total synthesis of 3.1. 
 Epilancin 15X does not contain either of the two described lipid II binding motifs of 
lantibiotics,
71-73
 and therefore its unusual N-terminal cluster of uncyclized α,β-unsaturated 
residues may play a role in target binding, potentially through a covalent mechanism.  To explore 
this possibility and to circumvent the issues involved with fragment 3.39, epilancin 15X 
analogues were successfully synthesized from intermediate 3.47 (Scheme 3.7) replacing the 
unsaturated Dha and Dhb residues with their saturated L-amino acid counterparts alanine and 2-
aminobutyric acid (Abu), respectively.  Following SPPS of the linear N-terminal segment and 
cleavage from resin with trifluoroacetic acid (TFA), epilancin 15X analogue 3.48 
(Dha3Ala/Dhb7Abu/Dhb8Abu) was obtained.  The N-terminal DLac cap was installed by 
activating D-lactic acid with 3-(diethoxyphosphoryloxy)-1,2,3-benzotrazin-4(3H)-one (DEPBT), 
an activator tolerant of residues containing unprotected alcohols.
74
  A second analogue, 3.49, was 
synthesized that included the three mutations of 3.48 and also an N-terminal Pyr cap produced by 
coupling and deprotecting fragment 3.42 (Scheme 3.6).  Finally, a truncated analogue 3.50 was 
produced, which replaced the eight N-terminal residues with an acetyl cap.  It should be noted 
that anisole was used in place of triisopropylsilane as the primary scavenging agent during resin 
cleavage of 3.49, as triisopropylsilane is known to partially reduce peptide ketones.
75
  Following 
RP-HPLC, these epilancin 15X analogues were obtained in overall yields of 1.6-1.9%, with an 
average yield of 92-93% per chemical step.  Analytical RP-HPLC and MS confirmed the 
homogeneity of each peptide after purification (Fig. 3.7), and tandem MS/MS confirmed the 
desired ring topology of analogue 3.48 compared to the authentic natural product (Fig. 3.8).  
Importantly, this methodology allowed production of multi-milligram quantities of final product 
within two weeks, thus permitting follow-up biological studies. 
85 
 
     
     
     
Figure 3.7.  Characterization of synthetic epilancin 15X analogues, showing analytical RP-HPLC chromatograms 
and HR-MALDI-TOF mass spectra for (a) analogue 3.48 (insert: zoom-in of expected product mass); (b) analogue 
3.49; and (c) analogue 3.50. 
a 
m/z = 3179.794 
[M+H]
+
 
b 
m/z = 3177.765 
[M+H]
+
 
 
[ 
c 
m/z = 2497.405 
[M+H]
+
 
 
[ 
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Figure 3.8. MALDI-MS/MS analysis of (a) authentic epilancin 15X, and (b) analogue 3.48.  Nearly identical 
fragmentation patterns are seen in both spectra, indicative of the desired ring topology in both peptides. 
a 
b 
[M+H]
+
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3.2.4. GC/MS analysis of epilancin 15X analogues 
 
 In order to confirm that the desired DL-configuration of the Lan and MeLan crosslinks 
remained unchanged over the course of the total synthesis, chiral gas chromatography-mass 
spectrometry (GC/MS) was used, as has been reported for lanthipeptides previously.
29, 30, 76
  In 
order to prepare samples for analysis, peptides were first hydrolyzed in refluxing 6 M HCl to 
their constituent amino acids, which were then derivatized to their corresponding 
pentafluoropropionamide methyl esters to increase volatility (Scheme 3.8).  Synthetic standards 
of derivatized Lan and MeLan amino acids with differing stereochemical configurations, 
provided by Ms. Weixin Tang (UIUC),
76
 could be resolved using a Varian CP-Chirasil-L-Val 
column.  Additionally, these derivatized Lan and MeLan amino acids fragment during MS 
analysis to give unique masses compared to proteinogenic amino acids, which permits selected 
ion monitoring (SIM) at these masses to simplify analysis. 
 
Scheme 3.8.  Procedure for peptide sample preparation for chiral GC/MS analysis. 
 
 
 
Purified epilancin 15X analogue 3.50 was hydrolyzed and derivatized as outlined in 
Scheme 3.8.  GC/MS analysis compared to synthetic standards revealed that both the Lan and 
MeLan amino acids possessed predominantly the desired DL-configuration (Fig. 3.9).  The small 
amounts of non-DL-configurations in the Lan sample is believed to result from epimerization 
during hydrolysis, as has been reported previously in other lanthionine-containing peptide 
samples.
29, 76, 77
 
 
3.2.5. Antibacterial activity of epilancin 15X analogues 
 
In order to assess the effect of each mutation/truncation on antibacterial activity, 
quantitative growth inhibition assays were performed in liquid culture against the indicator strain 
Staphylococcus carnosus TM300 for each of the synthetic analogues and compared to authentic 
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Figure 3.9.  Chiral GC/MS analysis of hydrolyzed and derivatized 3.50, confirming the desired DL-configuration of 
Lan and MeLan.  (a) SIM at 365 Da of hydrolysate compared to synthetic Lan standards.  (b) SIM at 379 Da of 
hydrolysate compared to synthetic MeLan standards.  (c) Representative mass spectrum of derivatized Lan.  (d) 
Representative mass spectrum of derivatized MeLan.  Data were recorded at the Metabolomics Center (UIUC). 
 
epilancin 15X (Fig. 3.10), which was isolated from its natural producing strain by Dr. Juan 
Velásquez (UIUC).
37
  Two-fold serial dilutions of each peptide were performed, giving a range 
of concentrations over three orders of magnitude to test for inhibition of bacterial growth.  
Replacement of the three N-terminal Dha/Dhb residues of epilancin 15X with their saturated 
counterparts in analogue 3.48 gave only a modest increase in the half maximal inhibitory 
concentration (IC50), from 95 ± 9.6 to 270 ± 23 nM.  This increase may be due to loss of the 
planarity of these α,β-unsaturated residues, but a mechanism-of-action involving covalent 
a b 
c d 
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attachment of epilancin 15X to its putative biological target can be ruled out.  Additional 
substitution of DLac for Pyr in 3.49 slightly increased the IC50 to 354 ± 8 nM.  This finding 
suggests that the N-terminal acyl group only plays a minor role in bioactivity.  Though both Pyr 
and DLac caps have been demonstrated to protect lantibiotics from aminopeptidases,
37
 the 
additional enzymatic reaction catalyzed by ElxO to reduce Pyr to DLac may further stabilize 
epilancin 15X by removing the ketone, a potential site of nucleophilic attack in vivo.  Truncation 
of the eight N-terminal residues in analogue 3.50, however, had a significantly deleterious effect 
on activity, with a 20-fold increase in IC50 and a 50-fold increase in minimal inhibitory 
concentration (MIC) compared to epilancin 15X.  This N-terminal tail region, primarily 
composed of nonpolar residues, may therefore be important for noncovalent binding interactions 
between epilancin 15X and its putative biological target. 
 
 
Figure 3.10.  Growth inhibition activity of authentic epilancin 15X and analogues 3.48, 3.49, and 3.50 against S. 
carnosus TM300.  Calculated IC50 and MIC values are shown in the legend. 
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3.2.6. Flow cytometry analysis of membrane disruption 
 The C-terminal portion of epilancin 15X, particularly the arrangement of its crosslinks, 
strongly resembles the C-terminal portion of nisin, which is responsible for pore formation.
14, 38-
40
  It was therefore hypothesized that epilancin 15X may similarly be able to form pores in the 
membranes of susceptible bacteria.  The linear N-terminal tail of epilancin 15X may be involved 
in target binding, as mentioned above, but it may otherwise be necessary for the molecule to span 
the length of the membrane.  To test these hypotheses, flow cytometry analysis was used to 
investigate alterations in membrane potential and permeability in S. carnosus cells treated with 
either full-length analogue 3.48 or truncated analogue 3.50 (Fig. 3.11).  Despite removal of eight 
residues, 3.50 retained the ability to disrupt both membrane potential and integrity.  Higher 
concentrations of 3.50 were required than for 3.48, but these correlated well with their relative 
differences in antibacterial potency (Fig. 3.10).  These findings are consistent with the suggested 
role of the nisin-like C-terminal portion of epilancin 15X for pore-forming activity, and further 
suggest the N-terminal portion to be involved in binding a putative non-lipid II target to increase 
potency.  Indeed, the pore-forming ability of nisin is enhanced about 1,000-fold through binding 
lipid II.
78
  The strongly positive charge of epilancin 15X may suggest a negatively-charged 
binding partner, but to date this putative biological target has not yet been identified. 
 
Figure 3.11.  Flow cytometry analysis of pore-forming abilities of 3.48 and 3.50 against S. carnosus TM300.  (a) 
Membrane depolarization activity as measured by DiOC2(3) mean fluorescence intensity (MFI).  (b) Membrane 
permeability activity as measured by propidium iodide (PI) uptake. 
91 
 
3.2.7. Total synthesis of lacticin 481 and ring stereoisomer analogues 
 
 Prior to 2013, all characterized Lan/MeLan crosslinks were reported to possess the DL-
configuration,
29, 30, 76, 79-81
 as depicted in Fig. 3.4.  This enforced an assumption that all 
lanthipeptide crosslinks contain this configuration, as they are made by homologous biosynthetic 
enzymes.  However, the very recent discovery of LL-crosslinks within biosynthesized 
lanthipeptides, including both peptides of the enterococcal cytolysin and the β-peptide of 
haloduracin,
44
 has challenged this assumption and also called into question the importance of 
crosslink stereochemistry to biological activity.  This observation, seemingly contradictory to the 
characteristically high stereochemical fidelity of enzymes, mirrors a growing awareness of 
natural products produced as stereoisomers, occasionally within the same organism.
82
 
 In order to assess the role of Lan/MeLan stereochemical configuration on antibacterial 
activity, lacticin 481 (3.2) was chosen as a model system.  Although the ring topology of this 
tricyclic lantibiotic was determined in 1996,
83
 the absolute stereochemistry of each ring had not 
yet been determined.  Using the Fmoc-SPPS approach described for the synthesis of epilancin 
15X analogues (see Section 3.2.1-3.2.3), Lan building blocks DL-3.3 and DL-3.4, MeLan building 
block DL-3.6, and dipeptide fragment 3.32 were incorporated into a solid-supported peptide 
backbone (Scheme 3.9); cyclization of each Lan/MeLan residue using the same conditions 
described in Section 3.2.3, acidic resin cleavage, and RP-HPLC purification resulted in the total 
 
Scheme 3.9. Solid-supported synthesis of lacticin 481 (2).
a,b
 
 
a 
Reagents and conditions: a) SPPS; b) SnCl2, HCl, DMF; c) piperidine, DMF; d) PyAOP, HOAt, 2,4,6-collidine, 
DMF; e) Pd(PPh3)4, PhSiH3, DMF, CH2Cl2; f) CF3CO2H, H2O, PhSiH3. 
b
 Prior to cleavage from resin (step f), all 
residues contained appropriate side-chain protecting groups for Fmoc-SPPS: Boc for Lys and Trp, 
t
Bu for Ser, O
t
Bu 
for Glu, and Trt for Asn, Gln, and His. 
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synthesis of 3.2.  Analytical RP-HPLC (Fig. 3.12a) confirmed co-elution of synthetic 3.2 with 
the authentic natural product, isolated by Dr. Juan Velasquez (UIUC) from the producing 
organism L. lactis subsp. lactis CNRZ 481.
65
  Mass spectrometry (Fig. 3.12b) and MS/MS (Fig. 
3.13) analyses confirmed the same molecular ion mass and fragmentation pattern.  Combined 
with biological activity (see Section 3.2.9), these data verify the successful synthesis of lacticin 
481, only the fifth lanthipeptide to succumb to total chemical synthesis. 
 
     
Figure 3.12.  Characterization of synthetic lacticin 481 (3.2).  (a) Analytical RP-HPLC chromatogram, showing co-
elution with authentic lacticin 481 (red).  (b) HR-MALDI-TOF mass spectrum (insert: zoom-in of product mass). 
 
 During the course of the synthesis, an appreciable amount of epimerization in one or both 
of the Lan residues was observed.  As epimerization was not seen during the synthesis of 
epilancin 15X analogues (Scheme 3.7), the larger ring sizes of lacticin 481 may be to blame, 
which necessitate repeated exposure of the ester-protected Lan residues to piperidine during the 
installation of intervening residues.  At least through anecdotal evidence, Lan appears to be less 
configurationally stable than MeLan, and this repeated basic exposure may slowly erode 
stereochemical integrity.  Fortunately, these epimerized byproducts were successfully separated 
from the desired full-length peptide during RP-HPLC purification.  The use of alternative bases 
for Fmoc-deprotection, such as 1,8-diazabicycloundec-7-ene or piperazine, may reduce the 
impact of this phenomenon on yield in future syntheses. 
 
 
a 
m/z = 2900.244 
[M+H]
+
 
[M+Na]
+
 
b 
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Figure 3.13. MALDI-MS/MS analysis of (a) authentic and (b) synthetic lacticin 418 (3.2).  Nearly identical 
fragmentation patterns are seen in both spectra, indicative of the same ring topology in both peptides. 
a 
b 
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With the total synthesis of 3.2 established, a systematic evaluation of crosslink 
stereochemistry was investigated.  As the absolute configuration of each Lan/MeLan building 
block is determined by the amino acid starting material, simply replacing the D-amino acid used 
to make each DL-building block (Schemes 3.1, 3.3, 3.4) with its corresponding L-enantiomer 
resulted in the generation of LL-Lan/MeLan building blocks (Fig. 3.14) by an analogous synthetic 
scheme.  In the case of LL-3.6, the use of L-threonine as starting material generated a change of 
two stereocenters, yielding an overall configuration of (2R,3R,6R) compared to (2S,3S,6R) in DL-
3.6.  Using these LL- instead of DL-building blocks, each ring of 3.2 was systematically changed 
using the synthetic scheme outlined in Scheme 3.9.  In this way, three additional peptides were 
constructed, containing the diastereomeric LL-crosslink stereochemistry for the A-ring (LL-A), the 
B-ring (LL-B) and the C-ring (LL-C) of lacticin 481.  Following RP-HPLC purification, these 
peptides were obtained in average overall yields of 1.3%, or 92% per step.  Interestingly, all 
three stereoisomeric analogues exhibited substantial deviations in analytical RP-HPLC retention 
time (Fig. 3.15) compared to 3.2 and authentic lacticin 481 (Fig. 3.12a) which may signify a 
change in the overall three-dimensional structure of the analogues. 
 
 
Figure 3.14.  Comparison of DL- and LL-Lan/MeLan building blocks used in the synthesis of lacticin 481 and ring 
diastereomer analogues. 
 
3.2.8. GC/MS analysis of lacticin 481 and analogues 
 
 To confirm the desired change in absolute Lan/MeLan stereochemistry in each analogue, 
chiral GC/MS analysis was employed as in Section 3.2.4.  The desired all-DL-configuration of 
hydrolyzed and derivatized 3.2 was observed, as well as LL-MeLan and DL-Lan in LL-A; both LL-
B and LL-C exhibited DL-MeLan and an approximately equal mixture of DL- and LL-Lan, as one of 
the two Lan rings in each peptide was altered (Fig. 3.16).  Considering that 3.2, but not any of 
the stereoisomeric analogues, co-eluted with authentic lacticin 481, an all-DL-configuration of 
authentic lacticin 481 was therefore verified. 
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Figure 3.15.  Characterization of synthetic lacticin 481 analogues, showing analytical RP-HPLC chromatograms 
and HR-MALDI-TOF mass spectra for (a) analogue LL-A; (b) analogue LL-B; and (c) analogue LL-C. 
b 
a 
[M+H]
+
 
m/z = 2900.278 
[M+Na]
+
 
[M+K]
+
 
[M+H]
+
 
m/z = 2900.279 
[M+Na]
+
 
[M+K]
+
 
c 
[M+H]
+
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+
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Figure 3.16.  Chiral GC/MS analysis of the derivatized hydrolysates of (a) 3.2, (b) LL-A, (c) LL-B, and (d) LL-C.  
Shown is the SIM analysis at both 365 Da and 379 Da for each sample, comparing elution times to synthetic 
standards (e).  Data were recorded at the Mass Spectrometry Laboratory (UIUC). 
a 
c 
b 
d 
e 
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3.2.9. Antibacterial activity of synthetic lacticin 481 and analogues 
 
 The antibacterial activity of synthetic 3.2 and analogues was compared to authentic 
lacticin 481 against the indicator strain L. lactis subsp. cremoris HP, analogous to the assays 
described in Section 3.2.5.  As expected, synthetic 3.2 (IC50 = 300 ± 70 nM; MIC = 625 nM) 
possessed comparable potency to the authentic natural product (IC50 = 250 ± 50 nM; MIC = 625 
nM) (Fig. 3.17).  However, none of the stereoisomeric analogues possessed detectible activity at 
concentrations up to the highest tested (10 μM).  These results indicate that the all-DL-
configuration of crosslinks is essential for biological activity.  As homologous LanM enzymes 
are able to produce both DL- and LL-crosslinks,
44
 this observation suggests that the 
stereochemistry of lacticin 481 evolved specifically to allow tight binding to lipid II, its likely 
biological target (see Chapter 2), and not because the biosynthetic machinery can only generate 
the DL-configuration.  Changing the stereochemical configuration of any crosslink likely alters 
the three-dimensional structure of the peptide (Figs 3.12a and 3.15), which in turn prevents 
target binding and abolishes activity. 
 
 
Figure 3.17.  Growth inhibition activity of authentic and synthetic lacticin 481 and analogues LL-A, LL-B, and LL-
C against L. lactis HP. 
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3.3. CONCLUSIONS AND OUTLOOK 
 
 In this chapter, the use of total chemical synthesis to construct lantibiotics and analogues 
was investigated.  Due to the independence of this approach from the biosynthetic machinery, the 
chemical space accessible in the production and engineering of analogues was widened greatly 
and encompassed modifications of the characteristic Lan/MeLan crosslinks themselves.  The 
development of synthetic schemes to stereochemically-pure, orthogonally-protected Lan/MeLan 
building blocks allowed for their application to peptide cyclization on the solid-phase, yielding 
lanthipeptide crosslinks with full control over regiochemistry.  Two lantibiotics were pursued as 
synthetic targets: epilancin 15X, in order to overcome complications in biosynthetic engineering 
of this compound for SAR analysis; and lacticin 481, in order to probe the importance of 
crosslink stereochemistry on biological activity.  An optimized Fmoc-SPPS approach accessed 
milligram quantities of analogues of these compounds in average yields of 92-93% per chemical 
step.  Analogues of epilancin 15X with substituted post-translational modifications in its linear 
N-terminus revealed the importance of this N-terminal portion for potency, potentially through 
binding of a putative biological target, and of the C-terminal ring system for pore formation.  
Analogues of lacticin 481 provided for the first time a systematic assessment of the importance 
of crosslink stereochemistry on biological activity, as replacement of the natural DL-configuration 
of any crosslink with its LL-isomer abolished antibacterial activity.  While wild-type epilancin 
15X could not be accessed due to the lability of its Dhb-Dhb motif, the successful synthesis of 
lacticin 481 represents only the fifth lanthipeptide to succumb to total synthesis, following 
nisin,
25
 lactocin S,
29
 and both peptides of lacticin 3147.
30
 
 With regard to epilancin 15X, a supply of the authentic natural product from the 
producing organism obviated the need to synthesize the wild-type compound in these studies.  
However, the total synthesis of epilancin 15X is still desirable.  As no information about its 
putative biological target is currently available, other than that lipid II does not appear to be 
involved,
41
 mode-of-action studies could be enabled by the chemical synthesis of epilancin 15X 
analogues containing a variety of chemical handles and probes, such as fluorophores, biotin, 
bioorthogonal moieties, and photoreactive groups.  In addition, other lanthipeptides contain 
adjacent α,β-unsaturated residues, such as paenibacillin84 and lichenicidin β,85, 86 and any 
synthetic efforts to produce these compounds necessitates a strategy to install such moieties.  A 
large fragment coupling approach reminiscent of the synthesis of lacticin 3147,
30
 in which the N-
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terminal octapeptide is synthesized separately, may permit the total synthesis of epilancin 15X.  
The Dha/Dhb residues may be installed into the octapeptide through the use of 
phenylselenocysteine surrogates
20, 60, 61
 or other orthogonal elimination chemistry.
25, 64
  
Alternatively, recent advances in peptide ligation chemistry may also be considered for attaching 
the linear N-terminal portion.
87-89
 
 Considering that the stereoisomeric analogues of lacticin 481 lacked biological activity, it 
appears that the three-dimensional structure of this compound, enforced by the absolute 
configurations of each of its DL-crosslinks, evolved to bind its biological target.  The discovery of 
other class II lantibiotics that contain both DL- and LL-crosslinks, biosynthesized by homologous 
LanM synthetases,
44
 begs the question of the role of LL-crosslinks in the bioactivity of these 
compounds.  The SPPS platform described here could be adapted to construct stereoisomeric 
analogues of enterococcal cytolysin or haloduracin β with the LL-crosslinks replaced by their DL-
counterparts in order to address this matter. 
 
3.4. EXPERIMENTAL 
 
3.4.1. Materials and general methods 
 
Authentic epilancin 15X from Staphylococcus epidermidis 15X154
37
 and lacticin 481 
from Lactococcus lactis subsp. lactis CNRZ 481
65
 were provided by Dr. Juan Velásquez 
(University of Illinois at Urbana-Champaign; UIUC) after isolation using known procedures.  
Amino acids for solution-phase synthesis, standard protected Fmoc-amino acids and resins for 
solid-phase peptide synthesis (SPPS), D-lactic acid, and peptide coupling reagents 3-
(diethoxyphosphoryloxy)-1,2,3-benzotriazin-4(3H)-one (DEBPT), N,N’-diisopropylcarbodiimide 
(DIC), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC), 1-hydroxy-7-
azabenzotriazole (HOAt), and 1-hydroxybenzotriazole monohydrate (HOBt) were purchased 
from ChemImpex International.  7-Azabenzotriazole-1-yloxy-tris-pyrrolidinophosphonium 
hexafluorophosphate (PyAOP) was purchased from AAPPTec.  Dimethylformamide (DMF), 
dichloromethane, and tetrahydrofuran (THF) were purchased at reaction grade from Fisher 
Scientific and dried via a solvent dispensing system prior to use in reactions.  Flow cytometry 
dyes 3,3'-diethyloxacarbocyanine iodide (DiOC2(3)) and propidium iodide (PI) were purchased 
from Invitrogen/Life Technologies.  Cell culture media were purchased from BD Biosciences.  
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Other chemical reagents and solvents were purchased from Sigma Aldrich or Alfa Aesar and 
used without further purification unless otherwise stated. 
All reactions were run under an atmosphere of N2 unless otherwise stated.  Reaction 
progress and chromatography fractions were monitored by thin layer chromatography (TLC) on 
silica gel-coated glass plates with a F254 fluorescent indicator.  Visualization was achieved by 
UV absorption by fluorescence quenching or permanganate stain (1.5 g KMnO4, 10 g K2CO3, 
1.25 mL of 10% NaOH in 200 mL of H2O).  Flash chromatography was performed using 
Silicycle SiliaFlash P60, 230-400 mesh silica gel.  Analytical reversed-phase high-performance 
liquid chromatography (RP-HPLC) was performed on an Agilent 1260 Infinity system with a 
Phenomenex Jupiter Proteo C12 (90 Å pore size, 250 mm × 4.6 mm × 10 μm) analytical column 
with a flow rate of 1 mL/min and solvent gradients as described for each peptide, observing at an 
absorbance of 220 nm.  Preparatory RP-HPLC was performed using a Waters Delta 600 system 
equipped with a Phenomenex Jupiter Proteo C12 (90 Å pore size, 250 mm × 15.0 mm × 10 μm) 
preparative column, a flow rate of 10 mL/min, and solvent gradients as described for each 
peptide.  All HPLC solvents were filtered with a Millipore filtration system equipped with a 0.22 
μm nylon membrane filter prior to use.  HPLC solvent compositions: solvent A is 0.1% 
trifluoroacetic acid (TFA) in H2O; solvent B is 80:20 MeCN/H2O with 0.087% TFA. 
NMR spectra were recorded using a Varian Unity 400 or Unity Inova 500 spectrometer at 
the NMR Laboratory (UIUC).  Small molecules (MW < 800 Da) were analyzed by electrospray 
ionization/time-of-flight (ESI-TOF) mass spectrometry using a Waters Quattro II quadrupole 
spectrometer at the Mass Spectrometry Facility (UIUC).  Peptides (MW > 800 Da) were 
analyzed by matrix-assisted laser desorption ionization/time-of-flight (MALDI-TOF) mass 
spectrometry using a Bruker Daltonics UltrafleXtreme TOF/TOF spectrometer at the Mass 
Spectrometry Facility (UIUC) in a matrix solution consisting of saturated α-cyano-4-
hydroxycinnamic acid in 1:1:0.1 H2O/MeCN/TFA.  If desalting was required prior to MS 
analysis, samples were desalted using ZipTipC18 pipette tips (Millipore) and eluted with 4 μL of 
matrix solution, then 2 μL was spotted onto a MALDI target and dried as described above. 
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3.4.2. Synthesis of allyl-protected Lan building blocks DL-3 and LL-3 
 
 
 
Compound D-3.7.  D-Serine (2.10 g, 20.0 mmol) and sodium carbonate (3.18 
g, 30.0 mmol) were dissolved in water (30 mL) and MeCN (15 mL) and 
chilled in an ice bath.  A solution of allyl chloroformate (AlocCl, 2.1 mL, 
20.0 mmol) in MeCN (15 mL) was added dropwise.  The reaction was stirred for 8 h, gradually 
warming to room temperature.  The reaction was concentrated under reduced pressure, then 
taken up in DMF (50 mL).  Sodium bicarbonate (1.68 g, 20.0 mmol) was added, followed by 
allyl bromide (AllBr, 3.5 mL, 40.0 mmol).  The reaction was stirred as a heterogeneous mixture 
under N2 for 15 h.  The reaction was concentrated under reduced pressure, then partitioned 
between water and EtOAc.  The organic layer was separated, washed with saturated aqueous 
NaHCO3, 0.1 M KHSO4 and brine, dried over Na2SO4, filtered, and concentrated under reduced 
pressure.  The crude material was purified by flash chromatography (SiO2, 2:1 hexane/EtOAc) to 
yield D-3.7 (2.67 g, 11.7 mmol, 59%) as a colorless oil.  Rf 0.32 (1:1 hexane/EtOAc).  Spectral 
data match those reported previously.
53
  See also Notebook VII, page 76. 
 
Compound D-3.8.  Compound D-3.7 (2.00 g, 8.73 mmol) and carbon 
tetrabromide (3.47 g, 10.5 mmol) were dissolved in CH2Cl2 (25 mL) and 
chilled in an ice bath.  Triphenylphosphine (2.75 g, 10.5 mmol) was 
dissolved in CH2Cl2 (10 mL) and added dropwise to the chilled solution.  The reaction was 
warmed to room temperature and stirred for 2.5 h, then washed with water and brine, dried over 
Na2SO4, filtered and concentrated under reduced pressure.  Excess 4:1 hexane/EtOAc was added 
to precipitate phosphine oxide byproducts, which were removed via filtration through Celite.  
The filtrate was concentrated under reduced pressure and purified by flash chromatography 
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(SiO2, 5:1 then 4:1 hexane/EtOAc) to yield D-3.8 (1.98 g, 6.78 mmol, 78%) as a colorless oil.  Rf 
0.50 (3:1 hexane/EtOAc).  Spectral data match those reported previously.
53
  See also Notebook 
II, page 78. 
 
Compound 3.9.  To a solution of L-cystine (6.01 g, 25.0 mmol) 
in 70% perchloric acid (10 mL) was slowly added tert-butyl 
acetate (62.5 mL).  The solution was stirred for 19 h, gradually 
becoming homogeneous.  Water was added, and the solution was chilled in an ice bath.  The pH 
was adjusted to 10 with 10 M NaOH, and the solution was extracted with EtOAc.  The organic 
layer was dried over Na2SO4, filtered, and concentrated under reduced pressure.  A portion of the 
residue (5.95 g, 16.9 mmol) was taken up in THF (85 mL), and N-methylmorpholine (3.85 mL, 
34.9 mmol) was added.  The solution was chilled in an ice bath, then N-(9-fluorenylmethoxy-
carbonyloxy)succinimide (FmocOSu; 11.75 g, 34.9 mmol) was added portionwise as a solid over 
10 min.  The reaction was allowed to warm to room temperature, then stirred for 19 h.  The 
reaction was concentrated under reduced pressure, taken up in EtOAc, washed with water and 
brine, dried over Na2SO4, filtered, and concentrated under reduced pressure.  The crude material 
was purified by flash chromatography (SiO2, 9:1 then 7:3 hexane/EtOAc) to yield 3.9 (10.69 g, 
13.4 mmol, 79%) as a white solid.  Rf 0.55 (2:1 hexane/EtOAc).  Spectral data matched those 
reported previously.
53
  See also Notebook I, pages 38-39. 
 
Compound DL-3.10.  Tributylphosphine (410 μL, 1.64 mmol) 
was added to a solution of 3.9 (1.09 g, 1.37 mmol) in THF (15 
mL) and stirred for 15 min.  Water (1.5 mL) was added, and the 
reaction was stirred an additional 2.5 h, and then concentrated under reduced pressure.  To the 
resulting oil was added D-3.8 (0.80 g, 2.74 mmol) in N2-sparged EtOAc (15 mL).  
Tetrabutylammonium bromide (3.55 g, 10.0 mmol) was dissolved in N2-sparged 0.5 M aqueous 
NaHCO3 (pH adjusted to 8.5, 15 mL), then added to the organic solution.  The biphasic mixture 
was stirred for 18 h, then washed with water and brine, dried over Na2SO4, filtered, and 
concentrated under reduced pressure.  The crude material was purified by flash chromatography 
(SiO2, 4:1 hexane/EtOAc) to yield DL-3.10 (1.29 g, 2.11 mmol, 77% over two steps) as a 
colorless oil.  Rf 0.28 (3:1 hexane/EtOAc).  Spectral data match those reported previously.
53
  See 
also Notebook VII, page 49. 
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Compound DL-3.3.  To a solution of DL-3.10 (1.80 g, 2.95 mmol) 
in CH2Cl2 (15 mL) was added phenylsilane (400 µL, 3.24 
mmol), followed by TFA (15 mL).  The reaction was stirred for 
2 h, then concentrated under reduced pressure to yield DL-3.3 (1.64 g, quant.) as a white solid 
after lyophilization from 1:1 benzene/MeCN.  Rf 0.20 (25:1:0.1 CH2Cl2/MeOH/AcOH).  Spectral 
data matched those reported previously.
53
  See also Notebook II, page 81. 
 
 
 
Compound L-3.8 was prepared as for its enantiomer D-3.8 in 34% yield over three steps from L-
serine.  See also Notebook III, pages 15, 18. 
 
Compound LL-3.10.  Tributylphosphine (310 μL, 1.23 mmol) 
was added to a solution of 3.9 (0.82 g, 1.03 mmol) in 
tetrahydrofuran (10 mL) and stirred under N2 for 15 min.  
Water (1.0 mL) was added, and the reaction was stirred an additional 3 h then concentrated under 
reduced pressure.  To the resulting oil was added L-3.8 (0.60 g, 2.05 mmol) in N2-sparged EtOAc 
(10 mL).  Tetrabutylammonium bromide (2.64 g, 8.20 mmol) was dissolved in N2-sparged 0.5 M 
aqueous NaHCO3 (pH adjusted to 8.5, 10 mL), then added to the organic solution.  The biphasic 
mixture was stirred under N2 for 16 h, then washed with water and brine, dried over Na2SO4, 
filtered, and concentrated under reduced pressure.  The crude material was purified by flash 
chromatography (SiO2, 4:1 hexane/EtOAc) to yield LL-3.10 (0.87 g, 1.42 mmol, 70% over two 
steps) as a colorless oil.  Rf 0.25 (3:1 hexane/EtOAc).  
1
H NMR (500 MHz, CDCl3) δ 7.77 (d, J = 
7.5 Hz, 2H), 7.62 (d, J = 7.5 Hz, 2H), 7.40 (t, J = 7.5 Hz, 2H), 7.32 (t, J = 7.5 Hz, 2H), 5.93-5.84 
(m, 2H), 5.69 (app t, J = 7.0 Hz, 2H), 5.40-5.20 (m, 4H), 4.65-4.55 (m, 5H), 4.50 (m, 1H), 4.41 
(m, 2H), 4.24 (t, J = 7.0 Hz, 1H), 3.10-2.95 (m, 4H), 1.49 (s, 9H).  
13
C NMR (125 MHz, CDCl3) 
δ 170.3, 169.5, 155.9, 155.7, 143.94, 143.86, 141.4, 132.6, 131.3, 127.8, 127.2, 125.2, 120.1, 
119.4, 118.1, 83.2, 67.3, 66.6, 66.1, 54.4, 53.9, 47.2, 35.6, 35.5, 28.1.  HRMS (ESI) calc. 
[M+H]
+
 for C32H39N2O8S 611.2427, found 611.2431.  See also Notebook VIII, page 16. 
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Compound LL-3.3.  To a solution of LL-3.10 (0.80 g, 1.31 
mmol) in CH2Cl2 (3 mL) was added phenylsilane (180 µL, 
1.44 mmol), followed by trifluoroacetic acid (3 mL).  The 
reaction was stirred under N2 for 2 h, then concentrated under reduced pressure.  The crude 
material was purified by flash chromatography (SiO2, 1% MeOH/CH2Cl2) to yield LL-3.3 (0.66 
g, 1.19 mmol, 91%) as a white solid after lyophilization from 1:1 benzene/MeCN.  Rf 0.03 (1:1 
EtOAc/hexane).  
1
H NMR (500 MHz, CD3OD) δ 7.73 (d, J = 7.5 Hz, 2H), 7.63 (m, 2H), 7.34 (t, 
J = 7.5 Hz, 2H), 7.27 (t, J = 7.5 Hz, 2H), 5.92-5.83 (m, 2H), 5.30-5.24 (m, 2H), 5.20-5.15 (m, 
2H), 4.58 (d, J = 5.0 Hz, 2H), 4.51 (m, 2H), 4.44 (m, 2H), 4.30 (m, 2H), 4.18 (t, J = 7.0, 1H), 
3.14-3.03 (m, 2H), 2.98-2.88 (m, 2H).  
13
C NMR (125 MHz, CD3OD) δ 173.7, 171.9, 158.4, 
158.1, 145.1, 145.0, 142.4, 134.0, 133.0, 128.7, 128.1, 126.3, 120.9, 118.8, 117.7, 68.1, 67.0, 
66.7, 55.3, 55.1, 48.2, 35.2, 34.9.  HRMS (ESI) calc. [M+H]
+ 
for C28H31N2O8S 555.1801, found 
555.1801.  See also Notebook VIII, page 17. 
 
3.4.3. Synthesis of epimerized Lan building block 3.13 
 
 
 
Compound 3.11.  D-Serine (1.00 g, 9.51 mmol) and sodium carbonate (1.01 
g, 9.51 mmol) were dissolved in water (10 mL) and acetonitrile (5 mL) and 
chilled on ice.  A solution of 4-nitrobenzyl chloroformate (2.05 g, 9.51 
mmol) in acetonitrile (5 mL) was added dropwise to the stirring aqueous solution.  The reaction 
was allowed to warm to room temperature and stirred under N2 for 7 h.  The reaction was 
concentrated under reduced pressure, and the residue was taken up in DMF (25 mL).  Sodium 
bicarbonate (0.80 g, 9.51 mmol) was added, followed by 4-nitrobenzyl bromide (2.26 g, 10.5 
mmol).  The reaction was stirred as a heterogeneous mixture for 23 h.  Additional 4-nitrobenzyl 
bromide (1.00 g, 4.6 mmol) was added at 15 h.  The reaction was concentrated under reduced 
pressure, then taken up in EtOAc, washed with saturated aqueous NaHCO3, water, 0.1 M KHSO4 
and brine, dried over Na2SO4, filtered, and concentrated under reduced pressure.  The crude 
material was precipitated from 1:1 hexane/EtOAc and isolated by filtration, yielding 3.11 (3.33 
g, 7.94 mmol, 83%) as a colorless oil.  Rf 0.10 (1:1 hexane/EtOAc).  
1
H NMR (400 MHz, d6-
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DMSO) δ 8.16 (dd, J = 8.5 Hz, 2.5 Hz, 4H), 7.82 (d, J = 7.5 Hz, 1H), 7.60-7.53 (m, 4H), 5.26 (d, 
J = 2.5 Hz, 2H), 5.17 (d, J = 2.5 Hz, 2H), 5.06 (t, J = 6.0 Hz, 1H), 4.23 (m, 1H), 3.71 (m, 2H).  
LRMS (ESI) calc. [M+H]
+
 for C18H16N3O9 418.1, found 418.2.  See also Notebook III, page 98. 
 
Compound 3.12.  Compound 3.11 (1.20 g, 2.86 mmol) and carbon 
tetrabromide (1.14 g, 3.44 mmol) were dissolved in THF (10 mL) and 
chilled on ice.  Triphenylphosphine (0.90 g, 3.44 mmol) was dissolved in 
THF (5 mL) and added dropwise to the chilled reaction.  The reaction was warmed to room 
temperature and stirred under N2 for 3 h.  The reaction was diluted with EtOAc, forming a 
precipitate that was removed by filtration through Celite.  The filtrate was washed with water and 
brine, dried over Na2SO4, filtered, and concentrated under reduced pressure.  The crude material 
was purified by flash chromatography (SiO2, 3:1 then 3:2 hexane/EtOAc) to yield 3.12 (1.05 g, 
2.18 mmol, 76%) as an off-white solid.  Rf 0.50 (1:1 hexane/EtOAc).  
1
H NMR (400 MHz, 
CDCl3) δ 8.22 (t, J = 8.0 Hz, 4H), 7.51 (t, J = 8.0 Hz, 4H), 5.72 (d, J = 8.0 Hz, 1H), 5.38-5.21 
(m, 4H), 4.88 (m, 1H), 3.88-3.72 (m, 2H).  LRMS (ESI) calc. [M+H]
+
 for C18H15BrN3O8 480.0, 
found 480.1.  See also Notebook V, page 96. 
 
Compound 3.13.  Fmoc-Cys-O
t
Bu
53
 (0.24 g, 0.59 mmol) and 
3.12 (0.30 g, 0.62 mmol) were dissolved in N2-sparged EtOAc (3 
mL) under N2.  Tetrabutylammonium bromide (0.76 g, 2.36 
mmol) was dissolved in N2-sparged 0.5 M aqueous NaHCO3 (pH 8.5, 3 mL), then added to the 
reaction.  The biphasic reaction was stirred for 23 h under N2.  The reaction was diluted with 
EtOAc, washed with water and brine, dried over Na2SO4, filtered, and concentrated under 
reduced pressure.  The crude material was purified by flash chromatography (SiO2, 3:1 then 3:2 
hexane/EtOAc) to yield 3.13 (0.39 g, 0.49 mmol, 87%) as a white foam.  Rf 0.19 (2:1 
hexane/EtOAc).  
1
H NMR (400 MHz, CDCl3) δ 8.16-8.10 (m, 4H), 7.72 (d, J = 7.5 Hz, 2H), 7.54 
(d, J = 7.0 Hz, 2H), 7.44-7.22 (m, 8H), 5.91 (m, 1H, diastereomers), 5.64 (m, 1H, diastereomers), 
5.20-5.11 (m, 4H), 4.62 (m, 1H), 4.44 (m, 1H), 4.32 (m, 2H), 4.17 (t, J = 7.0 Hz, 1H), 3.12-2.87 
(m, 4H), 1.45 (s, 9H).  
13
C NMR (125 MHz, CDCl3) δ 170.2, 169.3, 156.0, 155.5, 148.0, 147.7, 
143.8, 143.7, 143.5, 142.0, 141.4, 128.6, 128.1, 127.9, 127.2, 125.2, 124.0, 123.8, 120.2, 83.5, 
67.4, 67.3, 66.1, 65.7, 54.5-54.3 (diastereomers), 54.1-53.9 (diastereomers), 47.1, 36.1, 35.7 
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(diastereomers), 35.5-34.9 (diastereomers), 28.1.  LRMS (ESI) calc. [M+Na]
+
 for 
C40H40N4O12SNa 823.2, found 823.6.  See also Notebook V, page 98. 
 
3.4.4. Synthesis of epimerized MeLan building block 3.16 
 
 
 
Compound 3.14.  D-Threonine (4.00 g, 33.6 mmol) and sodium carbonate 
(3.56 g, 33.6 mmol) were dissolved in water (45 mL) and acetonitrile (20 
mL) and chilled in an ice bath.  Allyl chloroformate (3.57 mL, 33.6 mmol) 
was added dropwise.  The reaction was allowed to warm to room temperature and stirred under 
N2 for 23 h.  The reaction was concentrated under reduced pressure, and the residue was taken up 
in DMF (85 mL).  Sodium bicarbonate (2.82 g, 33.6 mmol) was added, followed by allyl 
bromide (3.20 mL, 37.0 mmol).  The reaction was stirred as a heterogeneous mixture for 30 h, 
with additional allyl bromide (1.50 mL, 17.3 mmol) added after 7 h.  The reaction was 
concentrated under reduced pressure, taken up in EtOAc, washed with saturated aqueous 
NaHCO3, water, 0.1 M KHSO4, and brine, dried over Na2SO4, filtered, and concentrated under 
reduced pressure.  The crude material was purified by flash chromatography (SiO2, 7:3 then 3:2 
hexane/EtOAc) to yield 3.14 (6.55 g, 26.9 mmol, 80%) as a colorless oil.  Rf 0.52 (1:1 
hexane/EtOAc).  
1
H NMR (400 MHz, CDCl3) δ 5.96-5.85 (m, 2H), 5.63-5.48 (m, 1H), 5.38-5.20 
(m, 4H), 4.68 (m, 2H), 4.60 (m, 2H), 4.38-4.30 (m, 2H), 2.0-1.8 (bs, 1H), 1.26 (d, J = 7.0 Hz, 
3H).  LRMS (ESI) calc. [M+H]
+ for C11H18NO5 244.1, found 244.2.  See also Notebook II, page 
69. 
 
Compound 3.15.  To a solution of carbon tetrabromide (1.43 g, 4.32 mmol) 
in benzene (15 mL) was added triphenyl phosphine (1.13 g, 4.32 mmol), and 
the reaction was stirred for 20 min, forming a precipitate.  This mixture was 
then added to a solution of 3.14 (0.70 g, 2.88 mmol) in benzene (15 mL) and stirred for 4 h under 
N2.  Solids were removed by filtration through Celite and washed with benzene.  The combined 
filtrates were concentrated under reduced pressure, taken up in EtOAc, washed with brine, dried 
over Na2SO4, filtered, and concentrated.  The crude material was purified by flash 
chromatography (SiO2, 5:1 hexanes/EtOAc) to yield 3.15 (0.70 g, 2.29 mmol, 80%) as a 
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colorless oil.  Rf 0.65 (3:1 hexanes/EtOAc).  
1
H NMR (400 MHz, CDCl3) δ 5.97-5.88 (m, 2H), 
5.61 (d, J = 7.5 Hz, 1H), 5.40-5.22 (m, 4H), 4.71 (m, 2H), 4.63-4.58 (m, 3H), 4.38 (m, 1H), 1.81 
(d, J = 7.0 Hz, 3H).  LRMS (ESI) calc. [M+H]
+
 for C11H17BrNO4 306.0, found 306.2.  See also 
Notebook VI, page 91. 
 
Compound 3.16.  Fmoc-Cys-O
t
Bu
53
 (1.74 g, 4.35 mmol) and 
3.15 (1.40 g, 4.57 mmol) were dissolved in N2-sparged EtOAc 
(20 mL) under N2.  Tetrabutylammonium bromide (5.61 g, 17.4 
mmol) was dissolved in 0.5 M aqueous NaHCO3 (pH 8.5, 20 mL), then added to the reaction.  
The reaction was stirred vigorously as a heterogeneous mixture for 40 h under N2.  The reaction 
was diluted with EtOAc, washed with water and brine, dried over Na2SO4, filtered, and 
concentrated under reduced pressure.  The crude material was purified by flash chromatography 
(SiO2, 6:1 hexane/EtOAc) to yield 3.16 (0.39 g, 0.49 mmol, 26%) as a colorless oil and a mixture 
of diastereomers.  Rf 0.39 (3:1 hexanes/EtOAc).  
1
H NMR (500 MHz, CDCl3) δ 7.76 (d, 2H), 
7.66 (m, 2H), 7.41 (t, 2H), 7.32 (t, 2H), 5.96-5.86 (m, 2H), 5.77-5.45 (m, 2H, diastereomers), 
5.37-5.19 (m, 4H), 4.69-4.40 (m, 6H), 4.38-4.34 (m, 2H), 4.24 (t, 1H), 3.50-3.25 (m, 1H, 
diastereomers), 3.14-2.93 (m, 2H, diastereomers), 1.49 (s, 9H), 1.35 (d, 1.5H, diastereomers), 
1.25 (m, 1.5H, diastereomers).  LRMS (ESI) calc. [M+H]
+
 for C33H41N2O8S 625.3, found 625.4.  
See also Notebook II, page 77. 
 
3.4.5. Synthesis of nitrobenzyl-protected Lan building blocks DL-3.4 and LL-3.4 
 
 
  
108 
 
Compound 3.17.  To a stirring suspension of N-Fmoc-L-serine (8.19 g, 
25.0 mmol) in ethyl acetate (125 mL) was added tert-butyl 2,2,2-
trichloroacetimidate (8.95 mL, 50.0 mmol) in cyclohexane (50 mL) by 
addition funnel over 15 min.  The reaction was stirred under N2 for 18 h, then washed with 
saturated aqueous NaHCO3, water and brine, dried over Na2SO4, filtered, and concentrated under 
reduced pressure.  The crude material was purified by flash chromatography (SiO2, 3:1 
hexane/EtOAc) to yield 3.17 (8.90 g, 23.2 mmol, 93%) as a white solid.  Rf 0.58 (1:1 
hexanes/EtOAc).  1H NMR confirms product.  Spectral data match those previously reported.
90
  
See also Notebook VII, page 89. 
 
Compound 3.18.  Compound 3.17 (2.00 g, 5.22 mmol) and carbon 
tetrabromide (2.08 g, 6.26 mmol) were dissolved in CH2Cl2 (10 mL) and 
chilled in an ice bath.  Triphenylphosphine (1.64 g, 6.26 mmol) was 
dissolved in CH2Cl2 (10 mL) and added dropwise to the chilled solution.  The reaction was 
warmed to room temperature and stirred under N2 for 2.5 h, then washed with water and brine, 
dried over Na2SO4, filtered, and concentrated under reduced pressure.  Excess 5:1 hexane/EtOAc 
was added to precipitate phosphine oxide byproducts, which were removed via filtration through 
Celite.  The filtrate was concentrated under reduced pressure and purified by flash 
chromatography (SiO2, 15% EtOAc/hexane) to yield 3.18 (1.83 g, 4.10 mmol, 79%) as an amber 
oil.  Rf 0.56 (3:1 hexane/EtOAc).  Spectral data match those reported previously.
91
  See also 
Notebook II, page 89. 
 
Compound D-3.19.  S-trityl-D-cysteine (1.82 g, 5.00 mmol) and sodium 
carbonate (0.53 g, 5.00 mmol) were dissolved in water (10 mL) and 
MeCN (5 mL) and chilled in an ice bath.  A solution of 4-nitrobenzyl 
chloroformate (1.08 g, 5.00 mmol) in MeCN (5 mL) was added dropwise over 10 min.  The 
reaction was stirred for 15 h, gradually warming to room temperature, then concentrated under 
reduced pressure.  The residue was taken up in DMF (10 mL), and sodium bicarbonate (0.50 g, 
6.00 mmol) was added, followed by 4-nitrobenzyl bromide (1.30 g, 6.00 mmol).  The reaction 
was stirred as a heterogeneous mixture for 21 h, then concentrated under reduced pressure and 
the residue taken up in EtOAc.  The organic layer was washed with saturated aqueous NaHCO3, 
0.1 M KHSO4, and brine, dried over Na2SO4, filtered, and concentrated under reduced pressure.  
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The crude material was purified by flash chromatography (SiO2, 2:1 hexane/EtOAc) to yield D-
3.19 (3.20 g, 4.72 mmol, 94%) as a yellow foam.  Rf 0.28 (2:1 hexane/EtOAc).  
1
H NMR (500 
MHz, CDCl3) δ 8.20 (m, 4H), 7.50 (d, J = 8.5 Hz, 2H), 7.46 (d, J = 8.5 Hz, 2H), 7.37 (m, 6H), 
7.33-7.20 (m, 9H), 5.35 (d, J  = 8.5 Hz, 1H), 5.28-5.16 (m, 4H), 4.38 (q, J = 6.5 Hz, 1H), 2.76 
(dd, J = 12.5 Hz, 6.5 Hz, 1H), 2.65 (dd, J = 12.5 Hz, 4.5 Hz, 1H).  
13
C NMR (125 MHz, CDCl3) 
δ 170.2, 155.3, 148.0, 147.8, 144.2, 143.6, 142.3, 129.5, 128.6, 128.2, 128.1, 127.2, 123.9, 67.3, 
66.0, 65.7, 53.2, 34.0.  HRMS (ESI) calc. [M+Na]
+
 for C37H31N3O8SNa 700.1730, found 
700.1733.  See also Notebook VIII, page 75. 
 
Compound D-3.20.  To a solution of D-3.19 (2.03 g, 3.00 mmol) in CH2Cl2 
(30 mL) under N2 was added triisopropylsilane (0.92 mL, 4.50 mmol), 
followed by trifluoroacetic acid (3.5 mL, 45.0 mmol).  A vivid yellow 
color appeared immediately, then faded over the reaction time (1.5 h).  The reaction was diluted 
with CH2Cl2 and water, then solid sodium bicarbonate (3.78 g, 45.0 mmol) was slowly added to 
neutralize the residual acid.  The organic layer was separated, washed with brine, dried over 
Na2SO4, filtered, and concentrated under reduced pressure.  The crude material was purified by 
flash chromatography (SiO2, 2:1 hexane/EtOAc) to yield D-3.20 (1.15 g, 2.64 mmol, 88%) as an 
amber solid.  Rf 0.53 (1:1 hexane/EtOAc).  
1
H NMR (500 MHz, CDCl3) δ 8.20 (m, 4H), 7.51 
(app t, J = 8.5 Hz, 4H), 5.80 (d, J = 7.5 Hz, 1H), 5.35-5.26 (m, 2H), 5.22 (m, 2H), 4.73 (m, 1H), 
3.10-2.98 (m, 2H), 1.38 (t, J = 9.0 Hz, 1H).  
13
C NMR (125 MHz, CDCl3) δ 169.7, 155.3, 148.0, 
147.8, 143.5, 142.1, 128.8, 128.3, 124.0, 123.9, 66.2, 65.8, 55.4, 27.1.  HRMS (ESI) calc. 
[M+H]
+
 for C18H18N3O8S 436.0815, found 436.0819.  See also Notebook VIII, page 76. 
 
Compound DL-3.21.  Compounds 3.18 (0.58 g, 1.29 mmol) 
and D-3.20 (0.45 g, 1.03 mmol) were dissolved in N2-sparged 
EtOAc (5 mL).  Tetrabutylammonium bromide (1.33 g, 4.12 
mmol) was dissolved in N2-sparged 0.5 M aqueous NaHCO3 (pH adjusted to 8.5, 5 mL), then 
added to the organic solution.  The biphasic mixture was stirred under N2 for 20 h, with 
tributylphosphine (130 μL, 0.52 mmol) added to the reaction after 5 h.  The organic layer was 
isolated, washed with water and brine, dried over Na2SO4, filtered, and concentrated under 
reduced pressure.  The crude material was purified by flash chromatography (SiO2, 30% 
EtOAc/hexane) to yield DL-3.21 (0.64 g, 0.80 mmol, 78%) as a colorless foam.  Rf 0.39 (2:1 
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hexane/EtOAc).  
1
H NMR (500 MHz, CDCl3) δ 8.15 (m, 4H), 7.74 (d, J = 7.5 Hz, 2H), 7.56 (m, 
2H), 7.44 (app d, J = 8.5 Hz, 4H), 7.39 (t, J = 7.5 Hz, 2H), 7.29 (t, J = 7.5 Hz, 2H), 5.96 (d, J = 
7.5 Hz, 1H), 5.74 (d, J = 7.5 Hz, 1H), 5.23 (m, 2H), 5.17 (m, 2H), 4.67 (m, 1H), 4.48 (m, 1H), 
4.34 (m, 2H), 4.20 (t, J = 7.0 Hz, 1H), 3.12 (dd, J = 14.0 Hz, 5.0 Hz, 1H), 3.08-3.01 (m, 2H), 
2.94 (dd, J = 14.0 Hz, 5.0 Hz, 1H), 1.47 (s, 9H).  
13
C NMR (125 MHz, CDCl3) δ 170.1, 169.2, 
156.0, 155.5, 147.8, 147.6, 143.8, 143.7, 143.5, 142.1, 141.3, 128.5, 128.0, 127.9, 127.2, 125.1, 
123.9, 123.8, 120.1, 83.4, 67.4, 66.1, 65.7, 54.5, 54.0, 47.1, 36.1, 35.4, 28.0.  HRMS (ESI) calc. 
[M+H]
+
 for C40H41N4O12S 801.2442, found 801.2447.  See also Notebook IX, page 68. 
 
Compound DL-3.4.  To a solution of DL-3.21 (0.50 g, 0.62 
mmol) in CH2Cl2 (3 mL) was added phenylsilane (80 µL, 0.66 
mmol), followed by trifluoroacetic acid (3 mL).  The reaction 
was stirred under N2 for 2.5 h, then concentrated under reduced pressure.  The crude material 
was purified by flash chromatography (SiO2, 2% MeOH/CH2Cl2) to yield DL-3.4 (0.44 g, 0.59 
mmol, 95%) as a colorless foam.  
1
H NMR (500 MHz, CD3OD) δ 8.10 (app t, J = 8.5 Hz, 4H), 
7.75 (d, J = 7.5 Hz, 2H), 7.63 (d, J = 7.5 Hz, 2H), 7.51 (app t, J = 7.5 Hz, 4H), 7.35 (dt, J = 7.5 
Hz, 3.5 Hz, 2H), 7.25 (dt, J = 7.5 Hz, 3.5 Hz, 2H), 5.25-5.15 (m, 4H), 4.56 (m, 1H), 4.44 (m, 
1H), 4.33 (m, 1H), 4.23 (m, 1H), 4.18 (t, J = 7.0 Hz, 1H), 3.10 (dd, J = 14.0 Hz, 5.0 Hz, 2H), 
3.05-2.91 (m, 2H).  
13
C NMR (125 MHz, CD3OD) δ 173.7, 171.8, 158.4, 157.9, 148.8, 148.7, 
145.7, 145.1, 144.3, 142.4, 129.3, 128.9, 128.8, 128.2, 126.3, 124.51, 124.47, 120.9, 68.2, 66.7, 
66.3, 55.8, 55.4, 48.2, 35.7, 35.2.  HRMS (ESI) calc. [M+H]
+
 for C36H33N4O12S 745.1816, found 
745.1823.  See also Notebook VIII, page 79. 
 
 
 
Compound L-3.20 was prepared as for its enantiomer D-3.20 in 63% yield over two steps from S-
trityl-L-cysteine.  See also Notebook IX, pages 19, 24. 
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Compound LL-3.21.  Compounds 3.18 (0.56 g, 1.26 mmol) 
and L-3.20 (0.50 g, 1.15 mmol) were dissolved in N2-sparged 
EtOAc (8 mL).  Tetrabutylammonium bromide (1.48 g, 4.60 
mmol) was dissolved in N2-sparged 0.5 M aqueous NaHCO3 (pH adjusted to 8.5, 8 mL), then 
added to the organic solution.  The biphasic mixture was stirred under N2 for 24 h, with 
tributylphosphine (140 μL, 0.58 mmol) added to the reaction after 4 h.  The organic layer was 
isolated, washed with water and brine, dried over Na2SO4, filtered, and concentrated under 
reduced pressure.  The crude material was purified by flash chromatography (SiO2, 30% 
EtOAc/hexane) to yield LL-3.21 (0.62 g, 0.78 mmol, 68%) as a colorless foam.  Rf 0.38 (2:1 
hexane/EtOAc).  
1
H NMR (500 MHz, CDCl3) δ 8.16 (m, 4H), 7.74 (d, J = 7.5 Hz, 2H), 7.56 (m, 
2H), 7.46-7.36 (m, 6H), 7.29 (t, J = 7.5 Hz, 2H), 5.91 (d, J = 7.5 Hz, 1H), 5.65 (d, J = 7.0 Hz, 
1H), 5.23-5.11 (m, 4H), 4.62 (m, 1H), 4.42-4.32 (m, 2H), 4.20 (t, J = 7.0 Hz, 1H), 3.12-3.03 (m, 
3H), 2.91 (dd, J = 14.0 Hz, 5.5 Hz, 1H), 1.47 (s, 9H).  
13
C NMR (125 MHz, CDCl3) δ 170.2, 
169.3, 156.0, 155.5, 147.8, 147.5, 143.7, 143.6, 143.5, 142.1, 141.3, 128.5, 127.9, 127.8, 127.1, 
125.1, 123.8, 123.7, 120.1, 83.4, 67.2, 66.0, 65.6, 54.3, 53.9, 47.1, 35.6, 34.8, 28.0.  HRMS 
(ESI) calc. [M+H]
+
 for C40H41N4O12S 801.2442, found 801.2443.  See also Notebook IX, page 
25. 
 
Compound LL-3.4.  To a solution of LL-3.21 (0.55 g, 0.69 
mmol) in CH2Cl2 (5 mL) and phenylsilane (80 µL, 0.72 
mmol) was added trifluoroacetic acid (5 mL).  The reaction 
was stirred for 2 h, concentrated under reduced pressure and the residue repeatedly redissolved in 
CH2Cl2 and concentrated to remove residual acid.  The crude material was purified by flash 
chromatography (SiO2, 2%-5% MeOH/CH2Cl2) to yield LL-3.4 (0.45 g, 0.61 mmol, 89%) as a 
white solid after lyophilization from 1:1 benzene/MeCN.  Rf 0.05 (EtOAc).  
1
H NMR (500 MHz, 
CD3OD) δ 8.10 (app t, J = 8.5 Hz, 4H), 7.74 (d, J = 7.5 Hz, 2H), 7.62 (d, J = 7.5 Hz, 2H), 7.49 
(app t, J = 7.5 Hz, 4H), 7.34 (t, J = 7.5 Hz, 2H), 7.26 (t, J = 7.5 Hz, 2H), 5.26-5.11 (m, 4H), 4.55 
(m, 1H), 4.43 (m, 1H), 4.31 (m, 1H), 4.24 (m, 1H), 4.18 (t, J = 7.0 Hz, 1H), 3.15 (dd, J = 14.0 
Hz, 4.5 Hz, 2H), 2.99 (dd, J = 14.0 Hz, 3.5 Hz, 1H), 2.90 (dd, J = 14.0 Hz, 4.0 Hz, 1H).  
13
C 
NMR (125 MHz, CD3OD) δ 173.7, 171.9, 158.4, 157.9, 148.9, 148.7, 145.7, 145.13, 145.11, 
144.3, 142.4, 129.3, 128.9, 128.8, 128.1, 126.3, 124.52, 124.47, 120.9, 68.2, 66.7, 66.3, 55.6, 
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55.2, 48.3, 35.4, 34.9.  HRMS (ESI) calc. [M+H]
+
 for C36H33N4O12S 745.1816, found 745.1817.  
See also Ting Chen Notebook I, page 20. 
 
3.4.6. Synthesis of allyl-protected MeLan building block DL-3.5 
 
 
 
Compound D-3.22.  D-Threonine (4.17 g, 35.0 mmol) and para-
toluenesulfonic acid monohydrate (7.99 g, 42.0 mmol) were combined in 
toluene (90 mL).  Allyl alcohol (AllOH, 24 mL, 350 mmol) was added, and 
the reaction was refluxed in an oil bath (110 
o
C) connected to a Dean-Stark apparatus for 15 h, 
then concentrated under reduced pressure and dried azeotropically with benzene.  The residue 
was taken up in CH2Cl2 (175 mL) and chilled in an ice bath.  Triethylamine (14.6 mL, 105 
mmol) was added, and the reaction was allowed to stir for 10 min.  4-Nitrobenzenesulfonyl 
chloride (NsCl, 8.53 g, 38.5 mmol) was added portionwise as a solid, and the reaction was stirred 
for 4 h at 0 
o
C.  The reaction mixture was washed with 1 M NaH2PO4, saturated aqueous 
NaHCO3 and brine, dried over Na2SO4, filtered, and concentrated under reduced pressure.  The 
crude material was purified by flash chromatography (SiO2, 7:3 then 3:2 hexane/EtOAc) to yield 
D-3.22 (9.48 g, 27.5 mmol, 79% over two steps) as a yellow solid.  Rf 0.43 (1:1 hexane/EtOAc).  
Spectral data match those reported previously.
92
  See also Notebook VII, pages 7-8. 
 
Compound D-3.23.  A solution of D-3.22 (2.70 g, 7.84 mmol) and 
triphenylphosphine (2.67 g, 10.2 mmol) in THF (30 mL) was chilled in an ice 
bath.  Diisopropylazodicarboxylate (1.7 mL, 8.63 mmol) was added dropwise, 
and the reaction was stirred for 2.5 h at 0 
o
C, then concentrated under reduced pressure.  The 
residue was taken up in EtOAc, washed with saturated aqueous NaHCO3 and brine, dried over 
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Na2SO4, filtered, and concentrated under reduced pressure.  The crude material was purified by 
flash chromatography (SiO2, 5:1 hexane/EtOAc) to yield D-3.23 (2.13 g, 6.53 mmol, 83%) as a 
yellow solid.  Rf 0.54 (2:1 hexane/EtOAc).  Spectral data match those reported previously.
92
  See 
also Notebook VIII, page 20. 
 
Compound D-3.24.  A solution of D-3.23 (0.65 g, 2.00 mmol) and 4-
methoxybenzyl mercaptan (1.12 mL, 8.00 mmol) in CH2Cl2 (20 mL) was 
chilled in an ice bath.  Boron trifluoride diethyl etherate (0.74 mL, 6.00 
mmol) was added dropwise to the stirring solution.  The reaction was stirred for 21 h at 4 
o
C, 
then washed with saturated aqueous NaHCO3 and brine, dried over Na2SO4, filtered, and 
concentrated under reduced pressure.  The crude material was purified by flash chromatography 
(SiO2, 4:1 hexane/EtOAc) to yield D-3.24 (0.82 g, 1.71 mmol, 86%) as a yellow solid.  Rf 0.47 
(2:1 hexane/EtOAc).  Spectral data match those reported previously.
92
  See also Notebook VI, 
page 39. 
 
Compound D-3.25.  To a stirring solution of D-3.24 (2.40 g, 5.00 mmol) in 49:1 
MeCN/dimethylsulfoxide (35 mL) were added 4-methoxybenzene thiol (1.84 
mL, 15.0 mmol) and potassium carbonate (2.76 g, 20.0 mmol).  The reaction 
was stirred as a heterogeneous mixture for 3 h, then concentrated under reduced pressure.  The 
residue was taken up in EtOAc, washed with water and brine, dried over Na2SO4, filtered, and 
concentrated under reduced pressure.   The crude mixture was purified by flash chromatography 
(SiO2, 3:2 then 2:3 hexane/EtOAc) to yield D-3.25 (1.35 g, 4.57 mmol, 91%) as a colorless oil.  
Rf 0.30 (1:1 hexane/EtOAc).  Spectral data match those reported previously.
92
  See also Notebook 
VII, page 17. 
 
Compound D-3.26.  Diisopropylethylamine (0.74 mL, 4.26 mmol) and 
allyloxycarbonyloxysuccinimide (AlocOSu; 0.74 g, 3.73 mmol) were added 
to a solution of D-3.25 (1.05 g, 3.55 mmol) in CH2Cl2 (20 mL) and the 
reaction was stirred for 12 h.  The reaction was washed with water, 10% citric acid and brine, 
dried over Na2SO4, filtered, and concentrated under reduced pressure.  The crude material was 
purified by flash chromatography (SiO2, 4:1 hexane/EtOAc) to yield D-3.26 (1.31 g, 3.45 mmol, 
97%) as a colorless oil.  Rf 0.58 (2:1 hexane/EtOAc).  
1
H NMR (500 MHz, CDCl3) δ 7.20 (dd, J 
= 9.5 Hz, 2.5 Hz, 2H), 6.84 (dd, J = 9.5 Hz, 2.5 Hz, 2H), 5.95-5.84 (m, 2H), 5.50 (d, J = 9.0 Hz, 
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1H), 5.37-5.20 (m, 4H), 4.66 (dd, J = 13.0 Hz, 6.0 Hz, 1H), 4.59-4.56 (m, 3H), 4.53 (dd, J = 9.5 
Hz, 3.5 Hz, 1H), 3.79 (s, 3H), 3.67 (d, J = 13.0 Hz, 1H), 3.64 (d, J = 13.0 Hz, 1H), 3.31 (m, 1H), 
1.30 (d, J = 7.0 Hz, 3H).  
13
C NMR (125 MHz, CDCl3) δ 170.6, 158.9, 156.4, 132.7, 131.5, 
130.1, 129.7, 119.3, 118.0, 114.1, 66.4, 66.1, 58.6, 55.4, 42.2, 35.2, 19.7.  HRMS (ESI) calc. 
[M+H]
+
 for C19H26NO5S 380.1532, found 380.1532.  See also Notebook VII, page 64. 
 
Compound DL-3.27.  Compound D-3.26 (0.68 g, 1.80 mmol) was 
dissolved in TFA (10 mL) and anisole (780 μL, 7.20 mmol).  
Mercury(II) acetate (1.15 g, 3.60 mmol) was added as a solid, 
and the purple solution was stirred for 4 h.  Dithiothreitol (DTT, 0.56 g, 3.60 mmol) was then 
added, forming a grey precipitate.  This heterogeneous mixture was stirred vigorously for 15 h, 
then diluted with CH2Cl2 and centrifuged (4600 g, 10 min) to remove the solids.  The 
supernatant was concentrated under reduced pressure, taken up in CH2Cl2 and water, and 
neutralized by slow addition of saturated aqueous NaHCO3 to pH 7.  The organic layer was 
separated, dried over Na2SO4, filtered, and concentrated under reduced pressure.  The crude 
material was purified by flash chromatography (SiO2, 15% EtOAc/hexane) to yield the 
intermediary thiol, which was used directly for the next reaction without complete concentration 
or characterization due to its instability.  Rf 0.52 (3:1 hexane/EtOAc).  To the partially-
concentrated thiol was added 3.18 (0.54 g, 1.20 mmol) and N2-sparged EtOAc (6 mL).  
Tetrabutylammonium bromide (1.55 g, 4.80 mmol) was dissolved in N2-sparged 0.5 M aqueous 
NaHCO3 (pH adjusted to 8.5, 6 mL), then added to the organic solution.  The biphasic reaction 
was stirred for 5 h, and the pH was adjusted to 8.5 as necessary with 1 M NaOH.  
Tributylphosphine (150 μL, 0.60 mmol) was added, and the reaction was stirred for an additional 
17 h.  The organic layer was isolated, washed with water and brine, dried over Na2SO4, filtered, 
and concentrated under reduced pressure.  The crude material was purified by flash 
chromatography (SiO2, 4:1 hexane/EtOAc) to yield DL-3.27 (0.48 g, 0.77 mmol, 64% over two 
steps) as a colorless foam.  Rf 0.34 (3:1 hexane/EtOAc).  
1
H NMR (500 MHz, CDCl3) δ 7.77 (d, 
J = 7.5 Hz, 2H), 7.62 (d, J = 7.5 Hz, 2H), 7.41 (t, J = 7.5 Hz, 2H), 7.32 (t, J = 7.5 Hz, 2H), 5.95-
5.88 (m, 2H), 5.62 (d, J = 7.5 Hz, 1H), 5.57 (d, J = 9.5 Hz, 1H), 5.37-5.20 (m, 4H), 4.70-4.53 (m, 
5H), 4.48-4.37 (m, 3H), 4.24 (t, J = 7.0 Hz, 1H), 3.43 (m, 1H), 3.02-2.89 (m, 2H), 1.48 (s, 9H), 
1.34 (d, J = 7.0 Hz, 3H).  
13
C NMR (125 MHz, CDCl3) δ 170.4, 169.4, 156.4, 155.8, 144.0, 
143.9, 141.4, 132.6, 131.4, 127.9, 127.2, 125.2, 120.1, 119.6, 118.1, 83.3, 67.3, 66.5, 66.2, 58.5, 
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54.3, 47.2, 44.0, 34.2, 29.8, 28.1, 19.8.  HRMS (ESI) calc. [M+Na]
+
 for C33H40N2O8SNa 
647.2403, found 647.2405.  See also Notebook VII, pages 35-36. 
 
Compound DL-3.5.  To a solution of DL-3.27 (0.45 g, 0.72 mmol) 
in CH2Cl2 (3 mL) was added phenylsilane (95 µL, 0.76 mmol), 
followed by TFA (3 mL).  The reaction was stirred for 2 h, 
concentrated under reduced pressure and repeatedly redissolved in CH2Cl2 and concentrated to 
remove residual TFA.  The crude material was purified by flash chromatography (SiO2, 1%-2% 
MeOH/CH2Cl2) to yield DL-3.5 (0.39 g, 0.69 mmol, 96%) as a white solid after lyophilization 
from 1:1 benzene/MeCN.  Rf 0.05 (2:1 EtOAc/hexane).  
1
H NMR (500 MHz, CD3OD) δ 7.80 (d, 
J = 7.5 Hz, 2H), 7.69 (d, J = 7.5 Hz, 2H), 7.39 (t, J = 7.5 Hz, 2H), 7.31 (t, J = 7.5 Hz, 2H), 5.99-
5.88 (m, 2H), 5.38-5.29 (m, 2H), 5.24-5.16 (dd, J = 22.5 Hz, 10.5 Hz, 2H), 4.65 (m, 2H), 4.55 (d, 
J = 5.5 Hz, 2H), 4.47 (d, J = 4.0 Hz, 1H), 4.41-4.30 (m, 3H), 4.25 (t, J = 7.0, 1H), 3.45 (m, 1H), 
3.08 (dd, J = 13.5 Hz, 4.5 Hz, 1H), 2.83 (dd, J = 13.5 Hz, 8.5 Hz, 1H), 1.31 (d, J = 7.0 Hz, 3H).  
13
C NMR (125 MHz, CD3OD) δ 173.7, 171.7, 158.6, 158.4, 145.3, 145.2, 142.6, 134.2, 133.1, 
128.8, 128.2, 126.3, 120.9, 119.2, 117.8, 68.2, 67.2, 66.8, 60.2, 55.3, 48.4, 43.8, 34.2, 19.8.  
HRMS (ESI) calc. [M+H]
+
 for C29H33N2O8S 569.1958, found 569.1959.  See also Notebook VII, 
page 38. 
 
3.4.7. Synthesis of nitrobenzyl-protected MeLan building blocks DL-3.6 and LL-3.6 
 
 
 
Compound D-3.56.  Diisopropylethylamine (1.4 mL, 8.1 mmol) and 4-
nitrobenzyl chloroformate (1.46 g, 6.77 mmol) were added to a solution of 
D-3.25 (2.00 g, 6.77 mmol) in CH2Cl2 (35 mL), and the reaction was stirred 
for 16 h.  The reaction was washed with water, 10% citric acid and brine, dried over Na2SO4, 
filtered, and concentrated under reduced pressure.  The crude material was purified by flash 
chromatography (SiO2, 4:1 hexane/EtOAc) to yield D-3.56 (3.10 g, 6.53 mmol, 96%) as a 
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colorless oil.  Rf 0.50 (2:1 hexane/EtOAc).  
1
H NMR (500 MHz, CDCl3) δ 8.21 (d, J = 9.0 Hz, 
2H), 7.51 (d, J = 9.0 Hz, 2H), 7.19 (d, J = 8.5 Hz, 2H), 6.83 (dt, J = 8.5 Hz, 2.0 Hz, 2H), 5.91-
5.83 (m, 1H), 5.62 (d, J = 9.0 Hz, 1H), 5.36-5.32 (dd, J = 17.0 Hz, 1.0 Hz, 1H), 5.27 (dd, J = 
10.5 Hz, 1.0 Hz, 1H), 5.23 (d, J = 13.5 Hz, 1H), 5.19 (d, J = 13.5 Hz, 1H), 4.66 (dd, J = 13.0 Hz, 
6.0 Hz, 1H), 4.58 (dd, J = 13.0 Hz, 6.0 Hz, 1H), 4.53 (dd, J = 9.0 Hz, 3.5 Hz, 1H), 3.78 (s, 3H), 
3.67 (d, J = 13.0 Hz, 1H), 3.63 (d, J = 13.0 Hz, 1H), 3.33 (m, 1H), 1.30 (d, J = 7.5 Hz, 3H).  
13
C 
NMR (125 MHz, CDCl3) δ 170.3, 158.9, 156.1, 147.7, 143.8, 131.4, 130.0, 129.5, 128.1, 123.9, 
119.4, 114.1, 66.5, 65.7, 58.7, 55.4, 42.1, 35.2, 19.8.  HRMS (ESI) calc. [M+H]
+
 for 
C23H27N2O7S 475.1539, found 475.1556.  See also Notebook VII, page 62. 
 
Compound D-3.28.  Tetrakis(triphenylphosphine)palladium(0) (390 mg, 
0.34 mmol) was added to a solution of D-3.56 (3.20 g, 6.74 mmol) and N-
methylaniline (1.5 mL, 13.5 mmol) in THF (60 mL).  The reaction was 
stirred for 1.5 h, protected from light, then concentrated under reduced pressure.  The resulting 
oil was taken up in DMF (25 mL), and sodium bicarbonate (1.13 g, 13.5 mmol) and 4-
nitrobenzyl bromide (3.65 g, 16.9 mmol) were added as solids.  The reaction was stirred for 30 h, 
with additional 4-nitrobenzyl bromide (pNbBr, 1.46 g, 6.74 mmol) added after 11 h.  The 
reaction mixture was concentrated under reduced pressure, taken up in EtOAc, washed with 
saturated aqueous NaHCO3, water and brine, dried over Na2SO4, filtered, and concentrated under 
reduced pressure.  The crude material was purified by flash chromatography (SiO2, 30% 
EtOAc/hexane) to yield D-3.28 (3.55 g, 6.23 mmol, 93% over two steps) as an amber foam.  Rf 
0.38 (2:1 hexane/EtOAc).  
1
H NMR (500 MHz, CDCl3) δ 8.19 (app. t, J = 8.5 Hz, 4H), 7.50 (d, J 
= 8.5 Hz, 2H), 7.45 (d, J = 9.0 Hz, 2H), 7.13 (d, J = 8.5 Hz, 2H), 6.78 (dt, J = 8.5 Hz, 2.0 Hz, 
2H), 5.60 (d, J = 9.0 Hz, 1H), 5.28-5.14 (m, 4H), 4.59 (dd, J = 9.0 Hz, 3.5 Hz, 1H), 3.75 (s, 3H), 
3.64 (d, J = 13.0 Hz, 1H), 3.59 (d, J = 13.0 Hz, 1H), 3.33 (m, 1H), 1.33 (d, J = 7.0 Hz, 3H).  
13
C 
NMR (125 MHz, CDCl3) δ 170.3, 159.0, 156.0, 147.9, 147.8, 143.6, 142.2, 129.9, 129.3, 128.7, 
128.2, 123.93, 123.89, 114.1, 66.0, 65.8, 58.8, 55.3, 41.7, 35.0, 19.4.  HRMS (ESI) calc. [M+H]
+
 
for C27H28N3O9S 570.1546, found 570.1566.  See also Notebook VII, page 63. 
 
Compound D-3.57.  Compound D-3.28 (0.85 g, 1.50 mmol) was dissolved in 
TFA (6 mL) and anisole (650 μL, 6.00 mmol).  Mercury(II) acetate (0.96 g, 
3.00 mmol) was added, and the purple solution was stirred for 4 h.  
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Dithiothreitol (0.46 g, 3.00 mmol) was added, immediately forming a grey precipitate.  This 
heterogeneous mixture was stirred vigorously for 15 h, then diluted with CH2Cl2 and centrifuged 
(4600 g, 10 min) to remove the solids.  The supernatant was concentrated under reduced 
pressure, the residue taken up in CH2Cl2 and water, and neutralized by slow addition of saturated 
aqueous NaHCO3 to pH 7.  The organic layer was separated, dried over Na2SO4, filtered, and 
concentrated under reduced pressure.  The crude material was purified by flash chromatography 
(SiO2, 3:1 hexane/EtOAc) to yield D-3.57, which was used directly for the next reaction.  Rf 0.60 
(1:1 hexane/EtOAc).  
1
H NMR (500 MHz, CDCl3) δ 8.23 (app. t, J = 8.5 Hz, 4H), 7.53 (d, J = 
8.5 Hz, 4H), 5.66 (d, J = 9.0 Hz, 1H), 5.34-5.21 (m, 4H), 4.66 (dd, J = 9.0 Hz, 3.0 Hz, 1H), 3.65 
(m, 1H), 1.68 (bs, 1H), 1.40 (d, J = 7.0 Hz, 3H).  
13
C NMR (125 MHz, CDCl3) δ 170.1, 156.2, 
148.3, 143.5, 142.1, 128.8, 128.3, 124.1, 124.0, 66.2, 66.0, 59.8, 37.4, 22.1.  HRMS (ESI) calc. 
[M+H]
+
 for C19H20N3O8S 450.0971, found 450.0982.  See also Notebook VII, page 28. 
 
Compound DL-3.29.  Compounds 3.18 (0.45 g, 1.00 mmol) and 
D-3.57 (assumed 1.50 mmol) were dissolved in N2-sparged 
EtOAc (5 mL).  Tetrabutylammonium bromide (1.29 g, 4.00 
mmol) was dissolved in N2-sparged 0.5 M aqueous NaHCO3 (pH adjusted to 8.5, 5 mL), then 
added to the organic solution.  The biphasic mixture was stirred under N2 for 7 h, and the pH was 
adjusted to 8.5 as necessary with 1 M NaOH.  Tributylphosphine (125 μL, 0.50 mmol) was 
added, and the reaction was stirred for an additional 17 h.  The organic layer was isolated, 
washed with water and brine, dried over Na2SO4, filtered, and concentrated under reduced 
pressure.  The crude material was purified by flash chromatography (SiO2, 4:1 then 2:1 
hexane/EtOAc) to yield DL-3.29 (0.69 g, 0.85 mmol, 85% over two steps) as a colorless foam.  Rf 
0.24 (2:1 hexane/EtOAc).  
1
H NMR (500 MHz, CDCl3) δ 8.17 (app. t, J = 8.5 Hz, 4 H), 7.75 (d, 
J = 7.5 Hz, 2H), 7.56 (m, 2H), 7.47 (app. d, J = 7.0 Hz, 4H), 7.39 (dt, J = 7.5 Hz, 3.0 Hz, 2H), 
7.29 (t, J = 7.5 Hz, 2H), 5.78 (d, J = 9.0 Hz, 1H), 5.66 (d, J = 7.0 Hz, 1H), 5.34-5.15 (m, 4H), 
4.57 (dd, J = 9.0 Hz, 3.0 Hz, 1H), 4.44 (m, 1H), 4.34 (d, J = 7.0 Hz, 2H), 4.19 (t, J = 7.0 Hz, 
1H), 3.48 (m, 1H), 3.01 (dd, J = 13.5 Hz, 4.5 Hz, 1H), 2.88 (dd, J = 13.5 Hz, 4.5 Hz, 1H), 1.47 
(s, 9H), 1.35 (d, J = 7.0 Hz, 3H).  
13
C NMR (125 MHz, CDCl3) δ 170.3, 169.2, 156.1, 155.8, 
148.0, 147.7, 143.8, 143.7, 143.5, 142.0, 141.4, 128.8, 128.1, 127.9, 127.2, 125.11, 125.08, 
123.94, 123.87, 120.2, 83.5, 67.4, 66.1, 65.8, 58.7, 54.5, 47.1, 43.5, 33.8, 28.1, 19.7.  HRMS 
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(ESI) calc. [M+Na]
+
 for C41H42N4O12SNa 837.2418, found 837.2416.  See also Notebook VII, 
page 31. 
 
Compound DL-3.6.  To a solution of DL-3.29 (0.65 g, 0.80 mmol) 
in CH2Cl2 (3 mL) and phenylsilane (105 µL, 0.84 mmol) was 
added TFA (3 mL).  The reaction was stirred for 2 h, 
concentrated under reduced pressure and repeatedly redissolved in CH2Cl2 and concentrated to 
remove residual TFA.  The crude material was purified by flash chromatography (SiO2, 1%-2% 
MeOH/CH2Cl2) to yield DL-3.6 (0.58 g, 0.76 mmol, 95%) as a white solid.  Rf 0.16 (EtOAc).  
1
H 
NMR (500 MHz, CD3OD) δ 8.12 (app. t, J = 8.5 Hz, 4 H), 7.75 (d, J = 7.5 Hz, 2H), 7.63 (d, J = 
7.5 Hz, 2H), 7.45 (app. t, J = 7.0 Hz, 4H), 7.35 (t, J = 7.5 Hz, 2H), 7.27 (t, J = 7.5 Hz, 2H), 5.30-
5.16 (m, 4H), 4.57 (d, J = 4.5 Hz, 1H), 4.39 (dd, J = 8.5 Hz, 4.5 Hz, 1H), 4.35-4.24 (m, 2H), 4.18 
(t, J = 7.0 Hz, 1H), 3.49 (m, 1H), 3.09 (dd, J = 13.5 Hz, 4.5 Hz, 1H), 2.83 (dd, J = 13.5 Hz, 8.5 
Hz, 1H), 1.33 (d, J = 7.0 Hz, 3H).  
13
C NMR (125 MHz, CD3OD) δ 173.6, 171.5, 158.4, 158.3, 
149.0, 148.8, 145.7, 145.2, 145.1, 144.2, 142.5, 129.7, 129.0, 128.8, 128.2, 126.3, 124.6, 124.5, 
120.9, 68.2, 66.8, 66.4, 60.4, 55.5, 48.3, 43.7, 34.1, 19.6.  HRMS (ESI) calc. [M+H]
+
 for 
C37H35N4O12S 759.1972, found 759.1964.  See also Notebook VII, page 34. 
 
 
 
Compound L-3.57 was prepared as for its enantiomer D-3.57 in 20% yield over nine steps from L-
threonine.  See also Notebook IX, pages 11, 14-18, 22. 
 
Compound LL-3.29.  Compounds 3.18 (0.66 g, 1.46 mmol) 
and L-3.57 (0.53 g, 1.17 mmol) were dissolved in N2-sparged 
EtOAc (10 mL).  Tetrabutylammonium bromide (1.51 g, 4.68 
mmol) was dissolved in N2-sparged 0.5 M aqueous NaHCO3 (pH adjusted to 8.5, 10 mL), then 
added to the organic solution.  The biphasic mixture was stirred under N2 for 24 h, with 
tributylphosphine (150 μL, 0.59 mmol) added to the reaction after 7 h.  The organic layer was 
isolated, washed with water and brine, dried over Na2SO4, filtered, and concentrated under 
reduced pressure.  The crude material was purified by flash chromatography (SiO2, 30% 
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EtOAc/hexane) to yield LL-3.29 (0.74 g, 0.91 mmol, 78%) as a colorless foam.  Rf 0.33 (2:1 
hexane/EtOAc).  
1
H NMR (500 MHz, CDCl3) δ 8.17 (d, J = 8.5 Hz, 2H), 8.12 (d, J = 8.5 Hz, 
2H), 7.74 (d, J = 7.5 Hz, 2H), 7.56 (m, 2H), 7.49 (d, J = 8.5 Hz, 2H), 7.40 (m, 4H), 7.29 (t, J = 
7.5 Hz, 2H), 5.89 (d, J = 8.5 Hz, 1H), 5.62 (d, J = 7.5 Hz, 1H), 5.29-5.10 (m, 4H), 4.56 (m, 1H), 
4.45 (m, 1H), 4.36 (d, J = 7.0 Hz, 2H), 4.19 (t, J = 7.0 Hz, 1H), 3.50 (m, 1H), 3.02 (dd, J = 14.0 
Hz, 4.5 Hz, 1H), 2.89 (dd, J = 14.0 Hz, 4.5 Hz, 1H), 1.48 (s, 9H), 1.35 (d, J = 7.0 Hz, 3H).  
13
C 
NMR (125 MHz, CDCl3) δ 170.2, 169.3, 156.0, 147.9, 147.6, 143.8, 143.7, 143.5, 142.1, 141.3, 
128.7, 128.0, 127.9, 127.2, 125.1, 123.9, 123.8, 120.1, 83.4, 67.4, 66.1, 65.7, 58.9, 54.4, 47.1, 
42.9, 34.0, 28.1, 19.4.  HRMS (ESI) calc. [M+H]
+
 for C41H43N4O12S 815.2598, found 815.2598.  
See also Notebook IX, page 23. 
 
Compound LL-3.6.  To a solution of LL-3.29 (0.50 g, 0.62 
mmol) in CH2Cl2 (5 mL) and phenylsilane (70 µL, 0.66 
mmol) was added trifluoroacetic acid (5 mL).  The reaction 
was stirred for 2 h, concentrated under reduced pressure and repeatedly redissolved in CH2Cl2 
and concentrated to remove residual acid.  The crude material was purified by flash 
chromatography (SiO2, 0%-5% MeOH/CH2Cl2) to yield LL-3.6 (0.42 g, 0.56 mmol, 90%) as a 
white solid after lyophilization from 1:1 benzene/MeCN.  Rf 0.05 (EtOAc).  
1
H NMR (500 MHz, 
CD3OD) δ 8.07 (d, J = 8.5 Hz, 2H), 8.03 (d, J = 8.5 Hz, 2H), 7.70 (d, J = 7.5 Hz, 2H), 7.59 (m, 
2H), 7.51 (d, J = 8.5 Hz, 2H), 7.43 (d, J = 8.5 Hz, 2H), 7.32 (t, J = 7.5 Hz, 2H), 7.24 (t, J = 7.5 
Hz, 2H), 5.26-5.04 (m, 4H), 4.52 (d, J = 4.5 Hz, 1H), 4.38 (m, 1H), 4.28-4.22 (m, 2H), 4.15 (t, J 
= 7.0 Hz, 1H), 3.46 (m, 1H), 3.08 (dd, J = 14.0 Hz, 4.5 Hz, 1H), 2.91 (dd, J = 13.5 Hz, 3.5 Hz, 
1H), 1.34 (d, J = 6.5 Hz, 3H).  
13
C NMR (125 MHz, CD3OD) δ 174.0, 171.6, 158.5, 158.2, 
149.0, 148.7, 145.6, 145.2, 145.1, 144.3, 142.5, 129.7, 128.9, 128.8, 128.1, 126.3, 124.55, 
124.46, 120.9, 68.2, 66.8, 66.4, 60.5, 55.7, 48.3, 43.9, 34.7, 19.6.  HRMS (ESI) calc. [M+H]
+ 
for 
C37H35N4O12S 759.1972, found 759.1962.  See also Ting Chen Notebook I, page 21. 
 
3.4.8. Synthesis of Dha/Dhb-containing peptide fragments 
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Compound 3.30.  L-Threonine tert-butyl ester hydrochloride (0.50 g, 
2.36 mmol) was dissolved in CH2Cl2 (12 mL) and 
i
Pr2NEt (620 μL, 
3.54 mmol).  N-Boc-L-phenylalanine (0.63 g, 2.36 mmol), HOBt 
(0.36 g, 2.36 mmol) and EDC (0.45 g, 2.36 mmol) were added as 
solids.  The reaction was stirred for 14 h, then washed with saturated aqueous NaHCO3, 10% 
citric acid and water.  Each aqueous wash was back-extracted with CH2Cl2.  The organic 
fractions were combined, washed with brine, dried over Na2SO4, filtered, and concentrated under 
reduced pressure, yielding 3.30 (0.98 g, 2.32 mmol, 98%) as a white solid.  Rf 0.82 (EtOAc).  
1
H 
NMR (400 MHz, CDCl3) δ 7.30-7.19 (m, 5H), 6.67 (d, J = 8.4 Hz, 1 H), 5.04 (d, J = 7.6 Hz, 
1H), 4.43 (dd, J = 8.4 Hz, 3.2 Hz, 1 H), 4.38 (m, 1H), 4.19 (m, 1H), 3.16-3.03 (m, 2H), 2.45 (bs, 
1H), 1.46 (s, 9H), 1.39 (s, 9H), 1.15 (d, J = 6.4 Hz, 3H).  
13
C NMR (125 MHz, CDCl3) δ 171.9, 
169.7, 155.7, 136.6, 129.5, 128.7, 127.0, 82.7, 80.4, 68.7, 58.1, 56.0, 38.1, 28.4, 28.1, 20.0.  
HRMS (ESI) calc. [M+H]
+
 for C22H35N2O6 423.2495, found 423.2499.  See also Notebook V, 
page 72. 
 
Compound 3.31.  A two-step dehydration selective for the Z-olefin 
was performed based on the procedure of Pattabiraman et al.
32
  
Compound 3.30 (1.19 g, 2.82 mmol) was dissolved in CH2Cl2 (30 
mL) and triethylamine (0.98 mL, 7.05 mmol) and chilled in an ice 
bath.  Methanesulfonyl chloride (MsCl, 0.44 mL, 5.64 mmol) was added dropwise, and the 
reaction was stirred for 1 h, gradually warming to room temperature.  The reaction was 
concentrated under reduced pressure, then taken up in 1,2-dichloroethane (DCE, 30 mL) and 1,8-
diazabicyclo[5.4.0]undec-7-ene (DBU, 1.69 mL, 11.3 mmol).  The reaction was heated to reflux 
in an oil bath (90 
o
C) for 4 h, then concentrated under reduced pressure.  The residue was taken 
up in EtOAc, washed with 10% citric acid, saturated aqueous NaHCO3 and brine, dried over 
Na2SO4, filtered, and concentrated under reduced pressure.  The crude material was purified by 
flash chromatography (SiO2, 7:1 then 4:1 hexane/EtOAc) to yield 3.31 (1.03 g, 2.55 mmol, 90% 
over two steps) as a white solid.  Rf 0.48 (2:1 hexane/EtOAc).  
1
H NMR (500 MHz, CDCl3) δ 
7.38 (s, 1H), 7.31-7.27 (m, 2H), 7.24-7.21 (m, 3H), 6.68 (q, J = 7.0 Hz, 1H), 5.00 (m, 1H), 4.49 
(m, 1H), 3.19 (dd, J = 13.5 Hz, 6.0 Hz, 1H), 3.07 (m, 1H), 1.67 (d, J = 7.0 Hz, 3H), 1.46 (s, 9H), 
1.40 (s, 9H).  
13
C NMR (125 MHz, CDCl3) δ 169.5, 163.4, 155.6, 136.6, 132.6, 129.5, 128.8, 
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127.1, 126.9, 81.8, 80.5, 56.1, 38.2, 28.3, 28.1, 14.8.  HRMS (ESI) calc. [M+H]
+
 for C22H33N2O5 
405.2389, found 405.2392.  See also Notebook VI, page 13. 
 
Compound 3.32.  Compound 3.31 (1.27 g, 3.14 mmol) was 
dissolved in CH2Cl2 (10 mL) and TFA (10 mL) and stirred for 1.5 h.  
The reaction was concentrated under reduced pressure, repeatedly 
taken up in CH2Cl2 and re-concentrated to remove residual acid.  To the resulting residue was 
added sodium carbonate (0.67 g, 6.28 mmol), water (30 mL) and 1,4-dioxane (30 mL), and the 
system was chilled in an ice bath.  N-(9-fluorenylmethoxycarbonyloxy)succinimide (FmocOSu, 
1.06 g, 3.14 mmol) was then added portionwise as a solid.  The reaction was stirred for 20 h, 
gradually warming to room temperature.  Volatile components were removed under reduced 
pressure, then the system was diluted with H2O and acidified to pH 2 with 2 M HCl.  The 
aqueous suspension was extracted with EtOAc (3x), then the combined organic layers were dried 
over Na2SO4, filtered, and concentrated under reduced pressure to ~20 mL.  Hexane (~150 mL) 
was added to form a precipitate, which was isolated by filtration and dried to yield 3.32 (1.40 g, 
2.98 mmol, 95% over two steps) as a white powder.  Rf 0.12 (EtOAc).  
1
H NMR (400 MHz, 
CD3OD) δ 7.75 (d, J = 7.2 Hz, 2H), 7.55 (m, 2H), 7.34 (t, J = 7.2 Hz, 2H), 7.29-7.15 (m, 7H), 
6.82 (q, J = 7.2 Hz, 1H), 4.50 (dd, J = 9.6 Hz, 5.2 Hz, 1H), 4.30-4.16 (m, 2H), 4.11 (t, J = 7.0 
Hz, 1H), 3.21 (dd, J = 13.8 Hz, 5.2 Hz, 1H), 2.89 (dd, J = 13.8 Hz, 9.6 Hz, 1H), 1.65 (d, J = 7.2 
Hz, 3H).  
13
C NMR (125 MHz, CD3OD) δ 173.1, 167.2, 158.2, 145.2, 142.5, 138.6, 136.8, 130.4, 
129.4, 128.7, 128.4, 128.1, 127.7, 126.3, 120.9, 68.0, 57.8, 48.3, 39.1, 14.1.  HRMS (ESI) calc. 
[M+H]
+
 for C28H27N2O5 471.1920, found 471.1923.  See also Notebook VI, page 14. 
 
 
 
Compound 3.33.  L-Serine tert-butyl ester hydrochloride (1.58 g, 
8.00 mmol) was taken up in CH2Cl2 (40 mL) and 
i
Pr2NEt (2.1 mL, 
12.0 mmol) and stirred for 10 min.  N-Boc-L-alanine (1.51 g, 8.00 
mmol), HOBt (1.35 g, 8.80 mmol) and EDC (1.53 g, 8.00 mmol) were added as solids.  The 
reaction was stirred for 13 h, then washed with saturated aqueous NaHCO3, 10% citric acid and 
water and brine.  Each aqueous wash was back-extracted with CH2Cl2.  The organic fractions 
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were combined, dried over Na2SO4, filtered, and concentrated under reduced pressure to yield 
3.33 (2.58 g, 7.76 mmol, 97%) as a white solid.  Rf 0.64 (EtOAc).  
1
H NMR (500 MHz, CDCl3) δ 
7.07 (d, J = 7.5 Hz, 1H), 5.36 (d, J = 6.5 Hz, 1H), 4.50 (m, 1H), 4.18 (m, 1H), 3.92 (dd, J = 11.5 
Hz, 3.0 Hz, 1H), 3.86 (dd, J = 11.5 Hz, 4.0 Hz, 1H), 1.46 (s, 9H), 1.41 (s, 9H), 1.36 (d, J = 7.5 
Hz, 3H).  
13
C NMR (125 MHz, CDCl3) δ 173.2, 169.4, 155.9, 82.8, 80.4, 63.2, 55.6, 50.6, 28.4, 
28.1, 18.4.  HRMS (ESI) calc. [M+H]
+
 for C15H29N2O6 333.2026, found 333.2029.  See also 
Notebook VII, page 37. 
 
Compound 3.34.  Compound 3.33 (1.66 g, 5.00 mmol) was 
dissolved in CH2Cl2 (25 mL) and triethylamine (1.7 mL, 12.5 mmol) 
and chilled in an ice bath.  Methanesulfonyl chloride (770 µL, 10.0 
mmol) was added dropwise, and the reaction was allowed to warm to room temperature and 
stirred for 1 h.  DBU (2.2 mL, 15.0 mmol) was then added, and the reaction was stirred for an 
additional 2 h, then concentrated under reduced pressure.  The residue was taken up in EtOAc, 
washed with 10% citric acid, saturated NaHCO3 and brine, dried over Na2SO4, filtered, and 
concentrated under reduced pressure.  The crude material was purified by flash chromatography 
(SiO2, 7:3 hexane/EtOAc) to yield 3.34 (1.51 g, 4.80 mmol, 96% over two steps) as a colorless 
oil.  Rf 0.79 (1:1 hexane/EtOAc).  
1
H NMR (500 MHz, CDCl3) δ 8.42 (bs, 1H), 6.51 (s, 1H), 5.81 
(s, 1H), 4.97 (m, 1H), 4.25 (m, 1H), 1.52 (s, 9H), 1.45 (s, 9H), 1.39 (d, J = 7.5 Hz, 3H).  
13
C 
NMR (125 MHz, CDCl3) δ 171.5, 162.9, 155.6, 132.1, 108.1, 82.9, 80.5, 51.1, 28.4, 28.0, 18.2.  
HRMS (ESI) calc. [M+H]
+
 for C15H27N2O5 315.1920, found 315.1919.  See also Notebook VII, 
page 39. 
 
Compound 3.35.  Compound 3.34 (0.94 g, 3.00 mmol) was 
dissolved in CH2Cl2 (10 mL) and TFA (10 mL) and stirred 1 h.  The 
reaction was concentrated under reduced pressure, repeatedly taken 
up in CH2Cl2 and re-concentrated to remove residual acid.  To the resulting residue was added 
sodium carbonate (0.64 g, 6.00 mmol), water (15 mL) and 1,4-dioxane (15 mL), and the system 
was chilled in an ice bath.  FmocOSu (1.01 g, 3.00 mmol) was then added portionwise as a solid.  
The reaction was stirred for 17 h, gradually warming to room temperature.  Volatile components 
were removed under reduced pressure, then the system was diluted with water and acidified to 
pH 2 with 2 M HCl.  The aqueous suspension was extracted with EtOAc (3x), then the combined 
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organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure.  The 
crude material was purified by flash chromatography (SiO2, 1%-5% MeOH/CH2Cl2) to yield 
3.35 (0.49 g, 1.23 mmol, 43% over two steps) as a white powder after lyophilization from 1:1 
benzene/MeCN.  Rf 0.07 (EtOAc).  
1
H NMR (500 MHz, CDCl3) δ 8.66 (bs, 1H), 7.76 (d, J = 7.5 
Hz, 2H), 7.57 (m, 2H), 7.40 (t, J = 7.5 Hz, 2H), 7.30 (t, J = 7.5 Hz, 2H), 6.68 (s, 1H), 6.03 (s, 
1H), 5.69 (m, 1H), 4.77 (m, 1H), 4.40 (d, J = 7.0 Hz, 2H), 4.20 (t, J = 7.0 Hz, 1H), 1.43 (d, J = 
6.5 Hz, 3H).  
13
C NMR (125 MHz, CDCl3) δ 172.1, 166.3, 156.5, 143.7, 143.6, 141.4, 130.7, 
127.9, 127.2, 125.2, 120.2, 111.2, 67.7, 50.9, 47.1, 19.2.  HRMS (ESI) calc. [M+H]
+
 for 
C21H21N2O5 381.1450, found 381.1448.  See also Notebook VII, page 40. 
 
 
 
Compound 3.36.  L-Threonine (1.43 g, 12.0 mmol) and para-
toluenesulfonic acid monohydrate (2.74 g, 14.4 mmol) were 
combined in toluene (30 mL).  Allyl alcohol (8.2 mL, 120 mmol) was 
added, and the reaction was refluxed in an oil bath (110 
o
C) 
connected to a Dean-Stark apparatus for 8 h, then concentrated under reduced pressure and dried 
azeotropically with benzene.  The resulting material was taken up in CH2Cl2 (60 mL) and 
i
Pr2NEt (6.3 mL, 36.0 mmol) and stirred for 10 min.  N-Boc-L-threonine (2.63 g, 12.0 mmol), 
HOBt (2.02 g, 13.2 mmol) and EDC (2.29 g, 12.0 mmol) were added as solids.  The reaction was 
stirred for 16 h, then washed with saturated aqueous NaHCO3, 10% citric acid, water and brine.  
Each aqueous wash was back-extracted with CH2Cl2.  The organic fractions were combined, 
dried over Na2SO4, filtered, and concentrated under reduced pressure to ~30 mL.   Upon the 
addition of 1:1 EtOAc/hexane (150 mL), a precipitate formed, which was isolated by filtration 
and washed with hexane to yield 3.36 (4.01 g, 11.1 mmol, 92% over two steps) as an off-white 
solid.  Rf 0.57 (EtOAc).  
1
H NMR (500 MHz, CDCl3) δ 7.40 (d, J = 9.0 Hz, 1H), 5.94-5.86 (m, 
1H), 5.67 (d, J = 8.0 Hz, 1H), 5.36-5.31 (dd, J = 17.5 Hz, 1.5 Hz, 1H), 5.26 (dd, J = 10.5 Hz, 1.0 
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Hz, 1H), 4.65 (d, J = 6.0 Hz, 1H), 4.59 (dd, J = 9.0 Hz, 2.5 Hz, 1H), 4.37 (m, 1H), 4.28 (m, 1H), 
4.18 (dd, J = 8.0 Hz, 2.0 Hz, 1H), 3.83 (bs, 2H), 1.44 (s, 9H), 1.22 (d, J = 6.5 Hz, 3H), 1.19 (d, J 
= 6.5 Hz, 3H).  
13
C NMR (125 MHz, CDCl3) δ 172.0, 170.7, 156.5, 131.5, 119.2, 80.6, 68.1, 
67.4, 66.5, 58.4, 57.9, 28.4, 20.2, 18.3.  HRMS (ESI) calc. [M+H]
+
 for C16H29N2O7 361.1975, 
found 361.1982.  See also Notebook VII, page 30. 
 
Compound 3.37.  Compound 3.36 (0.94 g, 2.62 mmol) was 
dissolved in CH2Cl2 (5 mL) and TFA (5 mL) and stirred for 
2 h.  The reaction was concentrated under reduced pressure, 
repeatedly taken up in CH2Cl2 and re-concentrated to remove 
residual acid.  The deprotected dipeptide was dissolved in 
CH2Cl2 (12 mL) and 
i
Pr2NEt (1.3 mL, 7.50 mmol) and stirred for 10 min.  Nα-Aloc-Nε-Boc-L-
lysine
93
 (0.83 g, 2.50 mmol), HOBt (0.42 g, 2.75 mmol) and EDC (0.48 g, 2.50 mmol) were 
added sequentially.  The reaction was stirred for 14 h, then washed with saturated aqueous 
NaHCO3, 10% citric acid, water and brine.  Each aqueous wash was back-extracted with CH2Cl2.  
The organic fractions were combined, dried over Na2SO4, filtered, and concentrated under 
reduced pressure to yield 3.37 (1.29 g, 2.25 mmol, 90% over two steps) as a colorless foam.  Rf 
0.36 (EtOAc).  
1
H NMR (500 MHz, CD3OD) δ 6.00-5.89 (m, 2H), 5.38-5.28 (m, 2H), 5.21 (app. 
dd, J = 22.5 Hz, 10.5 Hz, 2H), 4.65 (d, J = 5.5 Hz, 2H), 4.55 (d, J = 5.0 Hz, 2H), 4.49 (d, J = 3.0 
Hz, 1H), 4.44 (d, J = 4.0 Hz, 1H), 4.32 (m, 1H), 4.23-4.14 (m, 2H), 3.03 (m, 2H), 1.81 (m, 1H), 
1.68 (m, 1H), 1.51-1.41 (m, 13H), 1.22 (d, J = 6.5 Hz, 3H), 1.19 (d, J = 6.5 Hz, 3H).  
13
C NMR 
(125 MHz, CD3OD) δ 175.2, 172.7, 171.5, 158.6, 158.5, 134.3, 133.3, 118.7, 117.7, 79.9, 68.4, 
68.2, 67.0, 66.7, 59.8, 59.3, 56.5, 41.0, 32.8, 30.6, 28.8, 24.1, 20.4, 19.8.  HRMS (ESI) calc. 
[M+H]
+
 for C26H45N4O10 573.3136, found 573.3132.  See also Notebook VII, page 48. 
 
Compound 3.38.  Compound 3.37 (0.42 g, 0.73 mmol) and 
EDC (0.56 g, 2.94 mmol) were dissolved in 49:1 
CH2Cl2/DMF (15 mL).  Copper(I) chloride (0.17 g, 1.76 
mmol) was added as a solid, and the reaction was stirred for 
24 h, protected from light.  Additional portions of EDC (0.56 g, 2.94 mmol) and copper(I) 
chloride (0.17 g, 1.76 mmol) were added, and the reaction was stirred an additional 24 h.  The 
solution was concentrated under reduced pressure, taken up in 0.2 M aqueous EDTA and 
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extracted with EtOAc (3x).  The organic fractions were combined, washed with 10% citric acid 
and brine, dried over Na2SO4, filtered, and concentrated under reduced pressure.  The crude 
material was purified by flash chromatography (SiO2, 3:1 EtOAc/hexane) to yield 3.38 (0.25 g, 
0.47 mmol, 64%) as a white solid.  Rf 0.56 (EtOAc).  
1
H NMR (500 MHz, CDCl3) δ 7.87 (s, 1H), 
7.68 (bs, 1H), 6.84 (q, J = 7.0 Hz, 1H), 6.79 (q, J = 7.0 Hz, 1H), 5.95-5.82 (m, 3H), 5.34-5.26 
(m, 2H), 5.21 (app. t, J = 11.5 Hz, 2H), 4.74 (m, 1H), 4.65 (d, J = 5.5 Hz, 2H), 4.53 (d, J = 5.5 
Hz, 2H), 4.12 (m, 1H), 3.12 (m, 2H), 1.93 (m, 1H), 1.79 (m, 4H), 1.74 (d, J = 7.0 Hz, 3H), 1.54-
1.42 (m, 13H).  
13
C NMR (125 MHz, CDCl3) δ 171.3, 164.3, 162.9, 157.1, 156.9, 135.0, 132.4, 
132.1, 129.0, 126.5, 118.4, 79.8, 66.4, 66.0, 56.0, 39.5, 31.0, 29.8, 28.6, 22.5, 14.6, 13.8.  HRMS 
(ESI) calc. [M+H]
+
 for C26H41N4O8 537.2924, found 537.2921.  See also Notebook VII, page 33. 
 
Compound 3.39.  Tetrakis(triphenylphosphine)palladium(0) 
(70 mg, 0.06 mmol) was added to a solution of 3.38 (0.33 g, 
0.62 mmol) and N-methylaniline (200 μL, 1.86 mmol) in 
THF (6 mL).  The reaction was stirred for 2 h, protected 
from light, then concentrated under reduced pressure.  To the resulting oil was added sodium 
carbonate (0.13 g, 1.24 mmol), H2O (6 mL) and 1,4-dioxane (6 mL), and the reaction was chilled 
in an ice bath.  FmocOSu (1.01 g, 3.00 mmol) was then added portionwise as a solid.  The 
reaction was stirred for 22 h, gradually warming to room temperature.  Volatile components were 
removed under reduced pressure, then the system was diluted with water and acidified to pH 2 
with 2 M HCl.  The aqueous suspension was extracted with EtOAc (3x), then the combined 
organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure.  The 
crude material was purified by flash chromatography (SiO2, 2%-5% MeOH/CH2Cl2) to yield 
3.39 (0.35 g, 0.55 mmol, 89% over two steps) as a white solid.  Rf 0.02 (EtOAc).  
1
H NMR (500 
MHz, CD3OD) δ 7.78 (d, J = 7.5 Hz, 2H), 7.65 (app. dd, J = 15.0 Hz, 7.5 Hz, 2H), 7.38 (t, J = 
7.5 Hz, 2H), 7.30 (t, J = 7.5 Hz, 2H), 6.85 (q, J = 7.0 Hz, 1H), 6.77 (q, J = 7.0 Hz, 1H), 4.39-
4.31 (m, 2H), 4.18 (t, J = 7.0 Hz, 1H), 4.09 (t, J = 7.0 Hz, 1H), 3.05 (t, J = 6.5 Hz, 2H), 1.84 (m, 
1H), 1.78-1.73 (m, 4H), 1.71 (d, J = 7.0 Hz, 3H), 1.54-1.45 (m, 4H), 1.42 (s, 9H).  
13
C NMR 
(125 MHz, CD3OD) δ 174.6, 167.4, 165.2, 158.9, 158.4, 145.2, 144.9, 142.4, 137.0, 133.8, 
130.5, 128.61, 128.60, 128.5, 128.0, 126.06, 125.99, 120.7, 79.7, 67.9, 57.0, 48.2, 40.8, 31.9, 
30.4, 28.6, 24.1, 14.1, 13.5.  HRMS (ESI) calc. [M+H]
+
 for C34H43N4O8 635.3081, found 
635.3082.  See also Notebook VII, page 55. 
126 
 
 
 
 
Compound 3.40.  L-Alanine methyl ester hydrochloride (0.70 g, 5.00 
mmol) was taken up in CH2Cl2 (25 mL) and 
i
Pr2NEt (1.3 mL, 7.50 
mmol) and stirred for 5 min.  N-Boc-L-serine (1.03 g, 5.00 mmol), 
HOBt (0.84 g, 5.50 mmol) and EDC (0.96 g, 5.00 mmol) were added as solids.  The reaction was 
stirred for 21 h, then washed with saturated aqueous NaHCO3, 10% citric acid, water and brine.  
Each aqueous wash was back-extracted with CH2Cl2.  The organic fractions were combined, 
dried over Na2SO4, filtered, and concentrated under reduced pressure to yield 3.40 (1.24 g, 4.27 
mmol, 85%) as a white solid.  Rf 0.45 (EtOAc).  
1
H NMR (500 MHz, CDCl3) δ 7.32 (d, J = 7.0 
Hz, 1H), 5.69 (d, J = 6.5 Hz, 1H), 4.54 (pent, J = 7.0 Hz, 1H), 4.22 (m, 1H), 3.95 (dd, J = 11.0 
Hz, 4.0 Hz, 1H), 3.71 (s, 3H), 3.65 (dd, J = 11.0 Hz, 4.0 Hz, 1H), 1.41 (s, 9H), 1.38 (d, J = 7.0 
Hz, 3H).  
13
C NMR (125 MHz, CDCl3) δ 173.4, 171.1, 156.1, 80.4, 63.1, 55.3, 52.7, 48.3, 28.3, 
17.8.  HRMS (ESI) calc. [M+Na]
+
 for C12H22N2O6Na 313.1376, found 313.1377.  See also 
Notebook VIII, page 59. 
 
Compound 3.41.  Compound 3.40 (1.08 g, 3.72 mmol) was dissolved 
in CH2Cl2 (40 mL) and triethylamine (1.3 mL, 9.30 mmol) and 
chilled in an ice bath.  Methanesulfonyl chloride (580 µL, 7.44 
mmol) was added dropwise, and the reaction was allowed to warm to room temperature and 
stirred for 1 h.  DBU (2.8 mL, 18.6 mmol) was then added, and the reaction was stirred for an 
additional 2 h, then concentrated under reduced pressure.  The residue was taken up in EtOAc, 
washed with 10% citric acid, saturated aqueous NaHCO3 and brine, dried over Na2SO4, filtered, 
and concentrated under reduced pressure.  The crude material was purified by flash 
chromatography (SiO2, 7:3 hexane/EtOAc) to yield 3.41 (0.81 g, 2.97 mmol, 80% over two 
steps) as a pale yellow oil.  Rf 0.70 (1:1 hexane/EtOAc).  
1
H NMR (500 MHz, CDCl3) δ 7.25 (s, 
1H), 6.69 (d, J =7.0 Hz, 1H), 6.03 (s, 1H), 5.12 (t, J = 1.5 Hz, 1H), 4.61 (pent, J = 7.0 Hz, 1H), 
3.77 (s, 3H), 1.46-1.42 (m, 12H).  
13
C NMR (125 MHz, CDCl3) δ 173.1, 163.7, 152.7, 134.5, 
98.4, 80.6, 52.7, 48.6, 28.2, 18.2.  HRMS (ESI) calc. [M+Na]
+
 for C12H20N2O5Na 295.1270, 
found 295.1275.  See also Notebook VIII, page 60. 
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Compound 3.42.  To a solution of 3.41 (0.54 g, 2.00 mmol) in 1,4-
dioxane (5 mL) was added 1 M aqueous lithium hydroxide (5 mL).  
The reaction was stirred for 1 h, then volatile components were 
removed under reduced pressure.  The system was diluted with water and acidified to pH 3 with 
2 M HCl.  The aqueous suspension was extracted with EtOAc (10x), then the combined organic 
layers were dried over Na2SO4, filtered, and concentrated under reduced pressure to yield 3.42 
(0.34 g, 1.32 mmol, 66%) as a colorless foam.  Rf 0.03 (EtOAc).  
1
H NMR (400 MHz, CDCl3) δ 
7.28 (s, 1H), 6.71 (d, J = 7.2 Hz, 1H), 6.02 (s, 1H), 5.14 (s, 1H), 4.63 (pent, J = 7.2 Hz, 1H), 1.51 
(d, J = 7.2 Hz, 3H), 1.45 (s, 9H).  
13
C NMR (125 MHz, CDCl3) δ 176.1, 164.1, 159.9, 134.7, 
110.0, 81.0, 48.2, 28.4, 18.1.  HRMS (ESI) calc. [M+H]
+
 for C11H19N2O5 259.1294, found 
259.1288.  See also Notebook VIII, page 61. 
 
3.4.9. General procedure for SPPS 
 
Unless noted otherwise, standard cycles for SPPS were performed as follows, using a 
fritted glass reaction vessel equipped with a N2 inlet for resin/reagent agitation and a suction 
outlet for draining.  Fmoc deprotection was achieved by agitating resin with 20% piperidine in 
DMF (5 mL) for 10-20 min.  After draining the reaction vessel, the resin was washed with DMF 
(3 x 5 mL x 30 s) and CH2Cl2 (2 x 5 mL x 30 s).  The appropriately side-chain protected Fmoc-
amino acid (5 equiv.) in DMF (5-10 mL) was pre-activated with DIC and HOBt (5 equiv. each) 
for 5 min, then added to the resin and agitated for 45-60 min.  After draining the reaction vessel, 
the resin was washed as before.  The completion of all couplings was assessed by a Kaiser test; 
double couplings were performed for the residues following each cyclization and otherwise as 
needed.  Test cleavages were performed after all cyclization steps by removing a small portion of 
dry resin from the reaction vessel and treating with 90:5:5 TFA/H2O/triisopropylsilane for 1 h 
under N2.  After removing the cleaved resin by filtration, the filtrate was concentrated under a 
stream of N2.  The peptide was precipitated with cold Et2O, isolated by centrifugation at 12,000 
×g, and dissolved in 1:1 H2O/MeCN.  An aliquot of this solution was spotted onto a MALDI-
TOF MS target for analysis. 
 
3.4.10. Total synthesis of epilancin 15X analogues 
 
See also Notebook VII, pages 73-74, 94-96, 100; Notebook VIII, pages 5-7, 55-56, 65-67, 73. 
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Intermediate 3.43.  The substitution of the Fmoc-Lys(Boc)-Wang 
resin (initial substitution 0.36 mmol/g) was first reduced such that 1 
equiv. corresponded to 0.10 mmol/g.  To ensure local as well as 
global reduction in resin substitution, the resin was first swelled in 
DMF for 20 min, followed by addition of Fmoc-Lys(Boc)-OH (1 
equiv.) and Boc-Ala-OH (2 equiv.) that had been pre-activated with DIC and HOBt (3 equiv. 
each) for 5 min.  The reaction was performed for 15 h.  Any remaining free resin sites were 
capped with 1:2:7 Ac2O/pyridine/DMF (10 mL) for 15 min.  Adjusted resin substitution was 
calculated as follows: Fmoc-protected resin (10 mg) was agitated with 20% piperidine/DMF (1.0 
mL) for 15 min.  A 20 μL aliquot of this solution was diluted 100:1 with DMF.  The absorbance 
of this solution at 301 nm was recorded after blanking with pure DMF, and the resin substitution 
was calculated using the equation: substitution = 101(absorbance)/7.8(resin weight).
94
  After 
standard Fmoc deprotection and Fmoc-Gly-OH coupling/deprotection, dipeptide Fmoc-Phe-(Z)-
Dhb-OH (3.32, 2 equiv.) was pre-activated with DIC and HOAt (2 equiv. each) and 
i
Pr2NEt (5 
equiv.) in DMF for 10 min, reacted with the resin-bound peptide for 12 h, and deprotected by the 
standard protocol.  Fmoc-His(Trt)-OH was coupled/deprotected by the standard protocol.  
MeLan building block DL-3.6 (1.5 equiv.) was pre-activated with DIC and HOAt (3 equiv. each) 
in DMF for 5 min, then reacted with the resin-bound peptide for 2 h and deprotected by the 
standard protocol.  Fmoc-Gly-OH was coupled/deprotected by the standard protocol.  MeLan 
building block DL-3.5 (1.5 equiv.) was pre-activated with DIC and HOAt (3 equiv.) in DMF for 5 
min, then reacted with the resin-bound peptide for 2 h, but not Fmoc-deprotected, to yield resin-
bound intermediate 3.43. 
 
Monocyclic intermediate 3.44.  The nitrobenzyl protecting groups of 
3.43 were removed with two treatments of 6 M SnCl2 and 5 mM 
HCl/dioxane in DMF (5 mL) for 1 h each.  Following the second 
treatment, the reaction vessel was drained, and the resin was washed 
with DMF (3 x 5 mL x 30 s), 1:1 DMF/H2O (3 x 10 mL x 1 min), 1:1 
THF/H2O (3 x 10 mL x 1 min), DMF (3 x 5 mL x 30 s), and CH2Cl2 (2 x 5 mL x 30 s).  The 
Fmoc group was removed by the standard protocol, followed by washing with DMF (5 x 5 mL x 
30 s), CH2Cl2 (3 x 5 mL x 30 s), and DMF (2 x 5 mL x 30 s) to remove all traces of piperidine.  
Cyclization was promoted by adding PyAOP and HOAt (5 equiv. each) in DMF to the resin and 
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agitating for 5 min, then adding 2,4,6-collidine (10 equiv.) and agitating for 1.5 h.  After 
draining, this treatment was repeated for 1.5 h to yield 3.44.  Test cleavage analysis on a small 
sample was performed as described in Section 3.4.9 to confirm completed cyclization.  HRMS 
(MALDI-TOF) calc. [M+H]
+
 for C56H84N15O15S2 1270.571, found 1270.572. 
 
Bicyclic intermediate 3.45.  Fmoc-Leu-OH was coupled to 3.44 by the 
standard protocol, but not Fmoc-deprotected.  The allyl protecting 
groups were then removed by agitating resin with 
tetrakis(triphenylphosphine)palladium(0) (1 equiv.) and phenylsilane 
(10 equiv.) in 1:1 DMF/CH2Cl2 (10 mL) for 2 h, protected from light.  
After draining the reaction vessel, the resin was washed with CH2Cl2 (3 x 10 mL x 1 min), 0.5% 
diethyldithiocarbamate in DMF (3 x 10 mL x 1 min), DMF (3 x 5 mL x 30 s), and CH2Cl2 (2 x 5 
mL x 30 s).  The Fmoc group was removed by the standard protocol, followed by washing with 
DMF (5 x 5 mL x 30 s), CH2Cl2 (3 x 5 mL x 30 s), and DMF (2 x 5 mL x 30 s) to remove all 
traces of piperidine.  Cyclization was promoted by adding PyAOP and HOAt (5 equiv. each) in 
DMF to the resin and agitating for 5 min, then adding 2,4,6-collidine (10 equiv.) and agitating 
for 2 h.  After draining, this treatment was repeated for 2 h to yield 3.45.  Test cleavage analysis 
was performed to confirm completed cyclization.  HRMS (MALDI-TOF) calc. [M+H]
+ 
for 
C55H85N16O13S2 1241.592, found 1241.629. 
 
Tricyclic intermediate 3.47.  Fmoc-Phe-OH, Fmoc-Gly-
OH and Fmoc-Arg(Pbf)-OH were coupled to 3.45 and 
deprotected by the standard protocol.  Lan building 
block 2 (1.5 equiv.) was pre-activated with DIC and 
HOAt (3 equiv. each) in DMF for 5 min and coupled to 
the resin-bound peptide for 2 h, then deprotected by the standard protocol.  Fmoc-Leu-OH and 
Fmoc-Lys(Boc)-OH were coupled and deprotected by the standard protocol, then a second 
Fmoc-Lys(Boc)-OH was coupled but not Fmoc-deprotected.  Removal of the allyl and Fmoc 
groups, peptide cyclization and test cleavage analysis were performed as described for 3.45 to 
yield resin-bound intermediate 3.47.  HRMS (MALDI-TOF) calc. [M+H]
+ 
for C96H152N29O21S3 
2143.087, found 2143.117. 
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Analogue 3.48.  The next 10 residues were 
coupled to resin-bound 3.47 and 
deprotected by the standard protocol.  The 
N-terminus was acylated by treatment with 
D-lactic acid (5 equiv.), DEPBt (5 equiv.) 
and 
i
Pr2NEt (10 equiv.) for 2 h.  The peptide was cleaved from resin and globally deprotected 
with 90:5:2.5:2.5 TFA/H2O/triisopropylsilane/thioanisole under N2 for 2 h.  The cleaved resin 
was removed by filtration, and the filtrate was concentrated under a stream of N2.  The peptide 
was precipitated with cold Et2O, isolated by centrifugation at 12,000 ×g, dissolved in 1:1 
H2O/MeCN, and lyophilized to dryness.  Crude 3.48 was dissolved to 10 mg/mL in 5% 
MeCN/H2O with 0.1% TFA and purified by preparatory RP-HPLC using a solvent gradient of 
5% solvent B (see Section 3.4.1) for 1 min, then 5-25% over 4 min, then 25-50% over 25 min, 
then 50-100% over 1 min.  Partially-pure 3.48 eluted in fractions collected over 25.3-29.2 min.  
These fractions were lyophilized and re-purified under the same conditions, with pure product 
eluting over 27.1-28.0 min.  Lyophilization yielded 3.48 (2.0 mg, 0.63 μmol, 1.6% from a 40 
μmol scale synthesis, 93% per step over 59 steps) as a white powder.  HRMS (MALDI-TOF) 
calc. [M+H]
+ 
for C145H240N41O33S3 3179.752, found 3179.794. 
 
Analogue 3.49.  The next 9 residues were 
coupled to resin-bound 3.47 and 
deprotected by the standard protocol.  The 
N-terminal PyrAla moiety was 
incorporated by coupling Boc-Dha-Ala-
OH (3.38, 4 equiv.) with DIC and HOAt (4 equiv. each) in DMF for 3 h.  To prevent reduction 
of the ketone formed upon Boc deprotection, anisole was used in place of triisopropylsilane in 
the cleavage cocktail.  The peptide was cleaved from resin and globally deprotected with 
90:5:2.5:2.5 TFA/H2O/anisole/thioanisole under N2 for 3 h.  Crude 3.49 was isolated and 
purified as described for 3.48.  Partially-pure 3.49 eluted in fractions collected over 27.2-30.0 
min.  These fractions were lyophilized and re-purified under the same conditions, with pure 
product eluting over 27.5-28.5 min.  Lyophilization yielded 3.49 (1.3 mg, 0.41 μmol, 1.6% from 
a 25 μmol scale synthesis, 93% per step over 57 steps) as a white powder.  HRMS (MALDI-
TOF) calc. [M+H]
+ 
for C145H238N41O33S3 3177.736, found 3177.765. 
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Truncated analogue 3.50.  Fmoc-Ala-OH, Fmoc-
Lys(Boc)-OH and Fmoc-Ile-OH were coupled to 
resin-bound 3.47 and deprotected by the standard 
protocol.  The N-terminus was acetylated with 
1:2:4 Ac2O/pyridine/DMF for 30 min.  The peptide was cleaved from resin and globally 
deprotected with 90:5:2.5:2.5 TFA/H2O/triisopropylsilane/thioanisole under N2 for 2 h.  Crude 
3.50 was isolated and purified as for 3.48.  Partially-pure 3.50 eluted in fractions collected over 
14.4-17.0 min.  These fractions were lyophilized and re-purified under the same conditions, with 
pure product eluting over 16.1-17.0 min.  Lyophilization yielded 3.50 (1.2 mg, 0.48 μmol, 1.9% 
from a 25 μmol scale synthesis, 92% per step over 45 steps) as a white powder.  HRMS 
(MALDI-TOF) calc. [M+H]
+
 for C113H182N33O25S3 2497.314, found 2497.405. 
 
3.4.11. Total synthesis of lacticin 481 and analogues 
 
See also Notebook IX, pages 5-6, 20-21, 26-28, 36-37, 40-41. 
Intermediate 3.51.  The substitution of the Fmoc-Ser(
t
Bu)-Wang 
resin (initial substitution 0.55 mmol/g) was first reduced such that 1 
equiv. corresponded to 0.10 mmol/g.  The resin was swelled in 
DMF for 20 min, and the reaction vessel was drained.  To ensure 
local as well as global substitution reduction, Lan building block 
DL-3.4 (for 3.2, LL-A, and LL-B) or LL-3.4 (for LL-C) (1 equiv.) and Boc-Ala-OH (3 equiv.) were 
pre-activated with DIC/HOAt (4 equiv.) for 5 min, then added to the resin.  The reaction was 
performed for 3 h.  Any remaining free resin sites were capped with 1:2:7 Ac2O/pyridine/DMF 
for 30 min.  Adjusted resin substitution was calculated as follows: Fmoc-protected resin (20 mg) 
was agitated with 20% piperidine/DMF (1.0 mL) for 15 min.  A 20 μL aliquot of this solution 
was diluted 100:1 with DMF.  The absorbance of this solution at 301 nm (A301) was recorded 
after blanking with pure DMF, and the resin substitution was calculated using the equation: 
Substitution = 101(A301)/7.8(mg resin).
94
  After standard Fmoc deprotection, Lan building block 
DL-3.3 (for 3.2, LL-A, and LL-C) or LL-3.3 (for LL-B) (2 equiv.) was pre-activated with DIC/HOAt 
(2 equiv) for 5 min, then added to resin and reacted for 2 h.  After standard Fmoc deprotection, 
Fmoc-Phe-(Z)-Dhb-OH (3.32, 3 equiv.) was pre-activated with DIC/HOAt (3 equiv.) in DMF for 
10 min and reacted with the resin-bound peptide for 2 h; this coupling was repeated for an 
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additional 2 h, then the peptide was Fmoc-deprotected by the standard protocol.  Val22, Phe21 
and Gln20 were coupled/Fmoc-deprotected by the standard protocol, then Trp19 was coupled but 
not deprotected to yield the resin-bound intermediate 3.51. 
 
Monocyclic intermediate 3.52.  The nitrobenzyl protecting groups 
of 3.51 were removed with two treatments of 6 M SnCl2 and 5 mM 
HCl/dioxane in DMF (5 mL) for 1 h each.  Following the second 
treatment, the reaction vessel was drained, and the resin was 
washed with DMF (3 x 5 mL x 30 s), 1:1 DMF/H2O (3 x 10 mL x 1 
min), 1:1 THF/H2O (3 x 10 mL x 1 min), DMF (3 x 5 mL x 30 s), and CH2Cl2 (2 x 5 mL x 30 s).  
The Fmoc group was removed by the standard protocol, followed by washing with DMF (5 x 5 
mL x 30 s), CH2Cl2 (3 x 5 mL x 30 s), and DMF (2 x 5 mL x 30 s) to remove all traces of 
piperidine.  Cyclization was promoted by adding PyAOP and HOAt (5 equiv. each) in DMF to 
the resin and agitating for 5 min, then adding 2,4,6-collidine (10 equiv.) and agitating for 3 h.  
After draining, this treatment was repeated for an additional 3 h to yield the resin-bound 
intermediate 3.52.  Test cleavage analysis on a small sample was performed as described in 
Section 3.4.9 to confirm completed cyclization.  HRMS (MALDI-TOF) calc. [M+Na]
+
 for 
C65H83N13O17S2Na 1404.537, found 1404.530. 
 
Bicyclic intermediate 3.54.  Asn17, Met16 and Asn15 were 
coupled/Fmoc-deprotected to 3.52 by the standard protocol.  
MeLan building block DL-3.6 (for 3.2, LL-B, and LL-C) or LL-
3.6 (for LL-A) (2 equiv.) was pre-activated with DIC/HOAt 
(2 equiv) for 5 min, then added to resin and reacted for 2 h.  
After standard Fmoc-deprotection, Glu13 was coupled and Fmoc-deprotected by the standard 
protocol, then His12 was coupled but not deprotected.  The allyl protecting groups were then 
removed by agitating resin with tetrakis(triphenylphosphine)palladium(0) (1 equiv.) and 
phenylsilane (10 equiv.) in 1:1 DMF/CH2Cl2 (10 mL) for 2 h, protected from light.  After 
draining the reaction vessel, the resin was washed with CH2Cl2 (3 x 5 mL x 1 min), 0.5% 
diethyldithiocarbamate in DMF (3 x 10 mL x 1 min), DMF (3 x 5 mL x 30 s), and CH2Cl2 (2 x 5 
mL x 30 s).  The Fmoc group was removed by the standard protocol, followed by washing with 
DMF (5 x 5 mL x 30 s), CH2Cl2 (3 x 5 mL x 30 s), and DMF (2 x 5 mL x 30 s) to remove all 
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traces of piperidine.  Cyclization was promoted as for 3.52 to yield the resin-bound intermediate 
3.54.  Test cleavage analysis was performed to confirm completed cyclization.  HRMS (MALDI-
TOF) calc. [M+Na]
+
 for C104H130N26O32S4Na 2405.813, found 2405.835. 
 
Tricyclic intermediate 3.55.  Ile10 was coupled to resin-
supported 3.54 by the standard protocol but not Fmoc-
deprotected.  Removal of the nitrobenzyl and Fmoc groups, 
peptide cyclization and test cleavage analysis were 
performed as described for 3.52 to yield resin-bound 
intermediate 3.55.  HRMS (MALDI-TOF) calc. [M+Na]
+
 for C95H129N25O26S4Na 2186.832, 
found 2186.859. 
 
Lacticin 481 (3.2) and analogues LL-A, LL-B, and LL-
C.  The remaining eight residues were coupled to 
resin-supported 3.55 and deprotected by the standard 
protocol.  The peptide was cleaved from resin and 
globally deprotected with 92.5:5:2.5 TFA/H2O/ 
triisopropylsilane under N2 for 2 h.  The cleaved resin was removed by filtration, and the filtrate 
was concentrated under a stream of N2.  The peptide was precipitated with cold Et2O, isolated by 
centrifugation at 12,000 ×g, dissolved in 1:1 H2O/MeCN and lyophilized to dryness.  Crude 
peptide was dissolved to 10 mg/mL in 10% MeCN/H2O with 0.1% TFA and purified by 
preparatory RP-HPLC using a solvent gradient of 10% solvent B (see Section 3.4.1) for 1 min, 
then 10-25% over 4 min, then 25-50% over 25 min, then 50-100% over 1 min.  Partially-pure 
peptide eluted in fractions collected 23-28 min.  These fractions were lyophilized and re-purified 
under the same conditions, with pure product eluting as described below.  Lyophilization yielded 
the desired peptides 3.2, LL-A, LL-B, and LL-C (average yield 1.9 mg, 0.66 μmol, 1.3% from a 50 
μmol scale synthesis, 92% per step over 52 steps) as white powders. 
Synthetic lacticin 481 (3.2).  Rt = 26.3-27.0 min.  HRMS (MALDI-TOF) calc. [M+H]
+
 
for C127H183N36O35S4 2900.252, found 2900.244. 
Lacticin 481 LL-A.  Rt = 22.6-23.3 min.  HRMS (MALDI-TOF) calc. [M+H]
+
 for 
C127H183N36O35S4 2900.252, found 2900.278. 
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Lacticin 481 LL-B.  Rt = 22.7-23.4 min.  HRMS (MALDI-TOF) calc. [M+H]
+
 for 
C127H183N36O35S4 2900.252, found 2900.279. 
Lacticin 481 LL-C.  Rt = 23.0-23.6 min.  HRMS (MALDI-TOF) calc. [M+H]
+
 for 
C127H183N36O35S4 2900.252, found 2900.256. 
 
3.4.12. Chiral GC/MS analysis of synthetic peptides 
 
The enantiomeric purity of Lan/MeLan amino acids produced by hydrolysis of synthetic 
peptides was confirmed by chiral GC/MS, using a procedure modified from previous reports.
29, 95
  
Lyophilized peptides (0.1-0.2 mg) were dissolved in 6 M HCl (3 mL) and heated at 100 
o
C in a 
sealed, high-pressure reaction vessel for 18 h.  The reaction was cooled and concentrated with a 
stream of N2 over several hours.  Methanol (3 mL) was chilled in an ice bath, and acetyl chloride 
(1 mL) was added dropwise.  This solution was added to the dry hydrolysate, and the mixture 
was sealed and heated at 100 
o
C for 1 h.  The reaction was allowed to cool, then concentrated 
with a stream of N2.  The dry residue was suspended in CH2Cl2 (3.5 mL) and chilled in an ice 
bath.  Pentafluoropropionic anhydride (0.5 mL) was added, and the mixture was sealed and 
heated at 100 
o
C for 20 min.  The reaction was allowed to cool, then concentrated with a stream 
of N2.  The residue was dissolved in methanol and re-concentrated, then dissolved again in 
methanol (50 μL) for analysis.  Lan/MeLan standards of differing stereochemical configurations 
(DD, DL and LL for Lan; DL and LL for MeLan), synthesized using published procedures and 
similarly derivatized as their pentafluoropropionamide methyl esters,
30, 76
 were provided by 
Weixin Tang (University of Illinois at Urbana-Champaign) as solutions in methanol.  
The derivatized hydrolysate and standards were analyzed by GC/MS using an Agilent 
7890A gas chromatograph equipped with a Varian CP-Chirasil-L-Val fused silica column (25 m 
x 250 μm x 0.12 μm) and an Agilent 5975C Inert XL EI/CI MS (Metabolomics Center, UIUC) or 
a Waters Micromass GCT Premier detector (Mass Spectrometry Laboratory, UIUC).  Sample 
solutions in methanol were introduced to the instrument via splitless injection at an inlet 
temperature of 190-200 
o
C and flow rate of 1.7-2.0 mL/min helium gas.  The temperature 
gradient used was held at 160 
o
C for 5 min, then ramped from 160 
o
C to 180
 o
C at 3 
o
C/min, then 
held at 180 
o
C for 1-5 min.  The MS was operated in scan mode, and data was analyzed by 
selected ion monitoring (SIM) at known unique fragment masses of 365 Da for Lan and 379 Da 
for MeLan.  All standards eluted as distinct peaks.  Some observed epimerization of Lan/MeLan 
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amino acids is believed to result from hydrolysis, which has been reported previously.
29, 76
  See 
also Notebook VIII, pages 63-64; Notebook IX, pages 7-9. 
 
3.4.13. Liquid culture growth inhibition assays 
 
To generate stock concentrations of each peptide, lyophilized peptide was weighed using 
a Mettler-Toledo MT5 microbalance and dissolved in sterile deionized water (SDW) to give 200 
μM stock solutions.  Aliquots of these solutions were analyzed by analytical HPLC at an 
absorbance of 220 nm, and concentrations were normalized as necessary based on the integration 
under the expected peptide peak.  Serial two-fold dilutions of peptide stock solutions were 
prepared in SDW to give 4x working concentrations. 
For assays with epilancin 15X and analogues, cultures of the indicator strain 
Staphylococcus carnosus TM300 (5 mL) were grown at 37 
o
C in bovine heart infusion medium 
(BHI, 37 g/L) for 12 h, then diluted with fresh BHI to an optical density at 600 nm (OD600) of 
0.1.  For assays with lacticin 481 and analogues, cultures of Lactococcus lactis subsp. cremoris 
HP (ATCC 11602) were grown at 30 
o
C in GM17 medium (40 g/L M17, 0.5% glucose) for 12-
18 h, then diluted with fresh GM17 to an OD600 of 0.1, corresponding to approximately 1 × 10
8
 
colony forming units/mL.
96
  Corning-Costar 96-well flat-bottom assay plates were used to 
determine the activity of each peptide against its appropriate indicator strain, and experiments 
were performed in triplicate.  Experimental wells contained diluted culture (150 μL) and 4x 
peptide solution (50 μL).  Control wells contained either fresh media (150 μL) and SDW (50 μL, 
negative control) or diluted culture (150 μL) and SDW (50 μL, positive control).   OD600 was 
recorded at hourly intervals using a BioTek Synergy H4 plate reader, and plates were incubated 
at 37 
o
C (for S. carnosus) or 30 
o
C (for L. lactis) between readings.  After subtraction of blanks 
from experimental measurements, plots of OD600 vs. peptide concentration were fitted to a dose-
response function with the equation: y = A1 + (A2-A1) / (1 + 10
(logx0 – x)p
), where p = variable 
Hill slope.  Half maximal inhibitory concentration (IC50) and minimal inhibitory concentration 
(MIC) values were determined from this fit for each peptide after 5-6 h incubation, and triplicate 
calculations were averaged.  See also Notebook VIII, pages 71-72; Notebook IX, pages 88-89. 
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3.4.14. Flow cytometry analysis of membrane disruption 
 
Cultures of S. carnosus TM300 were grown as described for bioactivity assays and 
diluted with fresh BHI to an OD600 of 0.1.  For membrane depolarization assays, cells were 
combined with DiOC2(3) (final concentration 2 μM), 4-(2-hydroxyethyl)piperazine-1-
ethanesulfonic acid (HEPES, 1 mM), and glucose (1 mM) and incubated for 20 min at room 
temperature.  Stock solutions of epilancin 15X analogues 21 or 23 were added to final 
concentrations of 0.1, 1.0, or 10 μM and incubated for an additional 20 min prior to analysis; 
SDW was added for the negative control.  For membrane permeability assays, cells were 
combined with PI (final concentration 25 μM), HEPES (1 mM), glucose (1 mM), and epilancin 
15X analogues (0.1, 1.0, or 10 μM), incubated for 15 min at room temperature, and analyzed.  
Changes in cell-associated dye fluorescence were measured with a BD Biosciences LSR II flow 
cytometer at the Roy J. Carver Biotechnology Center (UIUC), using excitation at 488 nm with an 
argon laser and measurement of emission through a band-pass filter at 530/30 nm for DiOC2(3) 
or 695/40 nm for PI.  A minimum of 25,000 events were detected for each sample, and each 
peptide concentration was repeated in triplicate.  Data analysis to calculate the geometric mean 
fluorescence intensity (MFI) of each population was performed using FCS Express 3.00.0311 V 
Lite Stand-alone software.  See also Notebook VIII, pages 90-91, 97-98. 
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CHAPTER 4: SYNTHESIS OF ANALOGUES OF THE IMMUNOMODULATORY 
PEPTIDE COMPSTATIN WITH IMPROVED IN VIVO STABILITY
*
 
 
4.1. INTRODUCTION 
 
4.1.1. Disulfide bond engineering in bioactive peptides 
 
 Due to superior proteolytic stability compared to their linear counterparts (see Chapter 
1.2), cyclic peptides have received increased attention in recent years as therapeutic agents.
1-4
  
The designation “cyclic” encompasses a variety of structures, but most commonly found is the 
disulfide bond.  Beyond the ubiquitous role of disulfides in protein structure,
5-7
 several peptide 
natural product families, including conopeptides,
8-10
 cyclotides,
11-13
 and defensins,
14
 contain 
complex topologies enforced by this moiety.  Furthermore, a survey of approved peptide drugs 
reveals a variety of disulfide-containing compounds with numerous indications (Fig. 4.1), 
including eptifibatide,
15
 linaclotide,
16
 octreotide,
17
 oxytocin,
18
 pramlintide,
19
 and ziconotide.
20
  
Many of these drugs are produced synthetically.
1
  For most bioactive peptides, the structural 
constraint enforced by one or more disulfide bonds serves both to improve resistance to 
proteolysis and reduce the entropic cost of binding to their biological targets.
2, 13, 21-23
  However, 
the lability of the S-S bond to biological reducing agents, such as glutathione, limits its in vivo 
stability.  Indeed, this phenomenon has been exploited in the development of antibody-drug 
conjugates and drug delivery vehicles with conditionally-stable disulfide linkages.
24-27
 
 
Fig 4.1.  Representative disulfide-containing, approved peptide drugs, with disulfide bonds highlighted in red. 
                                                 
*
 Reproduced in part with permission from: Knerr, P. J.; Tzekou, A.; Ricklin, D.; Qu, H.; Chen, H.; van der Donk, 
W. A.; Lambris, J. D., “Synthesis and activity of thioether-containing analogues of the complement inhibitor 
compstatin.”  ACS Chem. Biol. 2011, 6, 753-760. 
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 In order to overcome this shortcoming inherent in many peptide drugs, disulfide bond 
engineering has been investigated extensively using reduction-stable moieties as mimics of the 
disulfide (Fig. 4.2).
28, 29
  Conotoxins containing diselenide bonds have been synthesized and 
evaluated, and several of these “selenoconotoxins” exhibited improved folding, target binding, 
and reductive stability compared to the parent disulfide-containing compounds.
30-32
  Analogues 
of oxytocin containing diselenide, ditelluride, selenylsulfide, methylene, and methine bridges 
have also demonstrated improved stability and, in some cases, potent activity.
33-36
  Other 
disulfide mimics, including lactam bridges,
37-39
 triazoles,
39, 40
 and noncovalent interactions,
41, 42
 
have been investigated in different systems with varying levels of success in preserving the 
biological activity of the parent disulfide.  Cystine to lanthionine (Lan) substitution, in which one 
sulfur atom is removed, has been shown to improve the in vivo stability of analogues of 
octreotide
43
 and cyclic enkephalin
21
 on the order of two- to five-fold.  However, the ring 
contraction resulting from this substitution decreased potency in the octreotide analogues,
43
 as 
well as in analogues of oxytocin,
33
 cell-adhesion molecule,
44
 and ligands for the low-density 
lipoprotein receptor.
39
  In comparison, the substitution of cystine with cystathionine (Cth) 
involves the change of only a single atom: a sulfur to a methylene (Fig. 4.2).  This isosteric 
substitution has been hypothesized to impart minimal structural perturbation in peptides,
45
 while 
removing the reductive lability of the S-S bond.  Indeed, Cth-containing analogues of α-
conotoxin ImI,
46
 oxytocin,
33, 47
 anticardiolipid antibody binders,
48
 and VCAM/VLA-4 
antagonists
49
 have been generated through a variety of synthetic approaches that largely maintain 
the potency of the parent disulfide-containing compounds.  Furthermore, two-dimensional NMR 
analysis of the α-conotoxin analogues revealed no structural perturbation by substituting one or 
both cystine moieties for Cth, providing additional evidence of the isosteric nature of this 
substitution.
46
 
 
Fig 4.2.  Examples of cystine disulfide mimics used in peptide disulfide bond engineering. 
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4.1.2. Compstatin, a peptide inhibitor of the complement immune system 
 
 As a central part of innate immunity, the complement system serves as a critical line of 
defense against bacterial infections, a link between innate and adaptive immunity, and a disposal 
system for immunity- and inflammation-related byproducts.
50-52
  Over 30 proteins are known to 
constitute this proteolytic cascade, along with multiple mechanisms of initiation and downstream 
effects.  Interestingly, the entire pathway converges at one keystone reaction, the proteolytic 
activation of complement factor 3 (C3) to produce anaphylatoxin C3a and opsonin C3b, which 
mediate all subsequent outcomes.  However, excessive or inappropriate activation of 
complement has been associated with host tissue damage in a variety of disease states, including 
ischemia-reperfusion injury, Alzheimer’s disease, rheumatoid arthritis, systemic lupus 
erythematosus, sepsis, and transplant rejection.
53-55
  Consequently, complement inhibition has 
been established as a potential therapeutic approach in these and other disorders. 
Compstatin (Fig. 4.3a) is a 13-residue, disulfide-containing peptide inhibitor of the 
complement pathway discovered by Prof. John Lambris and coworkers at the University of 
Pennsylvania in 1996, through screening of a phage-display library.
56
  This peptide binds directly 
                     
 
 
Fig 4.3.  Compstatin and complement inhibition.  (a) Structures of compstatin and acetylated analogue 4.1, 
highlighting altered structures in green.  (b) Schematic of the proposed mechanism of compstatin inhibition.  Three 
initiation pathways converge at the formation of the protease C3 convertase, a multiprotein complex, which cannot 
access its substrate C3 when C3 is bound by compstatin. 
b 
a 
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to both C3 and C3b, and thus inhibits the central reaction of complement activation via steric 
blocking of C3 convertase, the endogenous C3 protease, and other necessary binding partners 
(Fig. 4.3b).
57, 58
  Extensive structure-activity relationship analysis has yielded compstatin 
derivatives with up to 1000-fold improvement in potency,
59-64
 including an acetylated variant 
(4.1, Fig. 4.3a) that is currently in clinical trials for the treatment of age-related macular 
degeneration, a main cause of blindness in the elderly.
65
  The disulfide bond of compstatin, 
which enforces the constrained conformation necessary to bind C3,
57
 is critical for complement 
inhibition, as reduction-alkylation of the bond or substitution of cysteine with alanine abolishes 
biological activity,
56, 64
 and for protecting the peptide from in vivo degradation.
64
  Therefore, the 
identification of strategies to improve the metabolic stability of compstatin through disulfide 
replacement would be useful in improving its potential and impact in clinical application. 
 This chapter describes synthetic efforts to improve the pharmacokinetic properties of 
compstatin analogues.  A disulfide engineering approach was used to produce compstatin 
analogues containing Cth in place of cystine via solid-phase peptide synthesis (SPPS) in order to 
improve in vivo stability.  Strategic placement of this structural substitution yielded analogues 
with no sensitivity to reduction, but largely preserved binding and inhibitory activity.  
Furthermore, an alternative strategy to increase the in vivo half-life of compstatin was explored 
by appending an N-terminal albumin affinity tag shown in another peptide system to decrease 
drug clearance rate.
66
  This work was the result of a collaboration with Prof. John Lambris, 
whose laboratory first discovered compstatin, and his student Dr. Apostolia Tzekou in the 
Department of Pathology and Laboratory Medicine at the University of Pennsylvania School of 
Medicine (UPSM).  The individual contributions of these coworkers are mentioned throughout 
the chapter and are listed in detail in the Experimental (Section 4.4). 
 
4.2. RESULTS AND DISCUSSION 
 
4.2.1. Synthesis of Cth building blocks 
 
 Several strategies have been reported to generate cyclic Cth-containing peptides, 
including solid-supported intramolecular thioalkylation.
46, 47
  In this work, considering that Cth is 
the one-carbon homologue of Lan, an analogous synthetic approach to the SPPS-based 
construction of lantibiotics discussed in Chapter 3 was sought.  In this light, differentially-
protected Cth building blocks were necessary.  Allyl-based protection was chosen (as in Chapter 
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3.2) due to its orthogonality to the standard conditions of Fmoc-SPPS and ease of removal on the 
solid-phase.  Additionally, it is important to recognize that there are two possible isomers of Cth 
as a cystine isostere, depending on which sulfur atom of the original disulfide is replaced; this 
necessitates the construction of two different allyl-protected Cth building blocks.  Indeed, studies 
on VCAM/VLA-4 antagonists have shown that analogues containing different isomers of Cth 
exhibit different potencies.
49
   
 The nomenclature used to describe the two Cth isomers was based on the position of the 
sulfur atom relative to the Fmoc/free acid side of the molecule; the two isomers were 
consequently labeled γ- and δ-Cth.  The synthesis of γ-Cth building block 4.7 (Scheme 4.1) 
proceeded analogously to the Lan building blocks discussed in Chapter 3.2.1, via a base-
promoted phase-transfer condensation of cysteine 4.3 and 4-bromo-2-aminobutyrate 4.5 to 
generate thioether 4.6, followed by tert-butyl ester removal.  The resulting building block 4.7 
preserved the enantiomeric purity of the starting materials, as determined by GC/MS analysis 
(see Section 4.2.3) and 
13
C NMR spectroscopy.  The δ-Cth building block 4.13 (Scheme 4.2) was 
synthesized similarly to its isomer, again with preservation of stereochemical configuration. 
 In order to enable the synthesis of overlapping Cth bridges in peptides, a fully orthogonal 
Cth building block was also desired.  An isovaleryldimedonyl (Ddiv)/trimethylsilylethyl (Tmse) 
ester protection strategy was explored, which has been reported previously for a Lan building 
block.
67
  As described in Chapter 3.2.1, these protecting groups are orthogonal to both allyl and 
Fmoc and can be deprotected on the solid-phase under mild conditions.
68, 69
  The synthesis of this 
 
Scheme 4.1.  Synthesis of γ-Cth building block 4.7.a 
 
a
 Reagents and conditions: a) HClO4, 
t
BuOAc; b) FmocOSu, N-methylmorpholine, THF, 79% (two steps); c) PBu3, 
H2O, THF, 86%; d) AlocCl, Na2CO3, H2O, CH3CN; e) allyl bromide, NaHCO3, DMF, 77% (two steps); f) PPh3, 
CBr4, CH2Cl2, 80%; g) 4, Bu4NBr, NaHCO3, H2O, EtOAc, 84%; h) CF3CO2H, PhSiH3, CH2Cl2, 95%. 
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Scheme 4.2.  Synthesis of δ-Cth building block 4.13.a 
 
a
 Reagents and conditions: a) FmocOSu, Na2CO3, H2O, 1,4-dioxane; b) CCl3C(NH)O
t
Bu, CH2Cl2, THF, 52% (two 
steps); c) PPh3, CBr4, CH2Cl2, 94%; d) AlocCl, Na2CO3, H2O, CH3CN; e) allyl bromide, NaHCO3, DMF, 70% (two 
steps); f) CF3CO2H, 
i
Pr3SiH, CH2Cl2, 85%; h) Bu4NBr, NaHCO3, H2O, EtOAc, 93%; h) CF3CO2H, PhSiH3, CH2Cl2, 
98%. 
 
δ-Cth building block (4.19, Scheme 4.3) proceeded analogously to Schemes 4.1 and 4.2, except 
that an allyl ester was used in place of the tert-butyl ester for temporary carboxylate protection 
due to the sensitivity of Tmse to the acidic conditions necessary for tert-butyl ester removal.  
While this building block could be synthesized in acceptable yields, it was found to decompose 
via elimination in the presence of piperidine used during Fmoc-SPPS.  This instability was 
attributed to the Ddiv group, as observed for similarly-protected Lan building blocks (see Section 
3.2.1). 
 
Scheme 4.3.  Synthesis of δ-Cth building block 4.19.a 
 
a
 Reagents and conditions: a) FmocCl, Na2CO3, H2O, CH3CN; b) allyl bromide, NaHCO3, DMF, 64% (two steps); c) 
PPh3, CBr4, CH2Cl2, 60%; d) 2-isovaleryldimedone, 
i
Pr2NEt, MeOH, reflux; e) Me3SiEtOH, 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide, DMAP, CH2Cl2, 55% (two steps); f) CF3CO2H, 
i
Pr3SiH, CH2Cl2, 79%; g) 
Bu4NBr, NaHCO3, H2O, EtOAc, 82%; h) Pd(PPh3)4, PhNHCH3, THF, 78%.  Ddiv, isovaleryldimedonyl; Tmse, 
trimethylsilylethyl; Trt, trityl. 
 
150 
 
4.2.2. Synthesis of Cth-containing compstatin analogues 
 
 Following the successful syntheses of Cth isomers 4.7 and 4.13, the solid-phase 
construction of three Cth-containing compstatin analogues commenced (Fig. 4.4).  Both possible 
Cth isomers (4.20, 4.21) of second-generation compstatin derivative 4.1
61
 (Fig. 4.3) were 
constructed.  Based on biological data (see Sections 4.2.4 and 4.2.5), peptide 4.21, utilizing δ-
Cth building block 4.13 with the sulfur atom placed closer to the N-terminus, was found to be 
more active than the γ-Cth-containing analogue.  Therefore, the δ-Cth analogue (4.23) of the 
most potent compstatin derivative known to date (4.22) was also produced, which contains an 
acetyl cap and four mutations from compstatin, 1-methyltryptophan (Trp(Me)) in position 4, 
sarcosine (Sar) in position 8, alanine in position 9, and N-methylisoleucine (N-MeIle) in position 
13.  These modifications yield an overall 1000-fold increase in potency over compstatin due to a 
free conformation more favorable for binding and improved hydrophobic interactions.
59
 
 
Figure 4.4.  Sequences of compstatin derivatives and Cth-containing analogues studied in this work.  Mutations 
from compstatin are highlighted in green.  The two Cth isomers are depicted as Hcy-Ala (red, for γ-Cth) or Ala-Hcy 
(blue, for δ-Cth).  Hcy, homocysteine; Sar, sarcosine; Trp(Me), 1-methyltryptophan. 
 
 The Fmoc-SPPS of Cth-containing compstatin analogues (Scheme 4.4) mirrored the 
chemical synthesis of lantibiotics discussed in Chapter 3.  The substitution density of Rink amide 
AM resin was manually lowered to 0.2 mmol/g to prevent intermolecular reactions from 
occurring during peptide cyclization.  Fmoc-amino acids, including Cth building blocks 4.7 and 
4.13, were activated using O-(6-chlorobenzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium 
hexafluorophosphate (HCTU) and diisopropylethylamine (
i
Pr2NEt), and Fmoc groups were 
removed with piperidine.  After the construction of solid-supported linear intermediate 4.24, the 
allyl groups of the Cth residue were removed with tetrakis(triphenylphosphine)palladium(0) and 
phenylsilane, the N-terminal Fmoc group was removed, and the peptide was cyclized using 
(benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate (PyBOP), 1-hydroxy-7-
azabenzotriazole (HOAt), and 
i
Pr2NEt.  Cyclization was monitored by analytical reversed-phase 
high-performance liquid chromatography (RP-HPLC) and matrix-assisted laser desorption 
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Scheme 4.4.  Solid-supported synthesis of compstatin analogues 4.20, 4.21, 4.23.
a,b 
 
a
 Reagents and conditions: a) SPPS; b) Pd(PPh3)4, PhSiH3, DMF, CH2Cl2; c) piperidine, DMF d) PyBOP, HOAt, 
i
Pr2NEt, DMF; e) CF3CO2H, H2O, 
i
Pr3SiH, ethanedithiol. 
b 
Prior to cleavage from resin (step e), all residues 
contained appropriate side-chain protecting groups for Fmoc-SPPS: Boc for Trp, Pbf for Arg, 
t
Bu for Thr, O
t
Bu for 
Asp, and Trt for Gln and His. 
 
ionization/time-of-flight mass spectrometry (MALDI-TOF MS), which indicated complete 
conversion to the cyclic intermediate 4.25 within 3 h.  Subsequent isoleucine coupling, N-
terminal acetylation, and concurrent resin cleavage and global deprotection afforded Cth-
containing peptides 4.20, 4.21, and 4.23, which were purified by RP-HPLC.  The pure peptides 
were obtained in overall yields of 2.5-5%, or 88-90% per chemical step.  Analogue 4.23 gave the 
lowest yield, which was impacted in part by the difficulty in coupling amino acids to the N-
methylated residues at positions 8 and 13.  Analytical RP-HPLC and MALDI-TOF MS 
confirmed the homogeneity of each peptide after purification (Fig. 4.5) 
 
4.2.3. GC/MS analysis of Cth building blocks and compstatin analogues 
 
 In order to confirm that the desired absolute stereoconfiguration of the Cth building 
blocks as well as Cth bridges within the compstatin analogues was retained, chiral gas 
chromatography-mass spectrometry (GC/MS) was used, as described in Chapter 3.2.4 for Lan 
and reported previously for Cth.
70
  δ-Cth building block 4.13 was globally deprotected, and 
peptide 4.23 was hydrolyzed in refluxing 6 M HCl.  The resulting amino acids were then 
derivatized to their corresponding pentafluoropropionamide methyl esters and analyzed using a 
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Figure 4.5.  Characterization of Cth-containing compstatin analogues, showing analytical RP-HPLC chromatograms 
and MALDI-TOF mass spectra for (a) analogue 4.20; (b) analogue 4.21; and (c) analogue 4.23. 
b 
a 
c 
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Varian CP-Chirasil-L-Val column, compared to derivatized commercial Cth possessing the 
desired LL-configuration and a synthetic standard with an alternative DL-configuration.  The 
derivatized Cth amino acids fragment during MS analysis to give unique mass ions compared to 
proteinogenic amino acids, permitting selected ion monitoring (SIM) at these m/z values to 
unambiguously identify Cth.  Both building block 4.13 and hydrolyzed peptide 4.23 contained 
Cth bearing the desired LL-configuration (Fig. 4.6), indicating that minimal epimerization 
occurred during building block synthesis and SPPS. 
 
 
Figure 4.6.  Chiral GC/MS analysis of Cth building blocks and peptides, confirming the desired LL-configuration.  
(a) SIM at 379 Da of deprotected and derivatized 4.13 compared to Cth standards.  (b) SIM at 379 Da of hydrolyzed 
and derivatized 4.23 compared to Cth standards.  (c) Representative mass spectrum of derivatized Cth. 
 
154 
 
4.2.4. Kinetic binding analysis of compstatin analogues 
 
 The affinities of Cth-containing compstatin analogues 4.20, 4.21, and 4.23 for C3b were 
characterized by Dr. Apostolia Tzekou (UPSM) using an established surface plasmon resonance 
(SPR) assay (Fig. 4.7).
60
  Biotinylated C3b was site-specifically captured on a streptavidin-
coated sensor chip to prevent surface heterogeneity.  An initial kinetic ranking of the Cth-
containing analogues indicated that the association and dissociation profiles of δ-Cth-containing 
4.21 were comparable to those of the parent disulfide 4.1, while γ-Cth-containing 4.20 displayed 
much faster dissociation.  δ-Cth-containing 4.23 showed a similar association rate, but faster 
dissociation rate, compared to parent disulfide 4.22. 
 
 
Figure 4.7.  Kinetic ranking via SPR of compstatin analogues.  (a) 1 µM of peptide was injected over immobilized 
C3b at a surface density of 3000 resonance units (RU), and association and dissociation phases were observed.  Each 
plot is a representative of three data sets.  (b) Schematic representation of the SPR assay.  Figure courtesy of Dr. 
Apostolia Tzekou (UPSM). 
 
Given this initial ranking, a full kinetic analysis was performed by Dr. Tzekou to further 
characterize and quantitate the relationship between the structure and activity.  Due to the very 
slow dissociation rate constant of analogue 4.22,
59
 a single-cycle kinetics approach was used to 
allow for characterization of interactions with slow dissociation rates in a shorter period of time 
than does the traditional multi-cycle approach.
64, 71
  All peptides showed a binding response that 
could be fitted to a 1:1 binding model, allowing for the extraction of rate constants ka and kd (Fig. 
4.8).  The γ-Cth analogue 4.20 possessed 5.7-fold reduced affinity for C3b compared to parent 
4.1, while δ-Cth analogue 4.21 possessed only a 1.6-fold lower affinity, highlighting the 
b a 
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importance of the exact position of the sulfur atom.  δ-Cth analogue 4.23 possessed a 3.8-fold 
lower affinity than parent 4.22.  The chief differences between the Cth-containing analogues and 
their respective disulfide-containing parent peptides were found in kd, as ka remained rather 
similar (Fig. 4.8f).  The largely comparable association rate constants within each analogue 
series suggest that the Cth modification had little effect on complex formation with C3b, 
maintaining the ability of the peptides to adjust between distinct solution and bound 
conformations.
57, 59
  However, it is possible that a slightly changed geometry between cystine 
and Cth may influence the exact positioning of key residues and thereby affect the complex 
stability, as measured by kd.  This effect appears more pronounced in 4.23, as the mutations in 
parent peptide 4.22 were made specifically to tailor the peptide to its binding site. 
 
 
Figure 4.8.  Kinetic titration analysis via SPR of binding between compstatin analogues and C3b.  (a-e) Sets of five 
increasing analogue concentrations were consecutively injected over immobilized C3b at a surface density of 3000 
RU in a single cycle.  For (a) 4.1, (b) 4.20, and (c) 4.21, two sets of concentrations are superimposed for a better 
description of the full binding range and to achieve a well-defined affinity profile.  Data were fitted to a 1:1 binding 
model (orange line), from which kinetic rate constants were extracted.  (f) Kinetic rate constants ka and kd and 
binding affinity KD for each compstatin analogue, showing average and standard deviation of at least six data sets.  
Figure courtesy of Dr. Apostolia Tzekou (UPSM). 
 
a b c 
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4.2.5. Inhibition of complement activation by compstatin analogues 
 
The biological activities of the Cth-containing analogues were compared to that of their 
corresponding disulfide-containing parent peptides using an established enzyme-linked 
immunosorbent assay (ELISA) by Dr. Tzekou (Fig. 4.9).
61
  The ability of these compounds to 
inhibit antigen/antibody-induced complement activation was assessed by measuring the 
deposition of C3b on an ELISA surface, compared to controls with no peptide (Fig. 4.9b).  These 
assays yielded results consistent with the data obtained in the kinetic assays (Section 4.2.4).  
Analogue 4.20 was again identified as the least active analogue, thereby confirming the 
unfavorable effect of sulfur-to-methylene substitution on the C-terminal side of the original 
disulfide.  In both series, Cth-containing peptides 4.21 and 4.23 showed decreased inhibitory 
activity compared to parent peptides 4.1 and 4.22, respectively, but only by a factor of ~2.  The 
combined analyses confirm thioether-restricted compstatin analogues 4.21 and 4.23 as potent 
complement inhibitors. 
 
 
Figure 4.9.  Inhibitory activity of compstatin analogues.  (a) Representative results of at least five assays for 
inhibition of complement activation by compstatin analogues.  The calculated IC50 values are shown for each 
analogue.  (b) Schematic representation of the inhibition assay.  BSA, bovine serum albumin; OVA, ovalbumin; a-
hC3 HRP, anti-human C3 antibody conjugated to horseradish peroxidase.  Figure courtesy of Dr. Apostolia Tzekou 
(UPSM). 
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4.2.6. Effect of oxidation and reduction on compstatin analogue activity 
 
A disulfide-to-thioether substitution was hypothesized to improve the reductive stability 
of compstatin analogues; however, thioethers are labile to metabolic oxidation, as has been well 
documented in the case of methionine-containing polypeptide drugs.
72, 73
  In addition, thioether 
oxidation has been shown to severely decrease the activity of the lantibiotic nisin,
74
 although the 
lantibiotic actagardine contains an enzymatically-oxidized methyllanthionine bridge important 
for full activity.
75
  In this work, Cth building blocks and Cth-containing peptides appeared stable 
to spontaneous oxidation during synthesis, purification, biological testing, and storage.  
However, systematic assessment of the effect of oxidative and reductive treatments on analogue 
activity was desired, as such conditions may be encountered in vivo.  Since the binding and 
inhibitory activities of disulfide-containing 4.22 were largely maintained in δ-Cth-containing 
4.23, the effect of oxidation and reduction on these peptides was assessed by Dr. Tzekou.  Both 
peptides were treated with a 500-fold molar excess of tris(2-carboxyethyl)phosphine 
hydrochloride (TCEP); this treatment resulted in reduction of the disulfide of 4.22 (Fig. 4.10a) 
but no change in 4.23, confirming its stability to reduction.  Similarly, both peptides were also 
exposed to excess hydrogen peroxide, which resulted in oxidation of the thioether bridge of 4.23 
to the corresponding sulfoxide (Fig. 4.10b) but no modification of 4.22. 
The oxidant- and reductant-treated 4.22 and 4.23 were tested for complement inhibitory 
activity by ELISA (see Section 4.2.5).  In order to prevent re-formation of the disulfide bond 
during analysis, reduced 4.22 was treated with iodoacetamide to alkylate the cysteinyl thiols.  As 
expected based on previous studies,
56, 64
 reduction and alkylation of 4.22 severely diminished 
activity compared to 4.22, while treatment with H2O2 had only marginal consequences (Fig. 
4.11).  This confirmed the importance of both the cyclic structure and reductive stability to 
inhibitory activity.  Conversely, thioether-oxidized 4.23 showed a decrease in potency compared 
to 4.23, but as the magnitude of this reduction was a mere 4.4-fold, this sulfoxide-containing 
peptide remained a highly potent, sub-micromolar inhibitor of complement activation.  
Therefore, while a different metabolic lability was introduced in the thioether-containing 
analogues, oxidative treatment gave only modest effects on activity compared to disulfide 
reduction. 
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Figure 4.10.  MALDI-TOF MS analysis of redox treatment on compstatin analogues.  (a) Disulfide-containing 
analogue 4.22 before and after treatment with excess TCEP, showing a +2 Da mass shift indicative of disulfide 
reduction.  (b) Cth-containing analogue 4.23 before and after treatment with excess H2O2, showing a +16 Da mass 
shift indicative of thioether oxidation to sulfoxide.  In the reverse cases, treatment of 4.22 with H2O2 and 4.23 with 
TCEP, no changes in mass were observed.  Figure courtesy of Dr. Apostolia Tzekou (UPSM). 
 
b 
a 
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Figure 4.11.  Effect of redox modification on complement inhibition by compstatin analogues 4.22 and 4.23.  All 
data sets except reduced/alkylated 4.22 could be evaluated using a dose-response function to determine comparative 
IC50 values.  Figure courtesy of Dr. Apostolia Tzekou (UPSM). 
 
4.2.7. Synthesis of an albumin affinity tag to improve in vivo half-life 
 
Even if rendered stable to proteolysis and redox agents, small peptide therapeutics such 
as compstatin often suffer from short half-lives in vivo due to rapid clearance rates from the 
human body.
1, 76-78
  One approach to address this limitation is the attachment of serum albumin 
binding tags to peptide therapeutics, which has been shown to increase the in vivo half-lives of 
bioactive peptides up to 50-fold by slowing clearance rates.
66, 79
  It was therefore hypothesized 
that a similar approach could be used to broaden the therapeutic application of compstatin, 
including to systemic disease states.  A diphenylcyclohexyl phosphodiester moiety (4.27, Scheme 
4.5) was synthesized with modification from a previous report.
66
  A Robinson-type tandem 
Michael addition/aldol condensation furnished hexenone 4.24, which was reduced by sequential 
hydrogenation and borohydride treatment to give alcohol 4.25.  This alcohol was coupled to 
phosphoramidite 4.26, and the resulting phosphite was oxidized to the phosphate, followed by 
cyanoethyl and ethyl ester removal to give 4.27.  Conjugates of compstatin derivatives and 4.27 
are currently being investigated in the laboratory of Prof. John Lambris (UPSM) for alteration of 
complement inhibitory activity and in vivo clearance rates. 
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Scheme 4.5.  Synthesis of albumin affinity tag 4.27.
a
  
 
a
 Reagents and conditions: a) KOH, EtOH, 0 
o
C, 70%; b) H2, Pd/C, THF; then NaBH4, NaOH, H2O, THF, 96%; c) 
DIPEA, CH2Cl2, 78%; d) 4.25, 1H-tetrazole,
 t
BuOOH, MeCN; e) NH3, MeOH; f) LiOH, H2O, THF, 54% (three 
steps). 
 
4.3. CONCLUSIONS AND OUTLOOK 
 
In this chapter, the chemical synthesis of thioether-containing analogues of the 
complement inhibitor compstatin was described, confirming the cystathionine bridge as a viable 
disulfide mimic in a bioactive peptide system.  Replacing the cystine of compstatin with Cth was 
found largely to preserve the binding and inhibitory activities of the parent peptide while 
removing lability to reduction.  As suggested in other peptides,
49
 the position of the sulfur atom 
within the Cth bridge played a role in biological activity; placement closer to the N-terminus of 
the peptide (δ-Cth, as in 4.21) was found to give more potent activity than placement closer to 
the C-terminus (γ-Cth, as in 4.20).  In comparing potential metabolic alterations of disulfide- and 
thioether-containing analogues, reduction of the disulfide had a severely deleterious effect on 
potency while oxidation of the Cth thioether gave only a modest decrease, highlighting the 
benefit of Cth in this context.  While N-terminally acetylated compstatin analogues have been 
shown previously to possess high stability in plasma under normal conditions,
64
 a variety of 
complement-related pathologies can trigger changes in the reductive environment of blood.  For 
example, compstatin derivatives have shown promise in treating models of bacterial sepsis,
80
 but 
this disease state is also associated with a large increase in the plasma levels of thioredoxin
81
 that 
may threaten the disulfide structure.  Similarly, complement inhibition by compstatin has 
therapeutic potential in several hemolytic conditions,
54, 82
 during which the large reservoir of 
reduced glutathione in erythrocytes (1-3 mM) is released into the plasma.
83, 84
  In these relevant 
therapeutic applications, protection of compstatin analogues against reduction becomes even 
more important. 
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More generally, as the impact of peptide-based drugs has continued to develop, disulfide 
bond engineering has become a major focus of efforts toward in vivo stabilization (see Section 
4.1.1).  The versatile nature of this solid-supported synthesis allows for the production of a wide 
variety of cyclic Cth-containing peptides, in order to probe the effects of disulfide substitution on 
the activity and stability of other potential drugs.  Indeed, Cth-containing analogues replacing 
one or both of the disulfides of α-conotoxin ImI have been recently reported, which also largely 
maintain the structure and potency of the parent disulfide-containing peptide.
46
  The availability 
of Cth building blocks bearing orthogonal protecting groups (as described for lanthionine 
building blocks in Chapter 3) would allow for the controlled synthesis of overlapping Cth bonds.  
The recent synthesis of novel thioether-containing amino acids has already expanded the known 
suite of differentially-protected Cth building blocks useful in disulfide bond engineering.
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4.4. EXPERIMENTAL 
 
4.4.1. Materials and general methods 
 
Disulfide-containing compstatin derivatives 4.1 and 4.22 were synthesized in the 
laboratory of Prof. John Lambris (UPSM) as previously described.
59, 63
  Unprotected amino acids 
for solution-phase synthesis, standard protected Fmoc-amino acids for solid-phase peptide 
synthesis (SPPS), Fmoc-Rink amide AM resin, N-(9-fluorenylmethoxycarbonyloxy)succinimide 
(FmocOSu), and peptide coupling reagents 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
hydrochloride (EDC), benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate 
(PyBOP), O-(6-chlorobenzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium hexafluorophosphate 
(HCTU), and 1-hydroxy-7-azabenzotriazole (HOAt) were purchased from ChemImpex 
International or Advanced ChemTech.  N-Fmoc-1-methyl-L-tryptophan (Fmoc-Trp(Me)-OH) 
was synthesized from 1-methyl-L-tryptophan by an established procedure.
86
  Dimethylformamide 
(DMF), tetrahydrofuran (THF), and dichloromethane were purchased at ACS-grade from Fisher 
Scientific and dried via a solvent dispensing system prior to use in reactions.  Other chemical 
reagents, including an L-cystathionine standard for GC/MS analysis, and solvents were purchased 
from Sigma Aldrich, Alfa Aesar, or Fisher Scientific and used without further purification. 
All reactions were run under an atmosphere of N2 unless otherwise stated.  Reaction 
progress and chromatography fractions were monitored by thin layer chromatography (TLC) on 
silica gel-coated glass plates with a F254 fluorescent indicator.  Visualization was achieved by 
162 
 
UV absorption by fluorescence quenching or permanganate stain (1.5 g KMnO4, 10 g K2CO3, 
1.25 mL of 10% NaOH in 200 mL of H2O).  Flash chromatography was performed using 
Silicycle SiliaFlash P60, 230-400 mesh silica gel.  Analytical reversed-phase high-performance 
liquid chromatography (RP-HPLC) was performed using a Beckman System Gold instrument 
equipped with a Vydac C18 (300 Å pore size, 250 mm × 4.6 mm × 5 μm) analytical column, a 
flow rate of 1 mL/min, and a solvent gradient of 2% solvent B for 1 min, then 10-100% over 45 
min, observing at an absorbance of 220 nm.  Preparatory RP-HPLC was performed on a Waters 
600 system equipped with a Waters Delta-Pak C18 (100 Å pore size, 100 mm × 25 mm) column 
or a Phenomenex Luna C18 (100 Å pore size, 250 mm × 10.0 mm × 10 μm) column with a flow 
rate of 8 mL/min and solvent gradients as described for each peptide.  All HPLC solvents were 
filtered with a Millipore filtration system equipped with a 0.22 μm nylon membrane filter prior 
to use.  HPLC solvent compositions: solvent A is 0.1% trifluoroacetic acid (TFA) in H2O; 
solvent B is 80:20 MeCN/H2O with 0.087% TFA.  
NMR spectra were recorded using a Varian Unity 400 or Unity Inova 500 spectrometer at 
the NMR Laboratory (UIUC).  Small molecules (MW < 800 Da) were analyzed by electrospray 
ionization/time-of-flight (ESI-TOF) mass spectrometry on a Waters Quattro II quadrupole 
spectrometer at the Mass Spectrometry Facility (UIUC).  Peptides (MW > 800 Da) were 
analyzed by matrix-assisted laser desorption ionization/time-of-flight (MALDI-TOF) mass 
spectrometry using an Applied Biosystems Voyager-DE spectrometer at the Mass Spectrometry 
Facility (UIUC) in a matrix solution consisting of saturated α-cyano-4-hydroxycinnamic acid in 
1:1:0.1 H2O/MeCN/TFA. 
 
4.4.2. Synthesis of Cth building blocks 4.7, 4.13, and 4.19 
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Compound 4.2.  To a solution of L-cystine (6.01 g, 25.0 mmol) 
in 70% perchloric acid (10 mL) was slowly added tert-butyl 
acetate (62.5 mL).  The solution was stirred for 19 h, gradually 
becoming homogeneous.  Water was added, and the solution was chilled in an ice bath.  The pH 
was adjusted to 10 with 10 M NaOH, and the solution was extracted with EtOAc.  The organic 
layer was dried over Na2SO4, filtered, and concentrated under reduced pressure.  A portion of the 
residue (5.95 g, 16.9 mmol) was taken up in THF (85 mL) and chilled in an ice bath, and N-
methylmorpholine (3.85 mL, 34.9 mmol) was added.  FmocOSu (11.75 g, 34.9 mmol) was then 
added portionwise over 10 min.  The reaction was warmed to room temperature, then stirred for 
19 h.  The reaction was concentrated under reduced pressure, taken up in EtOAc, washed with 
water and brine, dried over Na2SO4, filtered, and concentrated under reduced pressure.  The 
crude material was purified by flash chromatography (SiO2, 9:1 then 7:3 hexane/EtOAc) to yield 
4.2 (10.69 g, 13.4 mmol, 79%) as a white solid.  Rf 0.55 (2:1 hexane/EtOAc).  Spectral data 
matched those reported previously.
87
  See also Notebook I, pages 38-39. 
 
Compound 4.3.  To a solution of 4.2 (3.00 g, 3.66 mmol) in 
tetrahydrofuran (45 mL) was added tributylphosphine (1.37 mL, 5.50 
mmol) under N2.  The reaction was stirred for 30 min, then water (4.5 mL) 
was added and the reaction stirred an additional 14 h.  Solvent was removed under reduced 
pressure, and the residue was taken up in EtOAc, washed with 10% citric acid and brine, dried 
over Na2SO4, filtered, and concentrated under reduced pressure.  The crude material was purified 
by flash chromatography (SiO2, 9:1 then 4:1 hexane/EtOAc) to yield 4.3 (2.53 g, 6.33 mmol, 
86%) as a colorless oil.  Rf 0.45 (4:1 hexane/EtOAc).  Spectral data matched those reported 
previously.
87
  See also Notebook I, page 42. 
 
Compound 4.4.  L-Homoserine (1.01 g, 8.48 mmol) and sodium carbonate 
(0.90 g, 8.48 mmol) were dissolved in water (10 mL) and acetonitrile (5 mL) 
and chilled in an ice bath.  Allyl chloroformate (900 µL, 8.48 mmol) was 
added dropwise.  The reaction was allowed to warm to room temperature 
and stirred under N2 for 18 h.  The reaction was concentrated under reduced pressure, and the 
residue was taken up in DMF (20 mL).  Sodium bicarbonate (0.71 g, 8.48 mmol) was added, 
followed by allyl bromide (810 µL, 9.33 mmol).  The reaction was stirred as a heterogeneous 
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mixture for 48 h, with additional allyl bromide (405 µL, 4.66 mmol) added after 22 h.  The 
reaction was concentrated under reduced pressure, then taken up in EtOAc, washed with 
saturated aqueous NaHCO3, water, 0.1 M KHSO4, and brine, dried over Na2SO4, filtered, and 
concentrated under reduced pressure.  The crude material was purified by flash chromatography 
(SiO2, 2:1 then 1:1 hexane/EtOAc) to yield 4.4 (1.58 g, 6.50 mmol, 77%) as a colorless oil.  Rf 
0.39 (SiO2, 1:1 hexane/EtOAc); 
1
H NMR (500 MHz, CDCl3) δ 5.94-5.86 (m, 2H), 5.67 (d, J = 
7.3 Hz, 1H), 5.35-5.21 (m, 4H), 4.65 (d, J = 6.0 Hz, 2H), 4.60-4.53 (m, 3H), 3.76-3.65 (m, 2H), 
2.64 (bs, 1H), 2.20-2.14 (m, 1H), 1.77-1.71 (m, 1H).  
13
C NMR (125 MHz, CDCl3) δ 172.3, 
156.7, 132.6, 131.5, 119.1, 118.1, 66.3, 66.2, 58.5, 51.5, 35.6.  HRMS (ESI) calc. [M+Na]
+
 for 
C11H17NO5Na 266.1004, found 266.1008.  See also Notebook I, page 47. 
 
Compound 4.5.  To a solution of 4.4 (4.00 g, 16.4 mmol) in CH2Cl2 (45 mL) 
was added carbon tetrabromide (6.53 g, 19.7 mmol), and the reaction was 
chilled in an ice bath.  A solution of triphenylphosphine (5.17 g, 19.7 mmol) 
in CH2Cl2 (20 mL) was added dropwise to the chilled reaction.  The reaction 
was warmed to room temperature and stirred under N2 for 1 h, then washed with water and brine, 
dried over Na2SO4, filtered, and concentrated under reduced pressure.  Excess 1:1 hexane/EtOAc 
was added to precipitate the phosphine oxide byproduct, which was removed via filtration 
through Celite.  The filtrate was concentrated under reduced pressure and purified by flash 
chromatography (SiO2, 4:1 then 2:1 hexane/EtOAc) to yield 4.5 (4.02 g, 13.1 mmol, 80%) as a 
colorless oil.  Rf 0.50 (2:1 hexane/EtOAc).  
1
H NMR (500 MHz, CDCl3) δ 5.95-5.85 (m, 2H), 
5.37-5.21 (m, 5H), 4.65 (dt, J = 5.6 Hz, 1.2 Hz, 2H), 4.58 (d, J = 5.6 Hz, 2H), 4.52 (m, 1H), 3.44 
(t, J = 7.0 Hz, 2H), 2.48-2.41 (m, 1H), 2.29-2.22 (m, 1H).  
13
C NMR (125 MHz, CDCl3) δ 171.3, 
155.9, 132.5, 131.4, 119.3, 118.1, 66.4, 66.1, 53.0, 35.7, 28.2.  HRMS (ESI) calc. [M+H]
+
 for 
C11H17BrNO4 306.0341, found 306.0339.  See also Notebook II, page 35. 
 
Compound 4.6.  Compounds 4.3 (1.60 g, 4.01 mmol) and 4.5 
(1.29 g, 4.21 mmol) were dissolved in N2-sparged EtOAc (20 
mL) under N2.  Tetrabutylammonium bromide (5.17 g, 16.0 
mmol) was dissolved in N2-sparged 0.5 M aqueous NaHCO3 (pH adjusted to 8.5, 20 mL), then 
added to the reaction.  The biphasic mixture was for 22 h under N2.  The reaction was diluted 
with EtOAc, washed with water and brine, dried over Na2SO4, filtered, and concentrated under 
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reduced pressure.  The crude material was purified by flash chromatography (SiO2, 4:1 then 2:1 
hexane/EtOAc) to yield 4.6 (2.10 g, 3.36 mmol, 84%) as a colorless oil.  Rf 0.20 (3:1 
hexane/EtOAc).  
1
H NMR (500 MHz, CDCl3) δ 7.76 (d, J = 7.5 Hz, 2H), 7.61 (d, J = 7.5 Hz, 
2H), 7.40 (t, J = 7.5 Hz, 2H), 7.32 (t, J = 7.5 Hz, 2H), 5.94-5.85 (m, 2H), 5.69 (d, J = 7.3 Hz, 
1H), 5.40 (d, J = 7.1 Hz, 1H), 5.34-5.17 (m, 4H), 4.63 (d, J = 6.0 Hz, 2H), 4.59-4.46 (m, 4H), 
4.39 (d, J = 7.0 Hz, 2H), 4.24 (t, J = 7.0 Hz, 1H), 2.97 (dq, J = 13.4 Hz, 4.9 Hz, 2H), 2.65-2.60 
(m, 2H), 2.15-1.96 (m, 2H), 1.49 (s, 9H).  
13
C NMR (125 MHz, CDCl3) δ 171.7, 169.8, 155.9, 
144.0, 143.9, 141.4, 132.7, 131.5, 127.8, 127.2, 125.3, 120.1, 119.2, 118.0, 83.1, 67.3, 66.3, 66.1, 
54.4, 53.1, 47.3, 34.9, 32.6, 28.8, 28.1.  HRMS (ESI) calc. [M+H]
+
 for C33H41N2O8S 625.2584, 
found 625.2582.  See also Notebook II, page 39. 
 
Compound 4.7.  To a solution of 4.6 (2.00 g, 3.20 mmol) in 
CH2Cl2 (16 mL) was added phenylsilane (440 µL, 3.52 mmol), 
followed by TFA (16 mL).  The reaction was stirred at room 
temperature for 2 h.  The system was concentrated under reduced pressure, then dissolved in 1:1 
benzene/acetonitrile, flash frozen, and lyophilized to yield 4.7 (1.72 g, 3.03 mmol, 95%) as a 
white powder.  Rf 0.34 (25:1 CH2Cl2/methanol).  
1
H NMR (500 MHz, CD3OD) δ 7.81 (d, J = 7.5 
Hz, 2 H), 7.70 (d, J = 7.5 Hz, 2H), 7.41 (t, J = 7.5 Hz, 2H), 7.35-7.30 (m, 2H), 5.98-5.90 (m, 
2H), 5.36-5.17 (m, 4H), 4.63 (m, 2H), 4.55 (m, 2H), 4.43-4.33 (m, 4H), 4.24 (t, J = 7.0 Hz, 1H), 
3.12-2.86 (m, 2H), 2.74-2.60 (m, 2H), 2.14-1.97 (m, 2H).  
13
C NMR (125 MHz, CD3OD) δ 
174.0, 173.4, 158.5, 158.4, 145.3, 145.2, 142.5, 134.2, 133.2, 128.8, 128.2, 126.3, 120.9, 118.7, 
117.6, 68.2, 66.8, 66.6, 55.2, 54.3, 34.6, 32.4, 29.4.  HRMS (ESI) calc. [M+H]
+
 for C29H33N2O8S 
569.1958, found 569.1957.  See also Notebook II, page 42. 
 
 
166 
 
Compound 4.8.  L-Homoserine (2.0 g, 16.8 mmol) and sodium carbonate 
(1.78 g, 16.8 mmol) were dissolved in water (35 mL) and chilled in an ice 
bath.  A solution of FmocOSu (5.67 g, 16.8 mmol) in 1,4-dioxane (15 mL) 
was added slowly to the aqueous solution.  The reaction was warmed to 
room temperature and stirred under N2 for 8 h.  The dioxane was removed under reduced 
pressure, and the remaining mixture was washed with EtOAc, then acidified to pH 2 with 2 M 
HCl.  A precipitate formed, which was extracted with EtOAc, dried over Na2SO4, filtered, and 
concentrated under reduced pressure to yield the amine-protected intermediate as a white solid.  
A portion of this intermediate (1.00 g, 2.93 mmol) was dissolved in CH2Cl2 (20 mL) and 
tetrahydrofuran (5 mL).  Tert-butyl 2,2,2-trichloroacetimidate (1.30 mL, 7.32 mmol) was added, 
and the reaction was stirred under N2 for 16 h.  The reaction was concentrated under reduced 
pressure, then taken up in EtOAc, washed with saturated aqueous NaHCO3 and brine, dried over 
Na2SO4, filtered, and concentrated under reduced pressure.  The crude material was purified by 
flash chromatography (SiO2, 2:1 hexane/EtOAc) to yield 4.8 (0.61 g, 1.53 mmol, 52%) as a 
white foam.  Rf 0.43 (1:1 hexane/EtOAc).  
1
H NMR (500 MHz, CDCl3) δ 7.77 (d, J = 7.5 Hz, 
2H), 7.60 (d, J = 7.5 Hz, 2H), 7.41 (t, J = 7.5 Hz, 2H), 7.32 (t, J = 7.5 Hz, 2H), 5.64 (d, J = 7.5 
Hz, 1H), 4.50-4.37 (m, 3H), 4.22 (t, J = 7.0 Hz, 1H), 3.75-3.58 (m, 2H), 2.59 (bs, 1H), 2.20-2.12 
(m, 1H), 1.67-1.61 (m, 1H), 1.48 (s, 9H).  
13
C NMR (125 MHz, CDCl3) δ 171.8, 157.0, 143.9, 
143.7, 141.4, 127.8, 127.2, 125.1, 120.1, 82.6, 67.2, 58.4, 51.6, 47.2, 36.1, 28.1.  HRMS (ESI) 
calc. [M+H]
+
 for C23H28NO5 398.1967, found 398.1958.  See also Notebook III, page 94; 
Notebook IV, page 6. 
 
Compound 4.9.  To a solution of 4.8 (0.70 g, 1.76 mmol) in CH2Cl2 (7 
mL) was added carbon tetrabromide (0.70 g, 2.11 mmol), and the solution 
was chilled in an ice bath.  A solution of triphenylphosphine (0.55 g, 2.11 
mmol) in CH2Cl2 (3 mL) was added dropwise.  The reaction was warmed 
to room temperature and stirred under N2 for 1 h, then washed with water and brine, dried over 
Na2SO4, filtered, and concentrated under reduced pressure.  Excess 1:1 hexane/EtOAc was added 
to precipitate the phosphine oxide byproduct, which was removed via filtration through Celite.  
The filtrate was concentrated under reduced pressure and purified by flash chromatography 
(SiO2, 5:1 hexane/EtOAc) to yield 4.9 (0.76 g, 1.65 mmol, 94%) as a colorless oil.  Rf 0.45 (3:1 
hexane/EtOAc).  
1
H NMR (CDCl3, 500 MHz) δ 7.77 (d, J = 7.5 Hz, 2H), 7.60 (d, J = 7.5 Hz, 
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2H), 7.40 (t, J = 7.5 Hz, 2H), 7.33 (dt, J = 7.5 Hz, 1.5 Hz, 2H), 5.38 (d, J = 7.7 Hz, 1H), 4.46-
4.35 (m, 3H), 4.23 (t, J = 7.0 Hz, 1H), 3.42-3.36 (m, 2H), 2.45-2.17 (m, 2H), 1.49 (s, 9H).  
13
C 
NMR (CDCl3, 400 MHz) δ 170.6, 156.0, 143.9, 143.8, 141.4, 127.9, 127.2, 125.2, 120.1, 83.0, 
67.1, 53.6, 47.3, 36.2, 28.3, 28.1.  HRMS (ESI) calc. [M+H]
+
 for C23H27BrNO4 460.1123, found 
460.1126.  See also Notebook IV, page 47. 
 
Compound 4.10.  S-trityl-L-cysteine (2.50 g, 6.88 mmol) and sodium 
carbonate (0.73 g, 6.88 mmol) were suspended in water (14 mL) and 
acetonitrile (7 mL) and chilled in an ice bath.  Allyl chloroformate (0.73 mL, 
6.88 mmol) was added dropwise.  The reaction was allowed to warm to room temperature and 
stirred under N2 for 16 h.  Acetonitrile was removed under reduced pressure, and additional 
water was added.  The pH was adjusted to 2 with 2 M HCl, forming a precipitate which was 
extracted with EtOAc.  The organic fractions were concentrated under reduced pressure, and the 
residue was taken up in DMF (18 mL).  Sodium bicarbonate (0.58 g, 6.88 mmol) and allyl 
bromide (0.72 mL, 8.26 mmol) were added, and the reaction was stirred as a heterogeneous 
mixture for 17 h, with additional allyl bromide (0.30 mL, 3.47 mmol) added after 7 h.  The 
reaction was concentrated under reduced pressure, taken up in EtOAc, washed with saturated 
aqueous NaHCO3, water, 0.1 M KHSO4, and brine, dried over Na2SO4, filtered, and concentrated 
under reduced pressure.  The crude material was purified by flash chromatography (SiO2, 5:1 
hexane/EtOAc) to yield 4.10 (2.34 g, 4.80 mmol, 70%) as pale yellow oil.  Rf 0.48 (3:1 
hexane/EtOAc).  
1
H NMR (500 MHz, CDCl3) δ 7.41 (m, 6H), 7.30 (m, 6H), 7.23 (m, 3H), 5.91-
5.85 (m, 2H), 5.35-5.21 (m, 5H), 4.62 (dt, J = 5.5 Hz, 1.5 Hz, 2H), 4.56 (d, J = 5.5 Hz, 2H), 4.37 
(m, 1H), 2.72-2.58 (m, 2H).  
13
C NMR (125 MHz, CDCl3) δ 170.2, 155.5, 144.3, 132.6, 131.5, 
129.5, 128.1, 127.9, 126.9, 118.8, 117.8, 67.0, 66.3, 65.9, 52.9, 34.2.  HRMS (ESI) calc. 
[M+Na]
+
 for C29H29NO4SNa 510.1715, found 510.1707.  See also Notebook IV, pages 49, 53. 
 
Compound 4.11.  To a solution of 4.10 (0.60 g, 1.23 mmol) in CH2Cl2 (12 
mL) was added triisopropylsilane (0.50 mL, 2.46 mmol), followed by TFA 
(1.9 mL, 24.6 mmol) under N2.  The reaction was stirred under N2 for 1 h, 
then partitioned between CH2Cl2 and water.  Solid NaHCO3 (2.07 g, 24.6 mmol) was slowly 
added to neutralize the residual acid.  The organic layer was separated, washed with brine, dried 
over Na2SO4, filtered, and concentrated under reduced pressure.  The crude material was purified 
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by flash chromatography (SiO2, 6:1 hexane/EtOAc) to yield 4.11 (0.26 g, 1.04 mmol, 85%) as a 
colorless oil.  This compound was used immediately for further reaction, as it is unstable for 
long-term storage.  Rf 0.51 (3:1 hexane/EtOAc).  
1
H NMR (400 MHz, CDCl3) δ 5.96-5.86 (m, 
2H), 5.65 (d, J = 7.0 Hz, 1H), 5.39-5.22 (m, 4H), 4.72-4.64 (m, 3H), 4.59 (d, J = 5.6 Hz, 2H), 
3.08-2.95 (m, 2H), 1.39 (t, J = 9.0 Hz, 1H).  
13
C NMR (125 MHz, CDCl3) δ 169.8, 155.6, 132.5, 
131.4, 119.4, 118.1, 66.5, 66.1, 55.3, 27.3.  HRMS (ESI) calc. [M+H]
+
 for C10H16NO4S 
246.0800, found 246.0797.  See also Notebook IV, page 55. 
 
Compound 4.12.  Compounds 4.11 (0.24 g, 0.96 mmol) and 4.9 
(0.44 g, 0.96 mmol) were dissolved in N2-sparged EtOAc (5 mL) 
under N2.  Tetrabutylammonium bromide (1.23 g, 3.82 mmol) 
was dissolved in N2-sparged 0.5 M aqueous sodium bicarbonate (pH 8.5, 5 mL), then added to 
the reaction.  The biphasic mixture was stirred for 20 h under N2.  The reaction was diluted with 
EtOAc, washed with water and brine, dried over Na2SO4, filtered, and concentrated under 
reduced pressure.  The crude material was purified by flash chromatography (SiO2, 4:1 then 3:1 
hexane/EtOAc) to yield 4.12 (0.56 g, 0.89 mmol, 93%) as a colorless oil.  Rf 0.22 (3:1 
hexane/EtOAc).  
1
H NMR (500 MHz, CDCl3) δ 7.76 (d, J = 7.5 Hz, 2H), 7.60 (d, J = 7.5 Hz, 
2H), 7.40 (t, J = 7.5 Hz, 2H), 7.32 (dt, J = 7.5 Hz, 1.5 Hz, 2H), 5.93-5.86 (m, 2H), 5.68 (d, J = 
7.5 Hz, 1H), 5.43 (d, J = 7.5 Hz, 1H), 5.36-5.18 (m, 4H), 4.65 (d, J = 5.5 Hz, 2H), 4.62-4.36 (m, 
3H), 4.23 (t, J = 7.0 Hz, 1H), 3.01 (d, J = 4.5 Hz, 2H), 2.58-2.55 (m, 2H), 2.12-1.88 (m, 2H), 
1.48 (s, 9H).  
13
C NMR (125 MHz, CDCl3) δ 171.0, 170.5, 156.1, 144.0, 141.4, 132.6, 131.4, 
127.8, 127.2, 125.2, 120.1, 119.3, 118.1, 82.7, 67.1, 66.5, 66.1, 53.8, 53.6, 47.2, 34.7, 32.9, 28.7, 
28.1.  HRMS (ESI) calc. [M+H]
+
 for C33H41N2O8S 625.2584, found 625.2592.  See also 
Notebook IV, page 56. 
 
Compound 4.13.  To a solution of 4.12 (0.53 g, 0.85 mmol) in 
CH2Cl2 (3 mL) was added phenylsilane (120 µL, 0.93 mmol), 
followed by TFA (3 mL).  The reaction was stirred at room 
temperature for 2 h.  The system was concentrated under reduced pressure, then dissolved in 1:1 
benzene/acetonitrile, flash frozen and lyophilized to yield 4.13 (0.48 g, 0.84 mmol, 98%) as a 
white powder.  Rf 0.33 (25:1 CH2Cl2/methanol).  
1
H NMR (500 MHz, CD3OD) δ 7.77 (d, J = 7.5 
Hz, 2H), 7.68-7.64 (m, 2H), 7.37 (t, J = 7.5 Hz, 2H), 7.29 (t, J = 7.5 Hz, 2H), 5.95-5.88 (m, 2H), 
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5.34-5.27 (m, 2H), 5.22-5.15 (m, 2H), 4.63 (d, J = 5.5 Hz, 2H), 4.53 (m, 2H), 4.42 (m, 1H), 4.36-
4.32 (m, 3H), 4.20 (t, J = 7.0 Hz, 1H), 3.03-2.84 (m, 2H), 2.68-2.56 (m, 2H), 2.15-1.95 (m, 2H).  
13
C NMR (125 MHz, CD3OD) δ 175.4, 172.1, 158.7, 158.2, 145.3, 142.5, 134.2, 133.1, 128.8, 
128.1, 126.3, 120.9, 118.8, 117.7, 67.9, 67.0, 66.7, 55.4, 54.0, 34.4, 32.5, 29.5.  HRMS (ESI) 
calc. [M+H]
+
 for C29H33N2O8S 569.1958, found 569.1953.  See also Notebook IV, page 70. 
 
 
 
Compound 4.14.  L-Homoserine (0.97 g, 8.14 mmol) and sodium carbonate 
(0.86 g, 8.14 mmol) were dissolved water (10 mL) and MeCN (5 mL).  9-
Fluorenylmethyl chloroformate (FmocCl; 2.11 g, 8.14 mmol) was added 
slowly as a solid over 5 min, and the reaction was stirred for 18 h.  The 
reaction was concentrated under reduced pressure, and the residue was taken up in DMF (20 
mL).  Sodium bicarbonate (0.68 g, 8.14 mmol) was added, followed by allyl bromide (780 μL, 
8.95 mmol).  The reaction was stirred for 48 h, with additional allyl bromide (350 μL, 4.07 
mmol) added at 21 h.  The reaction was concentrated under reduced pressure, taken up in EtOAc, 
washed with saturated aqueous NaHCO3, H2O, 0.1 M KHSO4, and brine, dried over Na2SO4, 
filtered, and concentrated under reduced pressure.  The crude material was purified by flash 
chromatography (SiO2, 3:2 then 1:1 hexanes/EtOAc) to yield 4.14 (1.98 g, 5.19 mmol, 60%) as a 
white solid.  Rf 0.45 (1:1 hexanes/EtOAc).  
1
H NMR (400 MHz, CDCl3) δ 7.78 (d, 2H), 7.59 (d, 
2H), 7.39 (t, 2H), 7.30 (t, 2H), 5.92-5.82 (m, 1H), 5.63 (d, 1H), 5.38-5.22 (m, 4H), 4.62 (d, 2H), 
4.57 (m, 1H), 4.48-4.37 (m, 2H), 4.20 (t, 1H), 3.75-3.55 (m, 2H), 2.23-1.65 (m, 2H).  LRMS 
(ESI) calc. [M+H]
+
 for C22H24NO5 382.2, found 382.2.  See also Notebook I, page 51. 
 
170 
 
Compound 4.15.  To a solution of 4.14 (4.15 g, 10.9 mmol) in CH2Cl2 (40 
mL) was added carbon tetrabromide (5.41 g, 16.3 mmol), and the solution 
was chilled in an ice bath.  A solution of triphenylphosphine (4.28 g, 16.3 
mmol) in CH2Cl2 (15 mL) was added via cannula.  The reaction was 
warmed to room temperature and stirred under N2 for 1 h, then washed with H2O and brine, dried 
over Na2SO4, filtered, and concentrated under reduced pressure.  The triphenylphosphine oxide 
byproduct was precipitated in 1:1 hexane/EtOAc and removed by filtering through Celite.  The 
filtrate was concentrated under reduced pressure and purified by flash chromatography (SiO2, 4:1 
then 2:1 hexanes/EtOAc) to yield 4.15 (2.92 g, 6.57 mmol, 60%) as a colorless oil.  Rf 0.52 (3:1 
hexanes/EtOAc).  
1
H NMR (400 MHz, CDCl3) δ 7.78 (d, 2H), 7.58 (d, 2H), 7.38 (t, 2H), 7.29 (t, 
2H), 5.95-5.83 (m, 1H), 5.41-5.23 (m, 3H), 4.65 (d, 2H), 4.50 (m, 1H), 4.45 (m, 2H), 4.20 (t, 
1H), 3.39 (t, 2H), 2.52-2.18 (m, 2H).  LRMS (ESI) calc. [M+H]
+
 for C22H23BrNO4 444.1, found 
444.2.  See also Notebook II, page 31-32. 
 
Compund 4.16.  S-trityl-L-cysteine (2.00 g, 5.50 mmol) was suspended in 
MeOH (40 mL), and 2-(3-methylbutyryl)-5,5-dimethyl-1,3-
cyclohexandione (DdivOH; 1.09 mL, 5.00 mmol) and 
i
Pr2NEt (3.48 mL, 
20.0 mmol) were added.  A condenser was installed, and the reaction was stirred at reflux for 16 
h.  The reaction was concentrated under reduced pressure, and the residue was partitioned 
between EtOAc and dilute aqueous HCl (pH 2).  The organic layer was isolated, dried over 
Na2SO4, filtered, and concentrated under reduced pressure to ~1/4 volume.  Excess cold hexane 
was added to form a precipitate, which was isolated by filtration and concentrated under reduced 
pressure to yield the amine-protected intermediate (2.83 g, 4.97 mmol, quant.) as a white 
powder.  A portion of this intermediate (1.30 g, 2.28 mmol) was dissolved in CH2Cl2 (15 mL) 
and chilled in an ice bath.  In succession, 4-dimethylaminopyridine (DMAP; 55 mg, 0.46 mmol) 
was added as a solid, followed by 2-trimethylsilylethanol (TmseOH; 390 µL, 2.74 mmol), and 
lastly EDC (0.61 g, 3.19 mmol).  The reaction was warmed to room temperature and stirred 
under N2 for 5.5 h, then diluted with CH2Cl2, washed with 1 M HCl and brine, dried over 
Na2SO4, filtered, and concentrated under reduced pressure.  The crude material was purified by 
flash chromatography (SiO2, 9:1 then 7:1 hexane/EtOAc) to yield 4.16 (0.84 g, 1.25 mmol, 55%) 
as a colorless oil.  Rf 0.58 (3:1 hexanes/EtOAc).  
1
H NMR (400 MHz, CDCl3) δ 7.58-7.26 (m, 
6H), 7.26-7.19 (m, 9H), 4.25-4.15 (m, 3H), 3.71 (dd, 2H), 2.68 (m, 2H), 2.39 (s, 4H), 1.78 (m, 
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1H), 1.02 (s, 6H), 0.95-0.80 (m, 8H), 0.02 (s, 9H).  LRMS (ESI) calc. [M+H]
+
 for C40H52NO4SSi 
670.3, found 670.1.  See also Notebook I, pages 60-61. 
 
Compound 4.17.  To a solution of 4.16 (3.10 g, 4.63 mmol) in CH2Cl2 (40 
mL) was added triisopropylsilane (1.90 mL, 9.26 mmol), followed by 
TFA (7.1 mL, 92.6 mmol) under N2.  The reaction was stirred under N2 
for 2 h, then partitioned between CH2Cl2 and H2O.  Solid NaHCO3 (7.78 g, 92.6 mmol) was 
added slowly to neutralize the acid.  The organic layer was isolated, washed with brine, dried 
over Na2SO4, filtered, and concentrated under reduced pressure.  The crude material was purified 
by flash chromatography (SiO2, 8:1 then 4:1 hexanes/EtOAc) to yield 4.17 (1.56 g, 3.65 mmol, 
79%) as a colorless oil.  Rf 0.37 (3:1 hexanes/EtOAc).  
1
H NMR (400 MHz, CDCl3) δ 4.66 (m, 
1H), 4.27 (m, 2H), 3.12-2.90 (m, 3H), 2.42 (s, 4H), 1.92 (m, 1H), 1.62 (t, 1H), 1.03-0.92 (m, 
14H), 0.03 (s, 9H).  LRMS (ESI) calc. [M+H]
+
 for C21H38NO4SSi 428.2, found 428.3.  See also 
Notebook II, page 48. 
 
Compound 4.18.  Compounds 4.17 (0.34 g, 0.79 mmol) and 
4.15 (0.37 g, 0.83 mmol) were dissolved in N2-sparged EtOAc 
(8 mL).  Tetrabutylammonium bromide (1.02 g, 3.16 mmol) 
was dissolved in N2-sparged 0.5 M aqueous NaHCO3 (pH adjusted to 8.5, 8 mL), then added to 
the organic solution.  The biphasic mixture was stirred under N2 for 24 h.  The organic layer was 
isolated, washed with water and brine, dried over Na2SO4, filtered, and concentrated under 
reduced pressure.  The crude material was purified by flash chromatography (SiO2, 4:1-2:1 
hexane/EtOAc) to yield 4.18 (0.51 g, 0.65 mmol, 82%) as a colorless foam.  Rf 0.33 (3:1 
hexanes/EtOAc).  
1
H NMR (400 MHz, CDCl3) δ 7.75 (d, 2H), 7.60 (d, 2H), 7.39 (t, 2H), 7.29 (t, 
2H), 5.95-5.88 (m, 1H), 5.85 (d, 1H), 5.38-5.22 (m, 2H), 4.62 (m, 3H), 4.47 (m, 1H), 4.39 (d, 
2H), 4.30-4.21 (m, 3H), 3.11-3.02 (m, 3H), 2.63 (m, 2H), 2.40 (s, 4H), 2.18-1.98 (m, 2H), 1.95 
(m, 1H), 1.05-0.95 (m, 14H), 0.02 (s, 9H).  LRMS (ESI) calc. [M+H]
+
 for C43H59N2O8SSi 791.4, 
found 791.0.  See also Notebook I, page 59. 
 
Compound 4.19.  To a solution of compound 4.18 (1.90 g, 
2.40 mmol) in THF (50 mL) was added N-methylaniline (785 
µL, 7.21 mmol).  The reaction was purged with N2, then 
tetrakis(triphenylphosphine)palladium(0) (140 mg, 5 mol%) was added.  The reaction was stirred 
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under N2 for 1.5 h, protected from light, then diluted with EtOAc, washed with saturated aqueous 
NH4Cl and brine, dried over Na2SO4, filtered, and concentrated under reduced pressure.  The 
crude material was purified by flash chromatography (SiO2, 50:1 then 20:1 CH2Cl2/MeOH) to 
yield 4.19 (1.41 g, 1.88 mmol, 78%) as a pale yellow solid.  Rf 0.35 (25:1 CH2Cl2/MeOH).  
1
H 
NMR (400 MHz, CDCl3) δ 7.73 (d, 2H), 7.57 (m, 2H), 7.38 (t, 2H), 7.28 (t, 2H), 5.80 (d, 1H), 
4.63 (m, 1H), 4.48 (m, 1H), 4.37 (d, 2H), 4.26 (t, 1H), 3.11-2.96 (m, 3H), 2.59 (m, 2H), 2.42 (s, 
4H), 2.22-1.95 (m, 2H), 1.87 (m, 1H), 1.07-0.92 (m, 14H), 0.02 (s, 9H).  LRMS (ESI) calc. 
[M+H]
+
 for C40H55N2O8SSi 751.3, found 751.5.  See also Notebook II, page 50. 
 
4.4.3. Synthesis of compstatin analogues 4.20, 4.21, and 4.23 
 
Unless noted otherwise, standard cycles for SPPS were performed as follows, using a 
fritted glass reaction vessel equipped with a N2 inlet for resin/reagent agitation and a suction 
outlet for draining.  Fmoc deprotection was achieved by agitating resin with 20% piperidine in 
DMF (5 mL) for two treatments of 10 min each.  After draining the reaction vessel, the resin was 
washed with DMF (3 x 5 mL x 30 s) and CH2Cl2 (2 x 5 mL x 30 s).  The appropriately side-
chain protected Fmoc-amino acid (4 equiv.) in DMF (5-10 mL) was pre-activated with HCTU (4 
equiv.) and 
i
Pr2NEt (8 equiv.) for 5 min, then added to resin and agitated for 45-60 min.  After 
draining the reaction vessel, the resin was washed as before.  The completion of all couplings 
was assessed by a Kaiser test; double couplings were performed as needed.  Test cleavages were 
performed periodically by removing a small portion of dry resin from the reaction vessel and 
treating with 90:5:5 TFA/H2O/triisopropylsilane for 1 h under N2.  After removing the cleaved 
resin by filtration, the filtrate was concentrated under a stream of N2.  The peptide was 
precipitated with cold Et2O, isolated by centrifugation at 12,000 ×g, and dissolved in 1:1 
H2O/MeCN.  An aliquot of this solution was spotted onto a MALDI-TOF MS target for analysis. 
Fmoc-Rink amide AM resin (initial substitution 0.6 mmol/g) was swelled in DMF for 20 
min.  The Fmoc group was removed, and the first amino acid (Fmoc-Thr(
t
Bu)-OH for 4.20 and 
4.21, Fmoc-N-Me-Ile-OH for 4.23) was pre-activated, coupled, and deprotected by the standard 
protocol.  Resin substitution was then reduced such that 1 equiv. corresponded to 0.2 mmol/g.  
Cth building blocks 4.7 or 4.13 (1 equiv.) were pre-activated with HCTU (1 equiv.) and 
i
Pr2NEt 
(2 equiv.) in DMF (5 mL) for 5 min, then added to resin and agitated for 3 h.  Remaining free 
resin sites were acetylated with a solution of 1:1:3 Ac2O/
i
Pr2NEt/DMF (10 mL) for 30 min.  The 
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resin-bound peptide was Fmoc-deprotected, and the next eight residues were coupled and 
deprotected by the standard protocol.  Fmoc-Val-OH was then coupled by the standard protocol, 
but not Fmoc-deprotected. 
Following the coupling of Fmoc-Val-OH, the allyl protecting groups were removed by 
agitating resin with tetrakis(triphenylphosphine)palladium(0) (1 equiv.) and phenylsilane (10 
equiv.) in 1:1 DMF/CH2Cl2 (10 mL) for 2 h, protected from light.  After draining the reaction 
vessel, resin was washed with CH2Cl2 (3 x 10 mL x 1 min), 0.5% diethyldithiocarbamate in 
DMF (3 x 10 mL x 1 min), DMF (3 x 5 mL x 30 s), and CH2Cl2 (2 x 5 mL x 30 s).  The Fmoc 
group was removed by the standard protocol, followed by washing with DMF (5 x 5 mL x 30 s), 
CH2Cl2 (3 x 5 mL x 30 s), and DMF (2 x 5 mL x 30 s) to remove all traces of piperidine.  
Cyclization was performed by adding PyBOP (5 equiv.), HOAt (5 equiv.), and 
i
Pr2NEt (10 
equiv.) in DMF to the resin and agitating for two treatments of 1.5 h each.  Fmoc-Ile-OH was 
then coupled and deprotected by the standard protocol, and the N-terminus was acetylated with a 
solution of 1:1:3 Ac2O/
i
Pr2NEt/DMF (10 mL) for 30 min.  The resin was washed with CH2Cl2 
and dried.  The peptide was cleaved from resin and globally deprotected with 91.5:5:2.5:1 
TFA/water/triisopropylsilane/ethanedithiol under N2 for 2 h.  The cleaved resin was removed by 
filtration, and the filtrate was concentrated under a stream of N2.  The peptide was precipitated 
with cold Et2O, isolated by centrifugation at 12,000 ×g, dissolved in 1:1 H2O/MeCN, and 
lyophilized to dryness.  The crude peptide was purified by RP-HPLC employing the conditions 
described below (see Section 4.1.1).  Product-containing fractions were pooled, lyophilized, and 
analyzed by MALDI-TOF MS.  See also Notebook II, pages 51-54, 56; Notebook III, pages 65-
66, 70; Notebook V, pages 16-17, 21. 
Compstatin analogue 4.20.  RP-HPLC: Waters Delta-Pak C18 column and a solvent 
gradient of 2% solvent B for 1 min, 2-20% over 2 min, 20-26% over 3 min, 26-41% over 30 min, 
41-100% over 1 min.  Rt = 31.9-32.8 min.  Yield: 8 mg pure peptide from a 0.1-mmol scale 
synthesis (5.0% total yield, 90% per step over 29 steps).  LRMS (MALDI-TOF) calc. [M+H]
+
 
for C72H103N22O18S 1595.7, found 1595.7.  
Compstatin analogue 4.21.  RP-HPLC: same conditions as 4.20.  Rt = 31.8-32.8 min.  
Yield: 6 mg pure peptide from a 0.1-mmol scale synthesis (3.8% total yield, 89% per step over 
29 steps).  LRMS (MALDI-TOF) calc. [M+H]
+
 for C72H103N22O18S 1595.7, found 1596.0. 
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Compstatin analogue 4.23.  RP-HPLC: Phenomenex Luna C18 column and a solvent 
gradient of 5% solvent B for 1 min, 5-24% over 2 min, 24-30% over 3 min, 30-45% over 30 min, 
45-100% over 1 min.  Rt = 26.7-27.8 min.  Yield: 12 mg pure peptide from a 0.3-mmol scale 
synthesis (2.4% total yield, 88% per step over 29 steps).  LRMS (MALDI-TOF) calc. [M+H]
+
 
for C77H113N22O17S 1649.8, found 1649.9. 
 
4.4.4. Chiral GC/MS analysis 
 
The enantiomeric purity of cystathionine building block 4.13 as well as cystathionine 
derived from hydrolyzed compstatin analogue 4.23 was confirmed by GC/MS after 
derivatization as the pentafluoropropionamide methyl esters.
88, 89
  Compound 4.13 was prepared 
for analysis by loading the protected amino acid (23 mg, 0.04 mmol) onto swelled 2-chlorotrityl 
chloride resin (31 mg, 0.02 mmol) in 
i
Pr2NEt (28 µL, 0.16 mmol) and 1:1 DMF/CH2Cl2 (2 mL) 
for 3 h.  Allyl protecting groups were removed with a solution of Pd(PPh3)4 (23 mg, 0.02 mmol) 
and PhSiH3 (21 µL, 0.1 mmol) in 1:1 DMF/CH2Cl2 (3 mL) for 2 h, protected from light.  The 
resin was drained, then washed with CH2Cl2 (3 x 5 mL x 1 min), 0.5% diethyldithiocarbamate in 
DMF (3 x 5 mL x 1 min), and DMF (3 x 5 mL x 30 s).  The Fmoc group was removed with 20% 
piperidine in DMF (2 mL) for three treatments of 10 min each.  The resin-bound amino acid was 
dried and cleaved from resin with 95:5 TFA/water for 1 h under N2.  The cleaved resin was 
removed by filtration, and the filtrate concentrated by a stream of N2.  The unprotected amino 
acid was precipitated with cold Et2O, isolated by centrifugation, and lyophilized from 1:1 
water/acetonitrile.  The resulting deprotected cystathionine as well as cystathionine standards 
were derivatized by dissolving the amino acid (2-5 mg) in 0.2 M HCl (1 mL), sealing in a high-
pressure reaction vessel and heating to 100 
o
C for 10 min.  The reaction was cooled and 
concentrated under reduced pressure.  Methanol (3 mL) was chilled in an ice-water bath, and 
acetyl chloride (1 mL) was added dropwise.  This solution was added to the amino acid, sealed in 
a high-pressure reaction vessel and heated at 100 
o
C for 45 min.  The reaction was allowed to 
cool and concentrated under reduced pressure, then chilled in an ice-water bath.  CH2Cl2 (2.5 
mL) and pentafluoropropionic anhydride (1 mL) were added, and the mixture heated at 100 
o
C 
for 20 min.  The reaction was allowed to cool and concentrated under reduced pressure, then 
taken up in methanol (200 μL) for analysis. 
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For compstatin analogue 4.23, lyophilized peptide (0.2-0.4 mg) was dissolved in 6 M 
HCl (3 mL) and heated at 100 
o
C in a sealed, high-pressure reaction vessel for 20 hr.  The 
reaction was cooled and concentrated under reduced pressure.  Methanol (3 mL) was chilled in 
an ice-water bath, and acetyl chloride (1 mL) was added dropwise.  This solution was added to 
the hydrolysate, sealed in a high-pressure reaction vessel and heated at 100 
o
C for 45 min.  The 
reaction was allowed to cool and concentrated under reduced pressure, then chilled in an ice-
water bath.  CH2Cl2 (2.5 mL) and pentafluoropropionic anhydride (1 mL) were added, and the 
mixture heated at 100 
o
C for 20 min.  The reaction was allowed to cool and concentrated under 
reduced pressure, then taken up in methanol (50-100 μL) for analysis. 
The derivatized samples and standards were analyzed by GC/MS using an Agilent 7890A 
gas chromatograph equipped with a Varian CP-Chirasil-L-Val fused silica column (25 m x 250 
μm x 0.12 µm) fused silica column and an Agilent 5975C Inert XL EI/CI MS (Metabolomics 
Center, UIUC).  Sample solutions in methanol were introduced to the instrument via splitless 
injection at an inlet temperature of 200 
o
C and flow rate of 1.5 mL/min helium gas.  The 
temperature gradient used was 160 
o
C for 5 min, then 160 
o
C to 200 
o
C at 3 
o
C/min, then held at 
200 
o
C for 20 min.  The MS was operated in simultaneous scan/single-ion monitoring (SIM) 
mode, monitoring at a known fragment mass of 379 Da.  Cystathionine standards eluted as 
distinct peaks, with the DL-isomer (19.6-19.8 min) eluting before the LL-isomer (20.0-20.2 min).  
A small amount of the DL-configuration in the hydrolysate is believed to result from 
epimerization during hydrolysis, as has been reported previously.
89
  See also Notebook IV, pages 
97-100; Notebook V, pages 13-14. 
 
4.4.5. Kinetic binding analysis of compstatin analogues 
 
Kinetic analysis via surface plasmon resonance (SPR) of the binding interaction between 
compstatin analogues and C3b was performed by Dr. Apostolia Tzekou in the laboratory of Prof. 
John Lambris (UPSM).  Briefly, C3b was generated by limited trypsinization of complement 
factor 3 and labeled with biotin-maleimide using established protocols.
62, 90
  Biotinylated C3b 
was captured site-specifically on a streptavidin chip at approximate densities of 3000, 4000, and 
5000 resonance units.  Interaction between the immobilized C3b and compstatin analogues were 
characterized using a GE Healthcare Biacore 3000 instrument in phosphate-buffered saline (10 
mM sodium phosphate, 150 mM NaCl, pH 7.4) containing 0.005% Tween-20.  An initial kinetic 
176 
 
ranking was performed by injecting a constant peptide concentration of 1 μM over the chip 
surface for 2 min.  Detailed kinetic parameters were obtained via a kinetic titration;
71
 consecutive 
injections of a set of five increasing peptide concentrations over the chip surface were performed 
in a single cycle without waiting for full dissociation between injections.  A three-fold dilution 
series (two sets at 0.46-37 nM and 111-9000 nM for 4.1, 4.20, and 4.21, one set at 0.46-37 nM 
for 4.22 and 4.23) was injected at a flow rate of 30 μL/min; each injection was done for 2 min, 
and the peptide was allowed to dissociate for 5 min before the next injection was started.  After 
the end of the last injection, a dissociation time of 10 min was used for 4.1, 4.20, and 4.21, and 
15 min for 4.22 and 4.23.  A series of blank injections was subtracted from the binding signals, 
and the processed signals were fitted to a single cycle 1:1 binding model using BIAevaluation to 
extract the kinetic rate constants (ka, kd) and calculate the binding affinity (KD = kd/ka). 
 
4.4.6. Complement inhibition assays 
 
Assessment of the complement inhibitory ability of compstatin analogues was performed 
by Dr. Tzekou, using an established enzyme-linked immunosorbent assay (ELISA) that initiates 
the classical pathway of complement activation via an ovalbumin-based antigen/antibody 
complex.
61
  Briefly, ovalbumin was immobilized on the ELISA well surface, which was then 
treated with normal human plasma containing serial dilutions of compstatin analogues in 
veronal-buffered saline.  Anti-ovalbumin antibody was used to initiate the complement pathway, 
and after a 15 min incubation, the deposition of C3b on the plate was measured with a polyclonal 
anti-C3 antibody.  The percentage of inhibition was plotted against compstatin analogue 
concentration and fitted to a logistic dose-response function. 
 
4.4.7. Effect of reduction and oxidation on compstatin analogue activity 
 
The effect of treating compstatin analogues with reducing and oxidizing agents on 
biological activity was performed by Dr. Tzekou.  Briefly, for reductive treatment, peptides 4.22 
and 4.23 were dissolved in 0.1% aqueous TFA to a concentration of 50 µM.  An aqueous 
solution of tris(2-carboxyethyl)phosphine hydrochloride (TCEP) was added to give a final 
concentration of 25 mM.  Samples were incubated for 1.5 h at room temperature, and reduction 
was monitored by MALDI-TOF MS.  To prevent re-formation of the disulfide bond during 
further characterization, the TCEP-treated solution of 4.22 was concentrated by lyophilization, 
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dissolved in a 1:1 mixture of 100 mM aqueous ammonium bicarbonate (pH 7.8) and 0.1% TFA 
in acetonitrile in the presence of a 10-fold molar excess of TCEP, and treated with a 20-fold 
molar excess of iodoacetamide.  A mass shift of +114 was observed by MALDI-TOF MS, 
corresponding to alkylation of both cysteine residues.  Peptides were then purified by RP-HPLC. 
For oxidative treatment, in order to provide the most general evaluation of the effect of 
sulfoxide formation on activity, a non-stereoselective sulfur oxidation method was used.  
Aqueous solutions of 4.22 and 4.23 (20 μM) were brought to slightly basic pH with ammonium 
hydroxide.  Hydrogen peroxide was then added to a final concentration of 0.4% by volume, and 
oxidation was monitored by MALDI-TOF MS.  After several hours of incubation at room 
temperature, 4.23 displayed a complete mass shift of +16, indicative of sulfoxide formation.  
Reactions were then concentrated by lyophilization.  The reduced/alkylated and oxidized 
derivatives of 4.22 and 4.23 were tested for their complement inhibitory activity as described in 
Section 4.4.6.   
 
4.4.8. Synthesis of albumin affinity tag 4.27 
 
 
 
 
Compound 4.24.  Diphenylacetaldehyde (3.58 mL, 20.0 mmol) and 3-buten-2-
one (2.46 mL, 30.0 mmol) were dissolved in anhydrous ethanol (15 mL) and 
chilled to 0 
o
C in an ice bath.  Potassium hydroxide pellets (0.56 g, 10.0 
mmol) were dissolved in anhydrous ethanol (10 mL) in a separate flask and 
chilled to 0 
o
C.  The cold hydroxide solution was slowly added to the 
aldehyde solution over 10 min, and the reaction was stirred at 0 
o
C for 3 h, over which time a 
precipitate formed.  The reaction was concentrated under reduced pressure, and the resulting 
residue was partitioned between H2O and Et2O.  The mixture was acidified to pH 3 with 2 M 
aqueous HCl, and the layers were separated.  The organic fraction was dried over Na2SO4, 
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filtered, and concentrated under reduced pressure.  The crude material was purified by flash 
chromatography (SiO2, 9:1 hexanes/EtOAc) to yield 4.24 (3.47 g, 14.0 mmol, 70%) as a white 
solid.  Rf 0.52 (4:1 hexane/EtOAc).  Spectral data matched those reported previously.
91
  See also 
Notebook X, page 5. 
 
Compound 4.25.  To a solution of 4.24 (3.40 g, 13.7 mmol) in THF (30 mL) 
was added 10% palladium on carbon (140 mg).  The reaction vessel was 
flushed with hydrogen gas, and the system was sealed under a hydrogen 
atmosphere (1 atm) and stirred vigorously for 20 h.  The catalyst was removed 
by filtration through Celite and washed with THF (15 mL).  The combined 
filtrate was chilled to 0 
o
C in an ice bath.  Sodium borohydride (0.26 g, 6.85 mmol) was 
dissolved in 0.1 M aqueous NaOH (7 mL) in a separate flask and chilled to 0 
o
C, then added 
dropwise to the organic solution.  The system was warmed to room temperature and stirred for 2 
h.  The reaction was then chilled to 0 
o
C, quenched with 2 M aqueous HCl (12 mL) and diluted 
with cold H2O (100 mL).  The system was stirred at 0 
o
C for 30 min, over which time a white 
precipitate formed.  The precipitate was isolated by filtration, washed with cold H2O, and dried 
under reduced pressure to yield 4.25 (3.32 g, 13.2 mmol, 96% over two steps) as a white solid.  
Rf 0.26 (4:1 hexanes/EtOAc).  Spectral data matched those reported previously.
92
  See also 
Notebook X, page 6. 
 
Compound 4.26.  To a solution of ethyl 6-hydroxyhexanoate 
(2.44 mL, 15.0 mmol) and 
i
Pr2NEt (10.4 mL, 60.0 mmol) in 
CH2Cl2 (60 mL) was added dropwise 2-cyanoethyl-N,N-
diisopropylchlorophosphoramidite (3.51 mL, 15.8 mmol).  The reaction was stirred for 2 h, then 
washed with ice-cold saturated aqueous NaHCO3, dried over Na2SO4, filtered, and concentrated 
under reduced pressure.  The crude material was purified by flash chromatography (SiO2, 9:1 
hexane/EtOAc with 0.1% Et3N) to yield 4.26 (4.20 g, 11.7 mmol, 78%) as a colorless liquid.  Rf 
0.80 (2:1 hexane/EtOAc).  Spectral data matched those reported previously.
93
  See also Notebook 
X, page 10. 
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Compound 4.27.  Compounds 4.26 (2.90 g, 8.05 
mmol) and 4.25 (2.13 g, 8.45 mmol) were combined 
in acetonitrile (30 mL).  A 0.45 M solution of 1H-
tetrazole in acetonitrile (18.8 mL, 8.45 mmol) was 
added, and the reaction was stirred under N2 for 3 h.  
A 70% w/w aqueous solution of tert-butylhydroperoxide (8 mL) was added, and the reaction 
stirred for an additional 1 h, then concentrated under reduced pressure.  The resulting residue 
was taken up in EtOAc, washed with 10% Na2S2O3, saturated aqueous NaHCO3, and brine, dried 
over Na2SO4, filtered, and concentrated under reduced pressure.  The crude material was purified 
by flash chromatography (SiO2, 1:1 hexanes/EtOAc with 0.1% Et3N) to yield a colorless oil (Rf 
0.13, 1:1 hexanes/EtOAc).  This oil was taken up in 2 M ammonia in methanol (80 mL) and 
stirred under N2 for 12 h to remove the cyanoethyl substituent.  The reaction was concentrated 
under reduced pressure, and the resulting oil was taken up in THF (10 mL) and chilled to 0 
o
C in 
an ice bath.  A 2 M aqueous solution of lithium hydroxide (5 mL) was added, and the reaction 
was warmed to room temperature and stirred for 2 h to hydrolyze the ethyl ester.  The reaction 
was concentrated under reduced pressure and taken up in water (100 mL).  The solution was 
acidified to pH 2 with 2 M aqueous HCl, forming a white precipitate that was extracted with 
EtOAc (3 x 50 mL).  The organic fractions were combined, dried over Na2SO4, filtered, and 
concentrated under reduced pressure to yield 4.27 (1.94 g, 4.35 mmol, 54% over three steps) as 
an off-white solid after lyophilization from 1:1 benzene/acetonitrile.  Rf 0.45 (4:1:1 
BuOH/H2O/AcOH).  
1
H NMR (500 MHz, CD3OD) δ 7.32-7.20 (m, 8H), 7.10 (q, J = 7.5 Hz, 
2H), 4.33 (m, 1H), 3.89 (q, J = 6.5 Hz, 2H), 2.60 (m, 2H), 2.28 (t, J = 7.5 Hz, 2H), 2.19 (m, 2H), 
1.89 (m, 2H), 1.74 (m, 2H), 1.66-1.58 (m, 4H), 1.45-1.39 (m, 2H).  
13
C NMR (125 MHz, 
CD3OD) δ 177.5, 149.2, 148.6, 129.3, 129.1, 128.2, 127.9, 126.6, 75.2, 66.8, 46.6, 34.9, 34.0, 
31.3, 30.8, 26.4, 25.7.  
31
P NMR (200 MHz, CD3OD) δ 0.64.  HRMS (ESI) calc. [M+H]
+
 for 
C24H32O6P 447.1937, found 447.1934.  See also Notebook X, pages 11-13. 
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